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Gambiense human African trypanosomiasis (gHAT) is a disease targeted for elimination
by the World Health Organization. In this thesis, I develop a stochastic mathematical
model for gHAT infection dynamics that can explore the infection on the level of
individual villages. This allows us to make predictions on the same scale at which the
active screening interventions occur. Since regional elimination is dependent on the
local elimination of transmission in villages, we then scale up the model to consider the
interaction of villages in relation to the infection.
The models show that infection is able to persist for long periods in relatively small
isolated populations due to the long time scales of infection, and that not observing any
cases is an indicator of local elimination, but not proof. Further analysis demonstrates
that using a net monetary benefit framework, active screening has the most benefit
when carried out at high coverage approximately annually. Modelling predictions also
show that elimination is unlikely to be achieved in all areas with active screening at the
current coverages alone.
These results provide quantitative support for some current intervention strategies, while
the insights given also highlight some potential difficulties for achieving and measuring




1.1 Introduction to modelling infectious diseases
Infectious diseases are illnesses caused by pathogenic microorganisms, which can include
viruses, bacteria, fungi and other parasites. These diseases are transmissible and can
be spread from person to person, either directly, or indirectly, passing between hosts
through the environment, or by secondary host or vector. The invasion of an organism by
a pathogen can cause any number of symptoms, of varying severity, if the host’s immune
mechanisms are compromised. Indeed, a large percentage of human deaths are caused
by infectious diseases; of the total number of deaths in 2017, approximately 18.6%
were caused by communicable, maternal, neonatal, and nutritional (CMNN) causes
[1]. Deaths by infectious disease also disproportionately affect low-income countries,
with CMNN conditions causing more than 50% of deaths, compared to less than 7% in
high-income countries [2].
The benefit of seeking to reduce the number of cases of people infected with infectious
diseases, and, for specific infections, striving for elimination of the disease, is primarily
the alleviation of suffering for the individuals inflicted. However, the health problems
of individuals are also an obstacle to economic development[3]. As such, investments
in healthcare can be economically beneficial. Therefore, in order to both limit disease
burden on individuals and to not impair human development, we need an understanding
of the spread of infectious diseases to be able to limit their impact. The potential
outcome of any intervention strategy, in terms of a reduction of case numbers, should be
recognised, along with which strategies are more likely to represent value for money,
if dealing with a limited budget. To gain this level of understanding, we can utilise
mathematical models.
1
Mathematical models can be designed to provide a precise description of a biological
process, and in particular, be used to simulate population-level infection dynamics.
Much of this work is development from the early twentieth century works of Ross [4]
and Kermack & McKendrick [5]. These models can be used for both predicting future
infection and for developing understanding of processes such as invasion dynamics or
the effects of interventions. Good mathematical models should provide robust insights,
either showing quantitative results or qualitative behaviour depending on their purpose.
The mechanisms within models should be clear, such that they provide intuition of
the processes involved, as well as the models being flexible, so they can be adapted to
multiple scenarios [6].
Mathematical models also need to be well-communicated if they are to have the intended
influence on policy decisions [7]. This requires a clear question to be stated that is a
known priority for policymakers, which the model can be used to address. To increase
the impact of mathematical modelling, the NTD Modelling Consortium has recently
released a systematic review that identifies five key principles for communication with
stakeholders [8]. These principles consist of: stakeholder engagement, complete model
documentation, complete description of data used, communicating uncertainty, and
testable model outcomes. Additionally, it is noted that models can have more impact
when accompanied by an interactive interface that allows policymakers and stakeholders
to change some initial assumptions of the modelling to suit their expert opinions. There
are examples of work that does this, although some challenges remain [9, 10].
In this thesis, I use mathematical modelling with a focus on a specific infectious disease
— gambiense human African trypanosomiasis (gHAT). gHAT is caused by the parasite
Trypanosoma brucei gambiense and transmitted by an insect vector, the tsetse. Our
mathematical modelling aims to extend the current literature, with a focus understanding
the dynamics of gHAT infection and the potential effects of interventions at the village-
scale, with a broader focus on the elimination of this disease, in line with targets set by
the World Health Organization (WHO) [11].
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1.2 Thesis structure
This thesis is divided into six chapters, including this introduction, which cover the
research I have conducted throughout my PhD.
Chapter 2 provides a background to all the work, giving an overview of the biology of
gambiense human African trypanosomiasis (gHAT), the historical context and current
status of the infection, along with the existing modelling literature, both briefly of
mathematical epidemiology in general, and of work specifically done for gHAT.
Chapter 3 considers the implementation of a mathematical model for gHAT infection on
the scale of single village populations in a region of the Democratic Republic of Congo
(DRC). This work investigates the long term persistence of the infection and assesses the
risks of recrudescence within a village after the infection has been locally eliminated.
I also explore how the probability of elimination of transmission is informed by the
absence of detection of cases when village populations are screened for gHAT.
Chapter 4 uses the village-scale model, re-parameterised for a different region, to anal-
yse the implementation of different strategies for screening and treatment interventions.
By evaluating this model with the addition of costs, I am also able to examine the
intervention strategies that maximise monetary benefits and to determine the cost-
effectiveness of these strategies.
Chapter 5 explores the effects of simplifying our model structure to use a master
equation implementation for predicting infection dynamics. Using this approach, I
consider the interactions between different villages, and scale up the village-level model
to make predictions at a health zone level.
Finally, chapter 6 summarises and contrasts the differing modelling approaches used
throughout and provides a discussion and of the whole thesis.
1.2 Thesis structure 3
2
Background
In this chapter, we give an overview of the disease human African trypanosomiasis (HAT)
and discuss its current status along with the efforts to reduce levels of infection, where
the ultimate goal is disease eradication. In addition, we review the modelling literature
for HAT, both in terms of the types of models and methods used for such vector-borne
diseases and implications of these models. For more details on HAT, a selection of recent
reviews from a range of viewpoints include Büscher et al. [12], Aksoy et al. [13] and
Rock et al. [14].
2.1 The biology of human African
trypanosomiasis
To understand the results of modelling human African trypanosomiasis, we first consider
the cause of the disease, its transmission, and how it presents itself in terms of clinical
signs and symptoms.
2.1.1 A fatal disease
Human African trypanosomiasis (HAT), commonly known as sleeping sickness, is a
vector-borne disease affecting human populations in sub-Saharan Africa. It is caused by
parasitic protists of the species Trypanosoma brucei, of which there are two subspecies
that can infect humans: gambiense and rhodesiense. Both types of the parasite are
typically transmitted to humans by infected tsetse (genus Glossina), a large biting fly that
inhabits affected regions. The diseases caused by these infections are almost invariably
4
Fig 2.1: Map of the historically 36 HAT-endemic countries. 24 countries are gHAT endemic
and 13 are rHAT endemic, including Uganda, which is endemic with both.
fatal without treatment [15]; in the last 100 years HAT has killed millions of people
[12].
HAT is historically endemic in 36 countries of sub-Saharan Africa, with most gambiense
human African trypanosomiasis (gHAT) cases occurring in West and Central Africa
and most rhodesiense human African trypanosomiasis (rHAT) cases occurring in East
Africa (see Figure 2.1); 24 of these counties are endemic with gHAT and 13 with rHAT
[16]. The disease distribution across these countries is highly focal [12, 17], where we
define a focus of infection as a place containing the epidemiological factors needed for
transmission of an infection. This heterogeneous clustering of incidence across space
is predominantly attributed to the habitat of the vector (tsetse), but is notable since
disease prevalence can vary greatly over short distances and even between neighbouring
villages [18]. Outside of the 36 endemic countries, a small number of cases have also
been diagnosed, mainly due to travellers and migrants from these countries [19].
Gambiense HAT is the more widespread of the two diseases, causing 98% of all reported
infections in the last 10 years of data (2009–2018) [20]; the Democratic Republic of the
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Congo (DRC) is the country with the highest proportion of gHAT cases with 82% in this
period [20]. And for much of this thesis, we will focus on gHAT in the DRC.
However, we note that trypanosomiasis is neither exclusive to Africa nor humans. Chagas
disease (sometimes known as American trypanosomiasis) is an infectious disease of
humans caused by Trypanosoma cruzi, while animal trypanosomiasis affects wild and
domestic animals across Africa. Indeed, animals can be infected by both the gambiense
and the rhodesiense forms of the trypanosome and can act as a reservoir to infection
[21–23].
2.1.2 Introduction to Trypanosoma brucei
Trypanosoma brucei is a species of parasitic kinetoplastid that can cause forms of try-
panosomiasis. Kinetoplastids are flagellated protists (eukaryotic organisms that are not
animal, plant or fungus) with a kinetoplast (a dense mass of DNA within the large mito-
chondrion) [24]. T. brucei are unicellular and between 3 and 30 µm long, depending on
life cycle stage, formed in a streamlined tapered shape [25]. Within the cell membrane
of T. brucei, there are organelles including the nucleus, mitochondria, endoplasmic
reticulum, Golgi apparatus, ribosomes and kinetoplast.
The parasite is grouped into three subspecies: the previously mentioned T. b. gambiense
and T. b. rhodesiense, both of which can cause human African trypanosomiasis (HAT),
and T. b. brucei, which only rarely infects humans [26]. T. b. gambiense and T.
b. rhodesiense are able to infect humans because they are able to express proteins
resistant to the trypanolytic factors of a human’s innate immune system response
[27]. These trypanolytic factors are serum complexes (TLF-1 and TLF-2) that contain
apolipoprotein L1 (ApoL1) and haptoglobin related protein (HPR) that can cause lysis
in other trypanosome subspecies [28, 29]. Trypanolytic factors are found in relatively
few species, such as humans, gorillas, mandrills, baboons and sooty mangabeys [30],
hence T. b. brucei is able to infect many other animals, and so all three forms (and other
forms, such as T. vivax and T. congolense) can cause animal trypanosomiasis [31].
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Trypanosoma brucei have different classes of cellular organisation, or morphological
forms, which are presented in different parts of their life cycle. When Trypanosoma
brucei is in a mammalian host, it is a trypomastigote, an elongated cell, circulating in
the blood. The kinetoplast is posterior of the nucleus and the flagellum arises from the
posterior end. When Trypanosoma brucei is in the tsetse, it becomes a epimastigote, with
its kinetoplast anterior to the nucleus and a long flagellum that starts at the centre of
the body is attached to the cell body [32].
2.1.3 The vector — tsetse
Tsetse are large biting flies that live by feeding on the blood of vertebrate animals.
They can carry Trypanosoma brucei and hence act as a facilitator for the transmission of
trypanosomiasis to humans and other animals. There are about 31 different species of
tsetse, which are part of the genus Glossina, and grouped as either ‘savannah’, ‘forest’, or
‘riverine’ flies [33]. T. b. gambiense is typically transmitted by ‘riverine’ tsetse, particularly
the subspecies of Glossina fuscipes and Glossina palpalis, which inhabit the vegetation
around the rivers and lakes in West and Central Africa [34]. On the other hand, T. b.
rhodesiense are transmitted by ‘savannah’ tsetse, particularly Glossina morsitans and
Glossina pallidipes, which occupy the woodlands of East Africa [35].
Adult tsetse are large for flies, approximately 8–17 mm. They have large heads, separated
eyes and a long proboscis extending forward from a bulb attached to the bottom of the
head [36]. The thorax is large and the abdomen wide, shorter than the wings, which
can fold completely to cover the top of the abdomen, distinguishing them from other fly
species [37]. These properties mean tsetse are easier to analyse in a laboratory setting
than other smaller flies [38–40].
Tsetse are also an unusual fly species due to their life cycle. The flies reproduce by
adenotrophic viviparity [41], whereby a female fly fertilises only one egg at a time, from
the age of about 6 days old, which remains and matures in the uterus for 7–12 days
during the first three larval stages [42]. In the third larval stage, the larva is deposited
by the female on loose soil and crawls into the ground to develop a hard outer shell
called the puparial case [43]. During this time, which lasts approximately 20–40 days,
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the morphological transformation into an adult fly occurs. This change occurs without
feeding and so the larva relies on the nutritional resources provided by the parent tsetse
while in its uterus. The intensive nature of this process means that the tsetse rate of
reproduction is very low [44]. Males can inseminate a female fly every 2–3 days [45].
The life expectancy of a female adult tsetse is only 20–40 days, while a male is 14–21
days [46]; although in a laboratory tsetse have been known to live for up to 120 days.
To ensure that a female fly produces two adult progeny and sustain the tsetse population,
the female fly needs to live for at least 25 days. Thus, it is expected that the mean
adult daily mortality needs to be less than 3.5% for tsetse populations to persist [44].
In addition, predation, parasites and extreme temperatures can induce mortality in the
pupal stage [47].
Tsetse typically feed every 2–5 days [48] and these blood-meals satisfy all the tsetse’s
requirements. Hosts therefore need to be found frequently in order to avoid starvation,
which many flies will die from. Tsetse may also die by attempting to feed on high-risk
hosts, such as humans, that kill them [49]. Tsetse populations can continue to exist at
densities as low as 1 tsetse per square kilometre [50], while densities are rarely seen
higher than 10,000 per square kilometre [51]. Tsetse are also highly mobile, known to
travel up to 1 kilometre per day [52].
2.1.4 The life cycle of Trypanosoma brucei
The life cycle of Trypanosoma brucei is split between the tsetse and a mammalian host
(humans, domestic animals, livestock, or wild animals). When an infected tsetse takes a
blood-meal on a host, the fly will inject metacyclic trypomastigotes into the skin tissue,
which then enter the lymphatic system and the bloodstream [53]. While initially short
and stumpy, the trypomastigotes will become long and slender and multiply. Daughter
cells will be short and stumpy. The long slender forms are able to spread to various
organs and tissues, eventually the central nervous system and brain [54]. The latent
period between inoculation and becoming infectious is typically 7–14 days [55]. In some
animals this process will not see the exhibition of severe adverse effects, yet the parasite
can still be transmitted onwards. Thus, the animals act as a reservoir of infection.
Animals that are able to maintain chronic infections, however, will predominantly have
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lower parasitaemia and so be less infectious [38]. This trypanotolerance may also occur
in some humans, who never show symptoms and may even self-cure, even after 5–15
years [15].
In order to evade a host’s immune system, the surface of Trypanosoma brucei is coated
in variant surface glycoprotein (VSG) [56]. A specific VSG coat will provoke a particular
immune response to attempt to kill the trypanosome, but on a cell division it is possible
that progeny will switch the VSG that is expressed and so a population of trypanosomes
in a host can have very diverse VSG coats. It is estimated that between 10−6 and
10−3 coat switches occur per doubling of the trypanosome population [57]. Host
immunity to specific VSG coats take time to develop and to infections can be prolonged
as trypanosomes multiply and this process can cause waves of trypanosomes in the blood
[12].
When a mammal has successfully been infected with trypanosomes, and a susceptible
tsetse takes a blood-meal on this mammal, there is a chance that the short and stumpy
trypomastigotes are consumed by the fly. These enter the midgut of the fly and become
procyclic trypomastigotes before dividing to become epimastigotes [58]. These travel to
the salivary glands, where they become attached to the salivary gland epithelium [59].
Some will transform back into short and stumpy trypomastigotes that can be injected
back into another mammal upon biting for further transmission. Trypanosomes in tsetse
do negatively affect the salivary gland function, but the overall impact is limited; and
once infected, tsetse stay infected for life [60].
Tsetse also have immune defences to resist infection, such as the production of hydrogen
peroxide, which damages DNA, and are in fact relatively resistant to Trypanosoma brucei
[61]. In addition, the probability of a tsetse will become infected will depend on the age,
sex and species of fly. In particular, tsetse susceptibility will be affected by the teneral
effect, whereby tsetse that have not yet consumed their first blood-meal will be more
susceptible to infection than older flies [62, 63].
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Other than tsetse bites, Trypanosoma brucei can be transmitted congenitally [64, 65],
sexually [66], by blood transfusion or organ transplantation [67], and by laboratory
accident [68]. However, all these forms of transmission are considered rare.
2.1.5 Clinical signs and symptoms of human African
trypanosomiasis
Upon infection, there are two distinct stages of human African trypanosomiasis (HAT)
[69]. Initially, a person with HAT will experience a fever, headaches, joint pain and
itching. This is Stage 1 (or the haemolymphatic stage [70]). In this stage, the fever
is intermittent, lasting between a day and a week, with intervals of days or months
in between. Trypanosomes invading the circulatory and lymphatic systems can cause
swelling of lymph nodes. A red sore may also develop around the initial tsetse bite,
which is more common in the rhodesiense form of the disease [71]. Other symptoms
such as anemia, endocrine, cardiac and kidney dysfunctions can occur.
Stage 2 of HAT is characterised by when the parasite has crossed the blood–brain barrier
and so invaded the central nervous system [70]. This is the neurological stage. While
fever is less common, the leading symptom is disruption of the sleep cycle. The infected
human will suffer drowsiness in the daytime and urges to sleep, coupled with nocturnal
insomnia [72]. Short, frequent periods of rapid eye movement sleep can also occur
preceded by wakefulness, which are equally likely to occur in the day or night [73, 74].
These effects on the sleep cycling is where HAT gets its colloquial name of ‘sleeping
sickness.’ Additional symptoms in Stage 2 include confusion, aggressive behaviour
and weakness or paralysis of limbs. The disruption of circadian rhythms also affects
hormonal secretion [75]. The neurological phase can cause irreversible damage, with the
neurological and psychiatric symptoms increasing significantly with disease progression
and will ultimately result in death for the vast majority of those infected and not treated,
typically from meningoencephalitis [76].
Gambiense HAT and rhodesiense HAT demonstrate different timescales and intensities
of these symptoms. Gambiense HAT is a chronic condition, where symptoms do not
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always present themselves immediately. The untreated duration of infection before
death is approximately 3 years, split roughly equally between Stage 1 and Stage 2 [77].
Conversely, in rhodesiense HAT symptoms can emerge within weeks, followed by death in
a period of months; this form of the disease is both faster to develop and more virulent
[78].
2.2 A brief history of human African
trypanosomiasis
Trypanosomes have been transmitted between animals and tsetse, since the emergence
of tsetse about 35,000,000 years ago [79]. This long coexistence explains why many
wild animal species are unaffected by the infection, since they have evolved to become
trypanotolerant [80]. Indeed, the fact humans are resistant to trypanosomes, other than
T. b. gambiense and T. b. rhodesiense, suggests that trypanosomes have long infected
humans, although human African trypanosomiasis (HAT) is a more recent development.
Sustained transmission of T. b. gambiense between tsetse and humans has led to the
parasite being less virulent, while in contrast, T. b. rhodesiense, which is mainly zoonotic
with few human infections, remains more virulent [80, 81].
2.2.1 Discovery and early history
While there is some evidence that animal African trypanosomiasis (AAT) was reported
in 2000 BC in ancient Egypt [82], some of the first written accounts of human African
trypanosomiasis (HAT) came from ship doctors and medical officers working for slave-
trade companies. The first accurate medical report of HAT was published in 1734 [83],
however this focused on the more pronounced Stage 2 symptoms and it was not until
1803 that work was published on Stage 1 of the disease [83].
In 1852, it was first noticed by the explorer David Livingston that cattle died from AAT
after being bitten by tsetse, hence establishing the link between the disease and the
flies [84]. Yet, the cause of trypanosomiasis, the trypanosome was not known until
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microbiologist David Bruce identified that T. brucei resulted in AAT in cattle in 1895 [85].
Several discoveries about trypanosomiasis quickly followed this, when surgeon Robert
Michael Forde observed trypanosomes in human blood in Gambia in 1901 [86], which
were identified as trypanosomes in 1902 by physician Joseph Everett Dutton and given
the name Trypanosoma gambiense, now T. b. gambiense [87]. Pathologist Aldo Castellani
was the first to suggest that trypanosomes were the cause of HAT, when, in 1902, he
observed them in the cerebrospinal fluid of patients [88]. In 1902, Émile Brumpt made
the first link between tsetse and HAT when he noticed the geographic distribution of
the flies and the disease was the same [84]. Building upon this in 1903, David Bruce
suggested that trypanosomes were actually transmitted by tsetse [79], and in 1909,
Fredrich Karl Kleine, proved the cyclical transmission from tsetse [89], which prompted
Bruce to describe the full life cycle of trypanosomes between tsetse and animal host
[83]. T. b. rhodesiense was only identified as a different human pathogenic species of
trypanosoma in 1910 [90].
2.2.2 Infection in the twentieth century
In the nineteenth century, there were a relatively small number of human African
trypanosomiasis (HAT) cases [84]. This changed at the end of the century, with the
invasion of European explorers, missionaries and soldiers. In particular, large numbers
of Belgian colonial personnel travelled to the present day Democratic Republic of the
Congo (DRC), such that King Leopold II of Belgium was allowed to formally acquire the
rights to the Congo territory in 1885, which became known as the Congo Free State
[91].
The colonial expansion caused movement of people into new territories. The imposition
of taxes, in particular, pushed people to expand crop farming into new tsetse-infested
lands. Colonial personnel with no knowledge of the dangers of tsetse, also forced the
establishment of new villages in many high-risk locations for HAT and continued to
explore these areas with the construction of roads and railways. The increased transport
links and movement, combined with forced labour, introducing further interactions
of people both with each other and tsetse flies, increased the probability of disease
transmission dramatically. This was further exacerbated by severe droughts driving
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both people and tsetse to converge of water sources, and a panzootic of rinderpest
killing much livestock and wildlife, forcing tsetse to feed more frequently upon a more
dangerous food source — humans [84].
These factors led to a severe epidemic of HAT in 1896–1906, which caused an estimated
800,000 deaths across the Congo basin and Uganda [92]. In total, it was thought up to
half the population living along the lower river Congo died of either HAT or smallpox
in this time [93]. These deaths forced the colonial administrations to invest in medical
research into HAT.
In 1905, the first drugs discovered to be effective in treating HAT were found. These
were organic arsenicals called atoxyl, which had mixed success, since while trypanocidal
and effective in reducing parasitaemia, they were less beneficial for patients in Stage
2 of the disease and were also relatively toxic themselves [79]. By 1919, a less toxic
and more effective compound called tryparsamide was discovered, which was also able
to treat Stage 2 and was particularly effective in combination with another drug called
suramin. These drugs helped to treat the disease and also to reduce case numbers when
a second HAT epidemic for the twentieth century occurred in 1920–1945 [79].
One of the biggest events in the pursuit of reducing HAT cases was the development of
systematic case detection and treatment. This simple principle was devised by Eugène
Jamot in the 1920s and was based on for the idea that for elimination of the parasite,
cases detection and treatment should be carried out by mobile teams that should cover
the highest possible percentage of the population at risk of HAT using only specifically
trained people with autonomy from other HAT services. In Cameroon, the special
services implemented by Jamot lead to a reduction in HAT prevalence from 60% in 1919
to 0.2–4.1% in 1930 [94]. This encouraged other colonial powers to introduce these
methods for HAT control.
In addition to systematic case detection, systematic vector control was also introduced
from as early as 1911. This was performed with tsetse traps and carrying cloths
coated in the sticky substance, birdlime, as well as the culling of animals to reduce the
potential reservoir of animals that could carry the disease [84]. Later, post-World War II,
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Fig 2.2: Cases and number of people screened for human African trypanosomiasis reported
to the World Health Organization between 1939 and 1998. Data taken from a
WHO report [95].
insecticide spraying was also used. These activities had some success in reducing the
tsetse population. Hence, helped by other HAT control activities, the transmission of
HAT reduced, resulting in a steady reduction of reported HAT cases after the end of the
second HAT epidemic, which ended in the 1940s (Figure 2.2).
While in the nineteenth and early twentieth centuries, colonialism had caused much
disruption and displacement of people and in many cases inducing famine, which meant
a rise in HAT cases, by the 1960s there had been progress in both medical practices,
disease control and general hygiene such that HAT case numbers were low and no longer
considered a priority. When endemic countries became independent (the current DRC
became independent and was no longer given the name Belgian Congo in 1960), the
lack of funding for health services and political instability meant that case detection
programmes were dramatically scaled back. The screened populations returned to the
previous very low numbers (Figure 2.2). In 1991, the Belgian government withdrew all
bilateral aid for the DRC, which included support for the national control programme
(Programme National de Lutte contre la Trypanosomiase Humaine Africaine, PNLTHA),
as part of sanctions against the President of the DRC, Mobutu Sese Seko [96].
Thus, with the lack of control, HAT started to have a resurgence from around 1970,
and particularly after 1991, with the third epidemic of the twentieth century declared
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Fig 2.3: Cases of gambiense human African trypanosomiasis (gHAT) reported to the World
Health Organization between 1998 and 2018. Data taken from WHO’s Global
Health Observatory data repository [20].
.
from 1970 until the late 1990s. By just before the turn of the century, case numbers had
returned to levels not seen since the 1940s (Figure 2.2).
2.2.3 Recent history
While the number of annual reported HAT cases has varied dramatically in the last
century as a consequence of different levels of investment in control [95] (Figure 2.2),
by end of the 1990s, it was clear that HAT cases would not return to the lows of
the early 1960s unless control programmes were reintroduced. In 1997, 29 mobile
teams resumed screening for HAT in the villages of the DRC [97]. Thus, HAT again
became a priority with coordination between the World Health Organization, national
HAT control programmes, funding agencies, industrial partners, and non-governmental
organisations [13]. This has improved the support of control activities within HAT-
endemic countries with better surveillance and access to diagnostic tools and treatments
[12]. This reinvestment, coupled with advancements in diagnostics and drugs to treat
the infection, as well as plausible elimination strategies, has led to a steep decline in
gHAT cases (Figure 2.3).
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2.3 Current status and eradication efforts
The current drive for a reduction in human African trypanosomiasis (HAT) cases stems
from the epidemic at the end of the twentieth century, when there were approximately
38,000 reported cases of HAT in 1998 and a further 300,000 estimated to be additionally
unreported and hence untreated [98]. This initial reinvestment was largely funded by
the resumption of Belgian bilateral cooperation [96].
With new case numbers for gambiense HAT (gHAT) now reported as below 1,000,
eventual elimination of the diseases appears to be more of a possibility than ever [99]
(Figure 2.3).
2.3.1 Current status
Annual newly reported gHAT cases have been steadily falling since 1998, in large
part due to the case detection and treatment systems implemented by national HAT
control programmes (PNLTHAs, Programme National de Lutte contre la Trypanosomiase
Humaine Africaine) with support from the World Health Organization (WHO), among
other stakeholders (Figure 2.3). Due to this initial success, the WHO set goals such that
this progress could be sustained, building towards the ultimate goal of eradication.
The Neglected Tropical Diseases (NTD) Roadmap, published in 2012, identified HAT as a
candidate for elimination as a public health problem [100]. The was formalised as a goal
in 2013, with the elimination definition, comprising of two global indicators, updated in
2017 to: (i) fewer than 2,000 reported cases per year, and (ii) reducing the area at risk
of reporting more than 1 case per 10,000 people per year by 90% as compared to the
baseline for 2000–2004. The Roadmap is due to be updated in 2020 and is proposed to
include the goal of zero reported gHAT cases by 2030 [11, 16, 101].
The first indicator for elimination as a public health problem is very likely to be met by
2020, since it is currently being achieved, with 977 cases reported to WHO (of which
953 were gHAT) in 2018, well below the target of 2,000 [20]. The second indicator is
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more challenging to assess; in 2014–2018, 195,000 km2 of land was estimated to be at
moderate risk or higher of HAT, a reduction of 72% compared to the baseline 790,000
km2 from 2000–2004 [99]. Therefore, the 90% reduction was not met by 2018, but the
progress is encouraging, with a continued decline in the at-risk area; the size of this area
was close to the milestone aim of 151,000 km2 for 2014–2018 [100]. It is expected that
these downward trends are indeed reflecting a real decline in transmission, rather than
simply under-reporting, since the number of health facilities providing HAT surveillance,
diagnosis and treatment is increasing [102].
There is less evidence that the 2030 elimination of gHAT transmission target [101] will
be met, but it remains an important aspirational goal to ensure that progress is sustained
and that the previous mistakes of early cessation of HAT programmes are not repeated
in the twenty-first century [103].
2.3.2 Interventions
To attain the targets set by WHO and break the transmission cycle, HAT interventions
need to be applied effectively at all levels, with an understanding of the geography, the
community and field workers, the technology, and the governance [104]. However, to be
able to implement intervention strategies successfully, there also needs to be adequate
surveillance; this allows both for long-term disease monitoring and early identification
of outbreaks [105]. HAT surveillance is recorded as screening and incidence data by the
WHO in the Atlas of Human African Trypanosomiasis [106, 107]. This is a systematic
approach of collating the number of new cases in villages across the endemic areas in
each year, as well as the number of people screened for HAT and a census estimate.
This data allows for the production of disease-risk maps, monitoring, planning of future
surveillance and data for modelling and making future predictions [108].
Active screening
Since there is no vaccine or chemoprophylaxis for HAT [109], case control for gHAT is
primarily through direct case detection by mass screening, followed by confirmation and
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treatment [110]. This has widely been considered to be the most effective method of
control, even since the early twentieth century [111–113].
Active screening is implemented by the operations of small mobile teams including
microscopists, secretaries, drivers, messengers, guards, and health workers, who travel
directly to villages in the HAT-endemic areas in four-wheel drive vehicles (or boats) and
aim to test full populations for the infection through mass screening [97]. The region a
mobile team can cover may include a population of up to 800,000, and teams typically
travel for twenty days each month to conduct active screening, staying for multiple days
in some large villages to ensure the available population is screened [97]. The choice
of villages visited is dependent on the history of screening and cases in the village and
area, the cases from nearby health centres, and local information [97]. Other predictive
methods to identify at-risk villages are being devised [114].
For active screening programmes to be effective, a high screening coverage is important
in all villages to ensure the detection and treatment of those infected and prevent onward
transmission. This requires a detailed knowledge of the area with notification ahead of
an active screening, to ensure that the village is ready for the maximum possible number
of people willing and available to be screened. It should not be on an inconvenient day,
such as when there is a market [115]. Furthermore, there also needs to be low drug
toxicity, low cost to the patients and some level of privacy to achieve high attendances
and treatment uptakes [113, 116, 117].
There is limited evidence for how frequently these active screenings should occur and
when they should stop if no cases are found. Van Nieuwenhove [118] recommends three
repeated screening rounds with one year intervals, while Simarro et al. [119] used six
month intervals. The current WHO recommendation is for yearly screening with three
years of zero case reporting before stopping active screening in the village [110]. There
have been many calls for the need to maintain active screening, even when no cases are
observed [120, 121], particularly given the feedback between surveillance and control
[122].
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In low-prevalence settings, due to consistent under-representation of certain demo-
graphics [117], targeted door-to-door screening can be more cost-effective and less
labour-intensive if there is knowledge of suspected cases, alongside the availability of
diagnostic tests and treatments for individuals suffering symptoms. Indeed, door-to-door
screening has been found to detect significantly more HAT cases than standard active
screening [123]. In locations where the terrain is difficult to traverse, active screening is
also carried out by light mobile teams using motorbikes [124].
Passive detection
To better detect cases, there needs to be additional support for those that are not
reached by active screening. As such, passive surveillance provides fixed health centres
with the capacity and tools required to test and treat for HAT [125]. This is crucial
in areas with low transmission intensity that will not be targeted in active screening
[126], which will become more common as total case numbers fall [13]. It also ensures
that individuals who miss active screening events or receive a false negative result in
previous active screening, can still access diagnosis and treatment. These facilities need
to be suitably equipped, such that infections are recognised promptly [127, 128]. Since
passive surveillance relies on individuals to self-present to these health centres, a high
proportion of them will be in the late stage of the disease, with significant symptoms
[129]. The ability to access facilities where HAT can be rapidly diagnosed shortens the
time between infection and treatment, reducing potential transmission opportunities.
Indeed modelling has suggested there is great potential in improving rates of passive
case detection [130].
Vector control
Since gHAT is largely considered an anthroponosis, control has heavily relied on active
and passive surveillance, directly treating humans, rather than considering the tsetse
[13]. However, if vector control can reduce the number of tsetse, there will be fewer
flies able to become infected, and hence a reduction in HAT transmission [131]. Vector
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control is frequently a staple component of other vector-borne disease intervention
strategies, such as malaria and dengue, due to its potential to avert transmission [132,
133].
Tsetse control can be implemented by traps, targets, insecticide-treated cattle, aerial
spraying, or sterile insect release [134]. One current strategy showing considerable
potential is the use of ‘tiny targets’ [109]. These are small blue squares of cloth attached
to a square of mesh impregnated with the insecticide, deltamethrin. They are attached to
a frame and either planted in the ground or hung from vegetation. Tsetse are attracted
to the blue colour, circle the cloth and come into contact with the insecticide, resulting
in their death [135–139]. These targets are both highly effective and easier to deploy
than traditional devices [131] in settings where livestock density is low. In regions with
higher cattle ownership, restricted application of insecticides can also be a cost-effective
approach to reduce tsetse populations [140].
The two main drawbacks of vector control until recently, were the expense [109]
and the associated logistics of repeatedly deploying multiple controls. However, with
developments in insecticide-treated targets and traps [109, 137, 141], tsetse control
can now be considered more cost-effective [142]. The smaller size of the targets has
helped reduce costs, while remaining effective [109]. Furthermore, tsetse control is
species-specific to tsetse and does not negatively impact the environment, since tsetse are
not a key species in the food chain. Therefore, it can be considered ethically defensible,
as human deaths are averted [143]; the objective is for local reduction of tsetse in HAT
foci to interrupt transmission, rather than global eradication of the fly [144].
‘Tiny targets’ have been introduced in several HAT foci, such as Guinea, Uganda and Chad
where reductions in the tsetse population of 80% in 18 months [145], 90% in 12 months
[144], and 99% in 4 months [146] have been observed respectively. Furthermore, no
gHAT cases have been found in areas where ‘tiny targets’ were deployed in North West
Uganda [147]. When challenges are presented to health services, tsetse control is often
easier to maintain than traditional medical interventions. For example, when active
screening was postponed in Guinea due to the 2014–2016 Ebola outbreak, a rise in
gHAT prevalence was observed; however, in the area where tsetse control had been
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implemented, no cases were found [148]. Vector control is also now part of HAT control
strategy in some high-burden areas in the DRC, the country with the highest HAT burden
[20, 149].
2.3.3 Diagnostics
Medical treatment of HAT patients can cure them of the infection and so prevent
suffering and potential death, however, early detection of the infection will also reduce
the duration a person is infectious and able to transmit the infection to biting tsetse.
Therefore, accurate diagnostic tools are essential to identify early stages of the infection
and both prevent the severe symptoms for the individual and reduce further transmission
to the population. Different diagnostics are available as field-applicable and laboratory-
bound tests.
The most commonly used and reliable test for gHAT infection in the field is the card
agglutination test for trypanosomiasis (CATT) [150]. This is a serological test developed
in the 1970s, which uses blood collected from a finger prick, plasma, or serum [151].
The test is most suited to be carried out by mobile teams in active screening since it is
relatively quick, inexpensive and reliable. However, the test does require an electricity
supply, a cold chain and trained personnel [152]. A positive CATT test requires additional
parasitological validation to visibly detect the presence of parasites by microscopy for
HAT confirmation [153].
More recently, rapid diagnostic tests (RDTs) have been available to screen for gHAT.
These tests have an important role in the fixed passive detection health centres, since
they do not require electricity and are instrument-free [154]. This means rural hospitals,
that are often ill-equipped, can still screen for HAT. Hence, RDTs have been widely
distributed in remote endemic areas [154–156]. While these tests are being developed
to have both high sensitivity and specificity (comparable to CATT) [157–162], in areas
where the infection numbers are low, the number of false positives from RDTs can far
outweigh the number of true positives, resulting in a very low positive predictive value
[12, 163]. Cost-effectiveness analysis has suggested RDTs could be more cost-effective
than CATT in both mobile and fixed health facilities [154].
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For laboratory-bound tests, the trypanolysis test is a confirmatory test with extremely
high specificity, such that positives from other tests can be verified and thus the patients
treated. However, this test is expensive to perform and can only be done in selected
laboratories in Europe and Africa [110]. Notwithstanding this, the trypanolysis test
is particularly useful in the context of elimination since its high specificity means it
can be used as a surveillance tool to identify areas which are disease-free [164, 165].
Enzyme-linked immunosorbent assays (ELISAs) can also be used as confirmatory tests
with high specificity, but are time-consuming, expensive and need to be performed in
large batches [166]. Molecular tests have also been developed to detect T. b. gambiense
[167] and exhibit high sensitivities and specificities. The fact these tests are not directly
applicable in the field yet, however, means the direct benefit remains limited [155,
168].
Rhodesiense HAT currently has no field-applicable serodiagnostic test [12], however
the more obvious symptoms and high levels of parasitaemia make this less crucial for
detection of the infection [110].
2.3.4 Treatments
Classically, because of the very different severity of symptoms and location of try-
panosomes in the two stages of HAT, treatments are generally stage specific [169]. The
earlier HAT is treated, the better prospects for the patient; drugs for Stage 1 will not
cure a patient in Stage 2, and drugs for Stage 2 are unnecessarily toxic for patients in
Stage 1. Hence staging is traditionally an important first step in determining whether
the parasite has passed the blood–brain barrier into the central nervous system. This
relies on a lumbar puncture to collect cerebrospinal fluid for the counting of white blood
cells and to ascertain whether trypanosomes are present [170].
Until recently, the drugs used to treat Stage 1 infection were pentamidine or suramin
[171]. Pentamidine has a high efficacy in treating gHAT and is administered intramuscu-
larly for seven days, with generally minimal ill-effects [12]. Suramin is effective too, but
is only used for rHAT as the slow intravenous infusion is more difficult to manage and
the side-effects more frequent [12].
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For Stage 2, the first-line treatment is nifurtimox–eflornithine combination therapy
(NECT) (nifurtimox is delivered orally and eflornithine delivered intravenously) [172,
173]. This is an aggressive treatment with common side-effects including abdominal
pain, vomiting and headaches, but a high probability of a successful treatment [12].
The alternative, melarsoprol, is now restricted to Stage 2 rHAT, due to the frequency of
life-threatening reactions it can induce [174].
All five of the drugs are donated by manufacturers to WHO, who is able to freely
distribute them across HAT-endemic countries [12].
In addition to these drugs, fexinidazole [175], an oral drug that is taken for ten days, was
recently included in WHO guidelines for gHAT treatment [176] and approved for use in
the DRC in December 2018 [177]. This drug is effective in treating both stages of gHAT,
when the symptoms are not overly severe [178]; so eliminating the need for a painful
lumbar puncture to determine the infection stage, and simplifying the treatment process
whilst improving access to care [149, 177]. However, it is notable that a lack of stage
determination provides less information for subsequent surveillance and can reduce the
accuracy of recommendations from predictive models [179]. Fexinidazole appears less
effective than NECT in treating late Stage 2 patients however [176], and the effect on
parasites in the skin is still unknown [180]. The safety profile of fexinidazole is not
sufficient to consider treatment without parasite confirmation as part of the diagnostic
algorithm.
Another drug, acoziborole [181] is currently being trialled as a one-day, one-dose oral
treatment for all gHAT patients. This could potentially revolutionise treatment due to
the ease with which it would be delivered and has the potential to be administered to
all at-risk populations based on RDT results, or even given to all high-risk individuals if
suitable safety standards are met [180].
2.3.5 Considering elimination
There are many reasons to be optimistic about the eventual elimination of HAT: the
declining trend in reported cases; the availability of accurate diagnostics; effective drugs
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that are freely donated; new diagnostics and drugs being developed; and continuing
operations to reduce infection numbers through both active and passive surveillance
and tsetse control. However, as the case numbers decrease to very low levels, there will
be more competition for funding with other diseases [182, 183] and activities will have
to continue to avoid resurgence [13]. In addition, other factors may emerge that were
undetectable at high prevalences but could pose problems for elimination and eventual
eradication:
Firstly, all figures for HAT infections are based on reported case numbers and it is
expected that the true number infected will be much higher. For rHAT in particular, with
very low case numbers, there has been a decrease in HAT-skilled staff, causing a decrease
in awareness and hence reporting as a consequence [102]. There is also an issue with
systematic non-participation in screening for gHAT, where sections of the population are
likely to avoid being screened [117]. Data on the age and gender of screened participants
could be used to determine which groups are not attending screening, although this
is not routinely collated in an electronic format. Anecdotal evidence suggests working
age individuals are the least likely to participate, as they may be away from the village
working when active screening teams visit. From the perspective of elimination, this
is particularly troubling since this group is also more likely to be working in the tsetse
habitat, close to the vegetation surrounding rivers. Hence, there could be a high-risk
(core) group for infection never being tested. If screening stops in areas where there
are no identified cases, transmission could be sustained by such a core maintenance
population, which could reinfect those who have partaken in active screening [184,
185].
Without active surveillance that can reach high proportions of the at-risk populations,
there is also the danger that gHAT could sustain itself in low numbers due to a possible
asymptomatic reservoir of humans [186]. It has been observed that some individuals
infected with gHAT do not present symptoms for a long time and so will not seek medical
attention or be detected, as they are unaware of the infection [15]. These individuals
may have the trypanosomes surviving in their skin with no blood parasitaemia, which is
difficult to screen for in large numbers [180]. However, the parasite can still be ingested
by tsetse and so transmitted [184, 187, 188]; modelling has suggested treatment of these
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asymptomatic cases should be considered [189]. Gaps in active screening coverage for
at-risk populations may also hinder elimination programmes [190], with high coverage
needed to be maintained to prevent a decrease in detected cases being due to a decrease
in screening effort [191].
Movement of infected people into disease-free areas should also be considered in
intervention planning, as this can lead to recrudescence [192]. This is especially
important in former-endemic areas, where HAT control is no longer considered a priority
and high influxes of refugees could be an ideal environment for parasite transmission
[193].
Finally, even if the gambiense form of the infection was eliminated from humans, there is
the possibility that the transmission cycle could be preserved through animal reservoirs
[194]. This is certainly the case for rHAT [12], but while T. b. gambiense infection exists
in animals, it remains unclear if animal hosts are able to sustain infection or are likely to
reinfect human populations [195]. Spraying livestock could prevent some transmission
in domestic animals, but pockets of infected wild animals could still pose a problem. The
existence of a T. b. gambiense infected animal on the island of Luba, where there have
been no reported human cases since 1995 [196], also provokes wider questions about
persistence in the absence of human cases and potential reintroduction from the animal
reservoir [184, 197]. To achieve rHAT elimination, there will need to be multisectoral
(One Health) cooperation, with impetus for improved surveillance of infection in both
humans and animals [198].
HAT cases have declined substantially in the twenty first century due to considerable
efforts to eliminate the diseases [20]. Elimination of transmission of gHAT has also been
shown to be cost-effective, with economic benefits greater than the costs [182, 199].
Efforts need to be maintained to sustain the current decline in cases, with continued
investment in diagnostics and treatment, as well as their implementation in active
and passive surveillance, and tsetse control; even recent interruption of interventions
has been known to lead to an increase in cases [200]. For rHAT, there are now only
tens of cases, but completely eliminating transmission could be less achievable due to
substantial zoonotic transmission. Despite over a century of study and data, there still
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remain key unknowns concerning the biology and epidemiology which influence the
likely success of the proposed elimination of these diseases [102, 184].
2.4 Mathematical modelling of human African
trypanosomiasis
Mathematical models are an important part of efforts for HAT elimination and have
been instrumental in identifying the likely effectiveness of different control strategies,
along with providing evidence for the timescales on which elimination could occur, and
answering many other questions, accounting for uncertainties [201]. Mechanistic models
can be attuned to be an accurate representation of reality with expert information used to
inform the implementation, such that the underlying biological processes are considered.
They provide a framework for the spread of infection and help understanding of the
processes involved.
Mathematical models should have some predictive power, with results able to be extrap-
olated to different scenarios and problems; the current process should also be described
as accurately as possible, such that intuition for the process can be attained. As such,
they should also give a solution. In addition, they must be useful in terms of the avail-
able data, such that parameter values should be identifiable in the fitting process or
biologically justifiable. Models can provide conflicting advice on occasion, since the
predictions are entirely dependent on the specific modelling assumptions and inherent
uncertainties. However, they are a useful conceptual tool for how reality might behave
and can be used to simulate scenarios before they are actually applied in real life.
Specific to human African trypanosomiasis, we want to use mathematical models to
gain a greater understanding of the disease and related processes and provide evidence
towards answering many questions the disease poses. These questions can be as simple
as forecasting future prevalence and when we might expect disease elimination to occur
given particular intervention strategies, or the lack of them, but also simulating the
effects of reservoirs of infection (animal or human asymptomatic) as to hypothesise their
biological importance. We could also predict how different diagnostics or treatments
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would impact our objectives, or movement of people or influxes of refugees. Using an
age-structured model, we could uncover which demographics are under-represented
in different parts of the infection and treatment process. Or we could examine why
in different locations HAT seems particularly persistent and so identify key areas for
future interventions. We can also optimise intervention processes to project what ideal
coverages, frequencies and cessation criterions of interventions might be. By considering
economic and health costs, we can also proffer which strategies might be the most
impactful or cost-effective subject to constraints.
Many of these questions have been considered in the pre-existing modelling literature
and these thesis will also attempt to address additional questions.
2.4.1 Modelling infectious diseases
The mathematical modelling literature on infectious diseases is vast and we only provide
a limited summary of some basics here. For more details see works such as Anderson
& May [202], Diekmann & Heesterbeek [203], Keeling & Rohani [6], or Andersson &
Britton [204]. As stated in Chapter 1, much of this work modelling infectious diseases
stems from Ross [4] and Kermack & McKendrick [5] in the early twentieth century and
has typically involved the use of compartmental models.
In a compartmental model, there are a number of distinct states and the number of units
in each state is tracked over time. One of the most common models is the SIR model,
where the number of people in three classes, susceptible (S), infected (I) and recovered
(R), is tracked over time t. In its most simplistic form, we assume there are only two
transitions between these classes: S to I, which describes the transmission of disease,
such that a susceptible person becomes infected, and I to R, whereby an infected person
recovers from the infection. The recovery transition occurs with recovery rate γ, which
is the inverse of the infectious period, the infection transmission is given by the force
of infection λ, the per capita rate at which a susceptible person becomes infected. The
force of infection can be further decomposed to its constituent parts, depending on the
assumption. Either λ = βI/N (frequency dependence) or λ = βI (density dependence),
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where β is the product of the contact rate and the transmission probability, I is the
number of infected (and so infectious) individuals, and N is the total population size.
Frequency dependence assumes the number of contacts is independent of population size,
and more to do with social constraints than the size of a village, town or city. Alternatively,
density dependence assumes the contact rate will increase with population size, as if
there are more people in a small area, they will have more contacts. Typically, frequency
dependence is used for vector-borne pathogens and where there are heterogeneous
contacts, while density dependence is used for plant and animal diseases [6].
Deterministic formulation
These compartmental models were originally formulated as systems of ordinary differen-
tial equations (ODEs), where the equations can be written as:
d
dt










R(t) = γI(t), (2.3)
noting the S(t), I(t) and R(t) ∈ [0, N ] are the numbers of susceptible, infected and
recovered people at time t > 0. Since we do not consider any demographic events and
the population size is constant, N , S(t) + I(t) + R(t) = N for all t > 0 and so we can
reduce the dimensionality of the system by ignoring R(t), which equals N−S(t)−I(t).
This ODE model is deterministic in that there is no randomness in the system and for a
specified initial state, the model will always evolve in time in exactly the same way.
Stochastic formulation
In contrast, in a stochastic model there is randomness and repeated simulation of the
system from the same initial condition will produce entirely different realisations of the
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process, building up an ensemble of different solutions. In the ODE formulation you
also have non-integer numbers of people in each infection class, whereas a stochastic
formulation can be implemented that only deals with integer values. This is useful in
that exact numbers of people are tracked and with the additional benefit that extinction
of the disease can occur, while the number of infecteds in an ODE model can only get
arbitrarily close to zero, but never completely die out.
One method of implementing a stochastic infectious disease SIR model is to use a
continuous time Markov process. This uses a discrete state space for the states S, I and
R, with events occurring at the points of independent Poisson processes. The rates are
defined by the current state of the system and are as follows:
s→ s− 1, i→ i+ 1 at rate βsi/N, (2.4)
i→ i− 1, r → r + 1 at rate γi. (2.5)
This describes the process of a susceptible individual meeting infected individuals at
points of a Poisson process with rate βi/N, and becoming infected for an exponentially
distributed time with mean 1/γ. Like the ODE model for a fixed population, we only
need two dimensions for the system as R(t) = N − S(t)− I(t).
One way of exploring the properties of this Markov chain is to directly simulate the
process. A common method for simulating a stochastic epidemic is the Gillespie al-
gorithm [205]. This algorithm works by firstly specifying the initial conditions of the
system, possible events that can occur, and rates these events happen. Then, to simulate
the epidemic, the time to any event is determined; this is exponentially distributed
with a rate equal to the sum of the rates of all possible events. The event that occurs
is determined by a probability in proportion to the rate this event occurs. These two
steps are then repeated until a maximum time is reached, giving one realisation of the
epidemic. The whole process can then be repeated multiple times to get a distribution
of possible epidemics. For a more formal algorithm, see Algorithm 2.1.
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Algorithm 2.1: The Gillespie algorithm.
Specify model run time Tmax;
Set initial conditions t = t0 and x(t0) = x0;
while t < Tmax do
Compute the event rates Ri (x (t)),...,Rn (x (t));
Define R (x (t)) =
∑n
i=1Ri (x (t));
δt ∼ exp (R (x (t)));
r ∼ Unif (0, 1);
a = rR (x (t));
if
∑j−1
i=1 Ri (x (t)) < a <
∑j




t = t+ δt
end
2.4.2 Vector-borne disease models
Basic mathematical models, such as the presented SIR model (see Equations 2.1–2.3),
assume that disease transmission occurs either by direct contact with an infected individ-
ual, or by contact with them through the air (such as a cough or sneeze). However, since
this is not the case for human African trypanosomiasis (HAT), as the primary method for
transmission is through a vector, an infected tsetse, we need to consider this biology in
our models.
To consider this problem in a simple way, we can take our SIR model and remove the
recovered (R) class, such the model becomes an SIS model, whereby upon recovery, an
individual returns to the susceptible class and can become reinfected later. We can now
add these two classes again for the vector population. As such, a simple vector-borne
infection model would have four classes: SH and SV for susceptible humans and vectors
respectively, and IH and IV for infected humans and vectors.
The force of infection for both humans and vectors is given by λi = αpiIj/NH , where
i 6= j and the subscripts can take the values of H or V . α is the biting rate of the vector,
pH and pV are the probability that a vector biting a human will lead to infected in that
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human or vector respectively, and NH is the population size of the humans. Thus, all












SH(t)IV (t)− γHIH , (2.7)
d
dt
SV (t) = −
apV
NH






SV (t)IH(t)− γV IV , (2.9)
where we now have separate recovery/mortality rates for infected humans and vectors,
γH and γV respectively.
Early work in mathematical epidemiology by both Ross and MacDonald [4, 206–208],
has led to the standard Ross–MacDonald model in usage for vector-borne disease
transmission today [202]. Many different modifications to this model have been used,
considering additions such as human demography [209], vector life expectancy [210],
latency periods [211], spatial heterogeneity [212], and many other variants.
2.4.3 Previous modelling work on human African
trypanosomiasis
The first vector-borne disease transmission models were focused on the modelling
of malaria [213], but these model, which are based on what is now known as the
Ross–MacDonald model, have been adapted to serve as a model for human African
trypanosomiasis (HAT). Some of the first HAT models were developed by Rogers [214] in
1988 for T. vivax, T. congolense and T. brucei. This extended the malaria model and made
it more applicable to HAT by including two host species with variable efficiencies of
transmission between host and vector and allowing for incubation and immune periods.
Parameter values were taken for a typical village in West Africa, with some data obtained
from East Africa [14, 214]. A subsequent model from Milligan & Baker [215], also in
1988, included enhanced susceptibility in teneral tsetse, disease-induced mortality and
multiple host types, such as distinguishing between cattle and wild animals. Other early
examples of HAT modelling include Artzrouni & Gouteux [216] and Baker et al. [217].
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More recently, there have emerged several different and independent models for gambi-
ense HAT [186, 218–221].
The model of Funk et al. [218] is a deterministic model composed of ODEs similar to the
Ross–MacDonald model presented in Equations 2.6–2.9. However, instead of a single
host species (humans), the model considers n different host species, with tsetse having
a preference and some rate of switching that preference. This study gave one of the
first estimates of the basic reproductive number for gHAT, as the average number of
secondary cases generated by a single infected individual in an otherwise susceptible
population [6], at approximately 1.1. The study also provided evidence for the existence
of an animal reservoir by indicating that with humans and vectors alone becoming
infected, transmission could not be sustained [218]. There is ongoing modelling work
to assess the potential for recrudescence of gHAT from animal reservoirs [184] and
some suggestion that elimination cannot be achieved or maintained without control of
non-human reservoirs [222].
Four other models for gHAT were published more recently (post-2015), and have also
been compared in a 2018 publication [221]. These models are referred to as the Warwick
Model [146, 219, 223–225], the Yale Model [186, 224, 226], the Swiss TPH Model
[220, 225] and the IDM Model. All four models are defined using ODEs, and so are
deterministic (although in some cases use a stochastic framework [225]), and all are
applied in the comparison publication of Rock et al. [221] (and later [179]) for the
purpose of evaluating intervention strategies. As such, they all include simulation of
passive detection and treatment of cases, active screening and and treatment at discrete
events, and vector control to reduce the tsetse population. However, the underlying
assumptions and implementation of model details are different, capturing different parts
of the biology and so provide different quantitative predictions.
The IDM Model defines four classes for humans (susceptible, infected Stage 1, infected
Stage 2, and recovered), while three for tsetse (susceptible, exposed and infected) and
then fit the model using a collection of data from HAT-endemic foci using the WHO HAT
Atlas [106, 107]. Applying this model to different endemicity settings was done simply
by scaling the value of R0.
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The Swiss TPH Model [220] considers two separate sets of populations of tsetse and
non-human animals to simulate the effects of humans moving between a village and a
‘high-transmission area’, such as around the bank of a river or a plantation. Humans
are then divided into two groups as well, those that are low-risk and thus remain in the
village at all times, and those that are high-risk and commute from the village to the
‘high transmission area’. In this model, humans are classified into five compartments:
susceptible, incubating (exposed), infective (Stage 1), removed (Stage 2) and treated
(recovered). High-risk humans in the infective (Stage 1) class cannot be detected in
passive and active surveillance. Tsetse are simply susceptible, exposed or infected; the
flies have an intrinsic preference for biting animals or humans (and animal bites are
assumed not to contribute to transmission).
This model suggests that if animal reservoirs do not contribute to transmission, the
attractiveness of these animals to tsetse may act as a sink for their bites, reducing
human transmission. In addition, increasing the intensity of screening and treatment
interventions reduces the time to gHAT elimination, particularly if targeting the high-risk
group. The model also suggests intensive vector control is likely to achieve elimination
[220].
The Yale Model [186], does not partition the population into risk groups like the Swiss
TPH Model, and instead achieves more heterogeneity through the use of an asymptomatic
compartment. This means the human population is subdivided into classes: susceptible,
exposed, asymptomatic, symptomatic Stage 1, symptomatic Stage 2 and recovered. After
exposure, only a proportion of infected human hosts become symptomatic and progress
through the infection stages, while a subset remain carriers and are less infectious
and recover on average after the same time as the sum of the time spent in the two
symptomatic classes. Tsetse are assumed to only be susceptible to infection for 24 hours
after they emerge as an adult fly. Thus, tsetse are susceptible, exposed, then infected, or
just susceptible and recovered for their lives.
This model has been applied to data from the Boffa focus in Guinea and predicts that
for this focus, annual vector control, with complementary active case detection gives
a high probability (90%) of achieving elimination as a public health problem in 2020,
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but high coverage needs to be maintained to prevent re-emergence [186]. Subsequent
analysis using this model has shown that in low-transmission areas, enhanced medical
interventions could be enough to interrupt transmission if treatment coverage is over
70%, however in moderate and high transmission areas vector control is likely required
for disease elimination with 10 years, with the probability of elimination decreasing with
a higher tsetse migration rate, highlighting the importance of vector control [226].
The Warwick Model [219] uses five different compartments for classifying humans:
susceptible, exposed, infected Stage 1, infected Stage 2 and recovered. However, like
the Swiss TPH Model uses risk classes for humans. The human population is partitioned
into high- and low-risk, whereby the high-risk population have a higher biting exposure,
although the same probability of being infected per single infective bite as the low-risk
group. High-risk humans do not participate in active screening, while low-risk humans
participate randomly. Unlike the Swiss TPH Model, however, there is no division of the
tsetse population between locations and the distinction between exposure to humans
comes from the higher biting rate. Tsetse are divided into unfed; fed, yet uninfected;
exposed; and infected classes. This is similar to the system in the Yale Model, however,
rather than tsetse becoming recovered after 24 hours, they just have a reduced chance
of becoming infected after their first blood-meal, simulating the teneral effect [63].
This model originally was used to be fitted using the WHO HAT Atlas [106, 107] for a
model selection exercise on the impact of human risk classes and an animal reservoir.
This found that variation in human risk and participation in active screening played a
key role in disease transmission, but the role of an animal reservoir was unclear, while
active screening campaigns were found to have been effective in reducing the number
of new human infections [219]. Subsequently, this work has been expanded to many
new contexts including projections for transmission in the Equator Province of the DRC
[224], predicting the impact of improved surveillance and vector control in the Kwilu
Province of the DRC [223], and modelling the reduction in infection from implementing
tsetse control in the Mandoul focus in Chad [146].
In the comparison piece on these current HAT models, which were applied to both
generic low- and high-risk gHAT settings, across the board vector control was shown
2.4 Mathematical modelling of human African trypanosomiasis 34
to be the most impactful intervention, with local elimination likely, even with only
moderate efficacy [221]. The Swiss TPH and Warwick models predicted that targeted
active screening averted the second most transmissions, while the IDM Model found
enhanced passive surveillance to be more effective, with the Yale model displaying
overlapping prediction intervals for these two interventions. Overall however, the four
models, which were built independently with different assumptions, demonstrated
qualitatively similar predictions [221].
Alternative modelling approaches, such as agent-based modelling have been considered
[227, 228]. Grébaut et al. [227] implement an agent-based model on a village in
Cameroon and suggest regular screening here could be enough to achieve elimination,
while Alderton et al. [228] consider an rHAT transmission model that considers season-
ality in the tsetse population. De Vries et al. [229] also consider the dynamics of HAT
within a single village and present a method for forecasting future HAT prevalence using
past observed prevalence levels and past screening activities in the village. The study
suggests that annual active screening is only expected to lead to local elimination if at
least half of the cases are detected during the screening rounds [229].
Additional to the direct modelling of gHAT, there is much existing modelling literature
for tsetse. There have been several studies on the population dynamics of tsetse [51,
230, 231]. The studies are useful for modelling gHAT to ensure the tsetse components
of the model are somewhat realistic, while the number of parameters is kept to a
minimum. Furthermore, the effects of tsetse control have also been modelled, aside
from considering HAT. This has involved considering how the population of tsetse might
bounce back or crash after a certain level of control, the feasibility of local elimination
and the cost-effectiveness of the intervention [50, 232]. Modelling of tsetse control using
insecticide-treated cattle (in rhodesiense HAT-endemic areas) has also been considered
[233, 234].
Developments in geo-statistics have also allowed maps of tsetse density to be produced
to guide interventions [235, 236] and patterns to be observed in HAT distribution [237].
And since the climate is known to affect tsetse abundance [238], modelling has been
used to predict where current HAT-free areas may become at risk, with Moore et al.
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[239] predicting that 46–77 million additional people may be at risk of exposure by
2090.
Understanding of the dynamics of tsetse and infection by T. brucei is also pivotal in
modelling for providing estimates of the various parameters that are required to make the
modelling realistic. Estimates for the tsetse bite rate [240], tsetse incubation rate [241,
242], proportion of blood-meals taken on humans [243] can be found in the literature,
along with the human mortality rate [244], incubation rate [214], progression from
Stage 1 to Stage 2 rate [77, 245], and recovery rate [117].
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3
Village-scale persistence and
elimination of gambiense human
African trypanosomiasis
Gambiense human African trypanosomiasis (gHAT) has recently seen a substantial decline
in the number of globally reported cases, largely driven by an intensive process of
screening and treatment. There continues to be pressure to reduce the number of new
infections, as gHAT has been targeted for elimination by the World Health Organization.
However, this infection is highly focal, continuing to persist at low prevalence even in
small populations. Regional elimination, and ultimately global eradication, rests on
understanding the dynamics and persistence of this infection at the local population
scale.
In this chapter, we develop a stochastic model of gHAT dynamics, which is underpinned
by screening and reporting data from one of the highest gHAT incidence regions, Kwilu
Province, in the Democratic Republic of Congo. We use this model to explore the
persistence of gHAT in villages of different population sizes and subject to different
patterns of screening. In contrast to other commonly studied infections, our models
demonstrate that infection is expected to persist for long periods even in relatively small
isolated populations, despite very low prevalence. We further use the model to assess the
risk of recrudescence following local elimination and consider how failing to detect cases
during active screening events informs the probability of elimination. These quantitative
results provide insights for public health policy in the region, particularly highlighting
the difficulties in achieving and measuring the 2030 elimination goal.
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3.1 Considering the village-scale
Mathematical models of gHAT have been beneficial in identifying the effectiveness of
differing control strategies and predicting when elimination is likely to occur [201].
However, much of the modelling work on the gHAT infection dynamics has been done
in large populations using deterministic models, either for an entire regional infection
focus or at a health zone level (approximately 100,000 people) [186, 219, 220]. We
focus on modelling gHAT infection within individual villages because we know that
gHAT is such a focal disease, with hot-spots around the tsetse habitats and minimal
incidence outside these areas; thus neighbouring villages can have entirely different
experiences with the infection [18].
By modelling the dynamics of gHAT within villages, we are considering the infection dy-
namics at the level at which the interventions are being deployed, since active screening
targets individual villages. To optimise deployment we need to understand the dynamics
at this level. From this information, we hope to build understanding of how villages
interact and so determine importation rates between villages, with the hope that the
results can then be scaled up to an infection focus, or the national level to measure
regional elimination, which is especially important as we approach zero transmission.
Some modelling work has been done on village level infections. De Vries et al. [229]
presented a model for predicting HAT prevalence using past observed prevalence levels
and past screening activities in the village. However, we have developed a new mecha-
nistic model that captures details of the epidemiology and tsetse biology. This process is
significantly more flexible and allows modification of model components, facilitating a
number of different scenarios and control options.
3.1.1 Gambiense HAT in the villages of the Kwilu province
The Kwilu province in the Democratic Republic of the Congo (DRC) has many areas
that are endemic with gHAT. This province (along with Mai-Ndombe to the north and
Kwango to the south) used to form a larger province called Bandundu (from 1966–2015)
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Fig 3.1: Locations of villages that have reported gHAT cases in the period 2000–2012. Inset
map shows the Kwilu province, which has a particularly high endemicity. Data
from the WHO HAT Atlas [106, 107].
and this province contained contained 46% of all reported gHAT cases in the DRC from
the period 2000–2012 [246]. Indeed, there are a high proportion of gHAT cases still in
this province (Figure 3.1).
For our model, we have chosen two health zones within the Kwilu province on which
to base our analysis: Yasa-Bonga and Mosango. Health zones are subdivisions within a
province that contain approximately 100,000 people; there are 519 health zones in the
DRC [247]. There are many villages within Yasa-Bonga and Mosango with populations
typically below 2,000 people, although there are a small number of larger villages
with populations of up to around 12,000 (Figures 3.2 and 3.3A). Both Yasa-Bonga and
Mosango contain rivers along which riverine tsetse inhabit, with villages along the rivers
and further away.
These chosen health zones historically have a high incidence of gHAT and have had
reported cases through both active and passive surveillance in the period 2000–2012.
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Fig 3.2: Locations of villages within Yasa-Bonga and Mosango at which an active screening
has occurred [106, 107].
Screening coverages (the proportion of a village population that was subjected to active
screening) varied between villages based on data from the WHO HAT Atlas [106, 107].
Typical screening coverages were in the reasonable zone of 20% to 90%, however there
were some very high coverages, including some over 100%. For a full histogram of the
coverages of all active screenings in Yasa-Bonga and Mosango in 2000–2012, see Figure
3.3B.
From the data, we have observed 2,701 active screenings in 2000–2012, across 559
different settlements, which resulted in 4,875 detected gHAT cases, with an additional
2,496 cases detected from passive surveillance. Population sizes for settlements were
obtained from census estimates within the WHO HAT Atlas [106, 107] (Figures 3.2 and
3.3A); we account for an estimated yearly population growth of 2.6% [248]. Screening
coverage from active surveillance is then calculated as the number of individuals screened
divided by this population estimate in each year. Annual screenings larger than the
estimated accessible population (yellow and red bars in Figure 3.3B) may indicate either
multiple screenings in a calendar year, incorrect census estimates, or misreporting of
individuals attending from neighbouring settlements. Low annual screening coverage (at
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Fig 3.3: Histograms of population and screening data from the WHO HAT Atlas [106, 107].
(A) Estimated population size in 2012. (B) Active screening coverage for each
active screening event 2000–2012.
less than 20% of the population size, gray bars in Figure 3.3B) is assumed to represent
when someone has travelled from their village to a different village to be tested; in this
instance, their home village has been recorded and represented in the data as a separate
active screening. Therefore this is not considered as a complete active screening of a
village. It is also notable that it may be more likely that someone who chooses to travel
to an active screening may be more likely to be infected as they have noticed symptoms
and hence this may also cause additional 100% screening coverages as well.
The full WHO HAT Atlas data [106, 107] includes information on the years active
screenings occurred in each village, the full location of the village (geo-coordinates,
health area, health zone, province), a census estimate, the number of people screened
and the number of resulting detected cases. Information is also included on the number
of passive cases detected in each year in a village.
3.2 A stochastic model of gHAT dynamics
To capture the village-scale infection dynamics for each individual population, we
introduce a stochastic compartmental model. We choose to implement a stochastic
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model rather than previous deterministic models because of the small population sizes
we are considering. With a stochastic model we take into account the element of
chance in infection extinction, rather than considering average behaviour; with small
populations and the small number of infections, these events will be relatively magnified
and so we consider different possibilities for the evolution of the dynamics. Since, the
probability of local gHAT extinction is high within the time frames we want to consider,
we can also model this directly and not consider thresholds below which the disease is
effectively extinct. We adapt a model of Rock et al. [219].
3.2.1 Model selection
Model selection from Rock et al. [219] considered seven different model structures, all
considered in an ODE framework, to determine the best fit to the gHAT incidence data
from the WHO HAT Atlas [106, 107]. This was done using the deviance information
criterion (DIC), which assigns low scores for models with high posterior mean log-






+ 4Var (LL (θ)) ,
where LL is the log-likelihood of unknown parameters θ, and where θ̄ is the expectation
of these parameters.
The models considered were:
Model 1: Homogeneous human risk and behaviour model.
Model 2: Low- and high-risk populations for exposure to tsetse bites.
Model 3: Random participation with and non-participation in active screening.
Model 4: Random participation in active screening for low-risk populations and
non-participation for high-risk.
Model 5: All combinations of low or high-risk and random or non-participation.
Model 6: Homogeneous human population and two animal populations – a reservoir
able to acquire and transmit disease and a non-reservoir, which still receive
tsetse bites.
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Model 7: Heterogeneous human populations, as in Model 4, with the animal reser-
voir.
Model 4 and Model 7 were found to have the smallest DIC, with the best model being
Model 7. The paper concluded that since the difference was negligible however, Model
4 should be used since DIC is known to over-favour over-fitted models and Model 7
has more parameters (associated with the animal component) [219]. Like this study,
we therefore favour and use Model 4, without the animal component but with human
risk structure, where high-risk individuals have a larger exposure to tsetse bites and
do not present for active screening, while low-risk individuals have a lower exposure
and present randomly for screening. We do not favour Model 7, since its role remains
unclear [12, 146, 186, 218, 219] and its inclusion does not significantly improve the
match between model outputs and currently available data in this setting [219].
Figure 3.4 shows the comparison of the models with the reported incidence data.
3.2.2 Model formulation
We adapted our new stochastic model using ‘Model 4’ from the work of Rock et al.
[219]. The compartments are the same as this model, where humans are classified
by: susceptible, exposed (but not infectious), Stage 1 infection, Stage 2 infection and
hospitalised (or recovering at home). These variables are denoted by SHj(t), EHj(t),
I1Hj(t), I2Hj(t) andRHj(t), where j = 1, 2, with j = 1 for low-risk individuals, randomly
participating in active screening, and j = 2 for high-risk individuals, never participating
in active screening, each at time t > 0. We assume that there is natural mortality from
all compartments, which leads to replacement of that individual as a susceptible in the
population. Thus, the population size is assumed constant:
NHj = SHj(t) + EHj(t) + I1Hj(t) + I2Hj(t) +RHj(t), j = 1, 2.
The given risk structure is used to capture the behaviour of the small proportion of
individuals that both work in the habitat of many tsetse and so have a higher biting
exposure and also do not partake in active screening, thereby acting as a human reservoir
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Fig 3.4: Deterministic model selection. Comparison of the reported incidence data aggre-
gated across the study region and the corresponding model output over the years
1998–2012, for the deterministic model with different model structures. Model 4 is
chosen as a good fit with the incidence data without unnecessary parameters. This
figure is adapted from Rock et al. [219].
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Fig 3.5: Compartmental model of gHAT infection dynamics in humans (low- and high-risk)
and tsetse. The transmission of infection between humans and tsetse is shown by
grey paths. Infected animals are not considered.
of infection [14, 117, 220]. The proportion of the individuals in the high-risk group is
estimated through extensive model fitting to be 7.6% of the population for these health
zones [219]. While the people in the high-risk group have a higher biting exposure, the
probability of tsetse infection per single infective bite is the same for both risk groups.
Tsetse in the model are similarly compartmentalised into four epidemiological states:
teneral (unfed); non-teneral yet uninfected; exposed (or latent); and infected. These
classes are given by the variables SV , E1V , E2V , E3V , IV and GV , where the exposed
class is divided into three classes, respectively. We make this distinction such that the
time a tsetse remains in the exposed class is gamma-distributed [250]. Furthermore,
the distinction between teneral and non-teneral yet uninfected is used to capture the
observation that tsetse are far more susceptible to infection at their first blood-meal than
at any subsequent blood-meals [63].
In considering the dynamics, humans can become exposed on a bite from an infective
tsetse and progress through the infection stages, Stage 1 and Stage 2, before moving to
the non-infectious class due to hospitalisation. The birth rates BHi are given by µHNHi
for i = 1, 2 and BV is equal to µV NH . Active screening moves exposed or infected people
directly to the hospitalised class. Unfed tsetse can become exposed then infected on con-
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Fig 3.6: Impact of the parameters forming the effective density of tsetse, meff. When the
probability of human infection per single infective bite is high the vector-to-host
ratio, V:H, is around 6.56, whereas when the probability is low, V:H becomes large
and deterministic models are valid for tsetse dynamics. The expected number of
yearly new infections for each population size, if the system were at equilibrium, is
also given by the top scale.
sumption of a blood-meal, of which a proportion are taken on humans. Alternatively, first
blood-meals not resulting in exposure means tsetse are less susceptible to trypanosomes








are defined fully in Table 3.2. fH = fH1 + fH2, where fH1 = fHR1/(R1 + rR2) and
fH2 = fHrR2/(R1 + rR2).
The compartments of the model and possible transitions between them are shown
graphically in Figure 3.5.
3.2.3 Tsetse density
One notable difference between the deterministic and stochastic formulation is the need
to delineate the effective tsetse density term in the equations. This is the product of
the relative tsetse density and the probability of human infection per single infective
bite meff = mpH . When using a deterministic model, Rock et al. [219] only needed
to estimate the parameter value of meff since m and pH are multiplied together in the
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equations, however, for our stochastic model, m determines the number of tsetse being
modelled for a particular village and so is needed explicitly. Therefore in this analysis,
we show some sensitivity analysis to estimate the effect of varying pH between 0 and
1 such that the value of meff remains fixed. For pH → 0, we take fixed pH = meff/m
and m→∞. Hence we are assuming an effectively infinite population of vectors (i.e.
the vector-to-host ratio, V:H → ∞). From a modelling perspective, this reduces the
equations down to the previously formulated deterministic approximation for the vector
population. From the sensitivity analysis (Figure 3.6), we see there is minimal effect of
varying the vector-to-host ratio, and hence for simplicity we choose to keep pH = meff/m
and m → ∞, to give the desired fixed value of meff = 6.56 (taken as the result from
fitting the ODE Model 4 from Rock et al. [219] to case data from the WHO HAT Atlas
[106, 107]).
In our analysis, the endemic disease equilibrium is calculated as the steady state of the
deterministic model, excluding control measures other than basic passive surveillance
[219]. Initial conditions for number of people in each infection class within a village
are taken by sampling from a multinomial distribution, where the probability of being
selected in a class is given by the proportion in that class in the steady state of the model.
Using random initial conditions with the mean at endemic equilibrium removes the
effects of rounding the initial conditions to the same integer values for each simulation.
3.2.4 Model equations
The model is formulated in two possible ways based on the choice of the vector-to-host
ratio (Table 3.1). It is either entirely a Markov-chain if pH > 0, or a Markov-chain for
the human compartments with an additional ordinary differential equation component
for the tsetse otherwise.
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Tab 3.1: The transition rates of the Markov-chain gHAT-infection model and additional
ordinary differential equation component of the model when m→∞ and pH → 0
(V:H→∞).
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Tab 3.2: Parameter notation and values for the stochastic model. We give the parameter
notation (Par), a description, the value and the source. In the value column,
d = days.
Par Description Value Source
µH Natural human mortality rate 5.4795 × 10−5 d−1 [244]
ωH Human recovery rate 0.006 d−1 [117]
σH Human incubation rate 0.0833 d−1 [214]
φH Stage 1 to 2 progression rate 0.0019 d−1 [77, 251]
γH
Exit rate from Stage 2 by treatment or
0.006 d−1 [219]
death
NH Human population size Varies N/A
µV Tsetse mortality rate 0.03 d−1 [214]
σV Tsetse incubation rate 0.034 d−1 [241, 242]
ε Reduced non-teneral susceptibility factor 0.05 [219]
α Tsetse bite rate 0.333 d−1 [240]
m Relative tsetse density Varies N/A
pH
Probability of human infection per single
Varies N/A
infective bite
meff Effective tsetse density 6.56 [219]
pV
Probability of tsetse infection per single
0.065 [214]
infective bite
fH Proportion of blood-meals on humans 0.09 [243]
R1








Relative bites taken on high-risk humans
6.6 [219]
compared to low-risk
u Reporting probability for Stage 2 cases 0.26 [219]
δ Importation of infection rate 3.4 × 10−6 d−1 fitted
3.2.5 Parameters
Model parameters for the compartmental model are taken from Rock et al. [219] (Model
4) and applied to our stochastic model. The values of these parameters were taken
from literature, where well-defined, and otherwise inferred by model fitting using a
Metropolis–Hastings MCMC algorithm, which sought to match the deterministic model
to observed cases and screening effort in Yasa-Bonga and Mosango; this is the process
that was used in model selection. The values used in this thesis are the median of the
distributions inferred using MCMC methodology applied to the aggregate annual data
from Yasa-Bonga and Mosango. Therefore, the parameter values are specific to the study
region, and the model is well-matched with the incidence data from active and passive
surveillance. A full list of parameters is given in Table 3.2.
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3.2.6 Active screening
Additional to the epidemiological and demographic processes, we simulate the effect of
active screening and passive detection of cases. Passive detection (and disease-induced
mortality) is assumed to occur at a fixed (per capita) rate for all Stage 2 infected
individuals [129]. Active screening takes place annually; the proportion screened is
either replayed from the historic pattern for that settlement or chosen randomly from
the set of all screening coverages recorded, allowing a greater range of scenarios to be
explored. Since Yasa-Bonga and Mosango are high endemicity regions, we assume that
the screening coverage and frequency remains constant over time but note that these
quantities are somewhat affected by population size (Figure 3.7).
Larger village populations tend to have more frequent screening, but with a lower
proportion of the population tested; small populations tend to have high coverage but
infrequent screens (Fig 3.7A and B). The smaller villages were also not typically screened
in 2000–2008, while villages with populations greater than 500 were screened over the
whole data period 2000–2012 (Fig 3.7C). We do not account for these differences in our
analysis but can use these trends to help explain any discrepancies between models and
the data.
Individuals in the low-risk group are selected uniformly at random for screening, irre-
spective of epidemiological status, and those that are found to be infected are moved
to the hospitalised class. We assume that screening only applies to low-risk individuals,
such that screening coverages greater than 92.4% (the estimated proportion in the low-
risk group) [219] are truncated (Fig 3.3B). In the field, the diagnostic process is complex
and multi-stage [240]; however, in the model, we collapse this into characteristics for
the whole algorithm, which is assumed to be 91% sensitive [252] but 100% specific.
False negatives remain undetected in the settlement, but by assuming 100% specificity,
there are no false positives since we assume confirmation by microscopy will be carried
out due to the low case numbers.
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A
B C
Fig 3.7: Differences in screening between villages. (A) Screening coverage in village pop-
ulations. (B) Number of screenings at each settlement in the period 2000–2012.
Small random perturbations are made to the integer values for visibility. (C) Years
in which the first active screenings occur in the villages (within the 2000–2012
period), with small random perturbations for visibility.
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3.2.7 Model implementation
To implement this model and generate realisations of the infection process, we employ
the tau-leaping algorithm [253]. This algorithm is an approximation for the Gillespie
algorithm [205, 254] that can improve the speed of the simulation at some loss of
precision. While the Gillespie algorithm simulates the time to the next event, the tau-
leaping algorithm ‘leaps’ forward by some time step and estimates how many of each
event occurred in this time interval. To get the best results, we can have an adaptive
time interval τ , such that the change in the state of the system is small, however, in this
case, we will choose to keep τ fixed and small enough such the value of this parameter
does not affect the results. For the full tau-leaping algorithm see Algorithm 3.1.
Algorithm 3.1: The tau-leaping algorithm.
Specify model run time Tmax;
Set initial conditions t = t0 and x(t0) = x0;
Label all events E1,...,En;
while t < Tmax do
Compute the event rates Ri (x (t)),...,Rn (x (t));
Choose time step τ ;
for i = 1 : n do
Compute occurence of event i ki ∼ Poisson (Ri (x (t)) τ);
end
Update x(t);
Ensure non-negativity of x(t);
t = t+ τ
end
Our fixed step size for the tau-leaping algorithm was chosen to be 0.1 days. However,
the results for persistence of gHAT after 15 years are qualitatively the same for time steps
of 0.01 and 1 days, so we are confident that a time step of 0.1 days is not introducing
numerical errors (Figure 3.8). 95% confidence intervals are all small, in the range
(0.0044, 0.0196) about the plotted mean values.
Using this algorithm, a sample realisation of the infection dynamics in a population with
three active screening events, where randomly sampled infected low-risk individuals are
moved directly into the hospitalised class, is shown in Figure 3.9.
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Fig 3.8: Probability of disease persistence under the tau-leaping algorithm for fixed step
size. Probability of HAT persistence after 15 years for V:H→∞, simulated using
three different tau-leaping time steps: τ = 0.01, 0.1 and 1. Since the resulting
curves are the same, the step size in the algorithm is suitable.
3.2.8 Population dynamics
For the majority of this thesis, we model the dynamics as a closed population, without
emigration or immigration, so that once the disease has gone extinct in a population it
cannot be re-introduced. This removes a critical dependency in model formulation, and
greatly simplifies the presentation of results. In reality, no population is ever completely
isolated; however we later show that the expected rate of infectious imports is very low
and does not affect our main results or conclusions (see Figure 3.18).
In all model simulations, we have assumed that the population size remains constant,
such that when a death occurs, the individual is replaced by a new susceptible individual
immediately. We have analysed this assumption by comparing this with different
population dynamics (Fig 3.10). We consider four additional population assumptions,
all where births and deaths have been decoupled. These are: births and deaths are
proportional to the number of individuals of that infection status; deaths are proportional,
but births are at the constant rate from the initial equilibrium; and the same two
mechanisms, but where the birth rate is increased by the population growth of 2.6%. As
the populations change in size, we keep the effective tsetse density constant.
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Fig 3.9: A single realisation of the simulated infection dynamics of the model. A population
of 514 is used with 404, 430 and 52 of the low-risk population randomly selected for
active screening after three, four and nine years, respectively. Note that the number
of hospitalised individuals increases at the first two active screening events, but
no infected individuals are randomly selected and detected in the third screening
event. We only plot those infected (or affected) by HAT, although we note that the
vast majority of both populations are susceptible.
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We see that the probability of gHAT persistence as time progresses is very similar for all
five assumptions, while it does diverge slightly with time (Fig 3.10). For a population size
of 2,000, after 15 years, the probability of gHAT persistence using all five assumptions
gives results less than 0.01 apart and the confidence intervals all overlap. For a smaller
population size, there is a bit more variation and the confidence intervals do not all
overlap. The assumptions where the population size grows by 2.6% each year has a
higher probability of gHAT persistence, although the maximum difference is still only
approximately 0.012 and this represents a significant increase in the village population
over the time span. Where there is no population growth the confidence intervals all
overlap.
Thus, we can use the assumption of constant population size, since it does not sig-
nificantly change the results, excluding large increases in population size for small
populations, and is significantly easier to implement. Keeping the population size con-
stant also decouples the stochastic extinction of the gHAT infection from any underlying
population dynamics. If we were to introduce more elaborate demographics into the
model structure, it would be unclear if the extinction of infection was due to the stochas-
tic process of transmission or the fluctuations in population size. Furthermore, we can
associate each simulation of a village with a single population size, and can hence show
probability of gHAT persistence as a function of population size.
3.3 Comparing the stochastic model to data
While the underlying deterministic model has been fitted to the aggregate data from
this region, it is important to assess the behaviour of the stochastic model against
village-scale observations.
Unfortunately, local disease extinctions cannot be directly observed; failure to discover
any cases does not necessarily mean that the infection is not present, simply that it
has not been detected. Thus, to validate our model, we make comparisons between
the simulated predictions and WHO HAT Atlas data [106, 107] for the probability of
detecting no cases on an active screening (termed zero-detections for brevity), which is
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Fig 3.10: Using different population dynamics assumptions. The probability of gHAT per-
sistence is very similar for different assumptions on the population dynamics,
diverging only slightly for larger times. Our typical assumption of a constant
population, achieved by coupling births with deaths, provides results within the
95% confidence intervals of when births and deaths are decoupled and when
births are constant. Results are shown for populations of size 2,000 and 250.
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Fig 3.11: Comparison of model predictions and data for active screenings with no detected
cases (zero-detections). (A) Histogram by population size of the percentage of
active screenings that find no new gHAT cases for both the model and the HAT
Atlas data. Each bar represents 100 screenings of simulated results (averaged over
10,000 replicates) from the model that uses the observed pattern of screenings
and compares to the data. Values where the model predictions have more zero-
detections than the data are in red, while the reverse is shown in yellow. Error
bars represent the 95th percentile of model results. (B) Map of populations in
Yasa-Bonga and Mosango showing the settlements with significant differences
(at the 95% level) in the expected proportion of active screenings with no cases
detected. Red circles are where the observed number of active screenings with
zero-detections is below the 95th percentile of the model; yellow circles are
where the data falls above the 95th percentile; small blue circles are for data
that lie within the 95th percentile of predictions and therefore are well described
by the model. The satellite image shown is from Landsat-8 accessed through
https://earthexplorer.usgs.gov/ from the U.S. Geological Survey.
a combination of failure to detect and local extinction. We compare model predictions
to observations by calculating the percentage of zero-detections in aggregations of 100
active screenings with similar village population sizes (Figure 3.11A). We find very
strong agreement between model predictions and data, with a pronounced decline in
zero-detections for larger populations.
For individual settlements, those where the number of zero-detections lie outside the
95th percentile of model predictions are notably spatially clustered (Figure 3.11B). In
2.1% of settlements (red), there are significantly fewer zero-detections than predicted
and hence greater persistence; these villages are generally localised around the main
river through the region. In 6.3% of settlements there are significantly more zero-
detections than expected (yellow), and these are clustered far from the major rivers
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A B
Fig 3.12: Expected proportion tests that are gHAT positive in an active screening. (A)
Histogram by population size of the percentage of positive tests in independent
active screenings for both the model and the WHO HAT Atlas data. (B) Map of
populations in Yasa-Bonga and Mosango showing the settlements with significant
differences in the expected proportion of tests positive. The underlying Landsat-8
satellite map is shown courtesy of the U.S. Geological Survey.
and in upland areas. Since tsetse are most densely distributed surrounding riverine
areas [81], this spatial clustering may indicate the need for spatially heterogeneous
parameters that reflect the suitability of the local environment for tsetse. However,
given that more than 90% of villages fall within our prediction intervals, we believe the
homogeneous parameters capture the general stochastic behaviour of this region.
Considering a different metric, and comparing the data on the proportion of tests that
result in a positive detection of gHAT to the output of the model demonstrates similar
results to comparing the screenings with no detected cases, as in Figure 3.11 (Figure
3.12). The difference in coverages of an active screening event mean the results have
more variation than simply not detecting any new cases, yet the model is similarly
capturing the behaviour seen in the data; there are a few more settlements that stand
out as significantly different from the model (69 settlements, 12.3%), but these are
similarly clustered where expected.

















































Fig 3.13: Predicted probability of gHAT persistence in isolated settlements. Simulations are
started at the endemic (uncontrolled with passive surveillance only) equilibrium
from the deterministic model and iterated forwards (without infectious imports),
while the persistence of infection is recorded. This is repeated 100,000 times
for settlement population sizes between 50 and 2,000 individuals. The expected
number of yearly new infections if the system were at deterministic equilibrium is
proportional to the population size and is given by the top scale. (A) Impact of ac-
tive screening on gHAT persistence; annual screening at a fixed coverage per year
yields a drop in persistence with increased coverage. (B) Comparison of screening
assumptions on the persistence of gHAT. The solid curve shows results where
annual screening coverages were randomly sampled from all observed coverages;
dots represent the individual settlements recorded in the WHO HAT Atlas for
Yasa-Bonga and Mosango health zones[106, 107], where the reported coverage in
each year is used. There were sufficient simulations such that confidence intervals
are too small to be visible.
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3.4 Considering village-scale persistence
Local gHAT persistence, where human infection is maintained in a settlement, is affected
by many factors (Figure 3.13), including the population size of the settlement; the vector-
to-host (tsetse-to-human) ratio; the exposure to the tsetse; the screening procedure; and
any movement of infected individuals between populations. We calculate the probability
of persistence by stochastically simulating the epidemic for 16 years from the endemic
(uncontrolled, passive surveillance only) disease equilibrium found in the deterministic
model. If there is zero gHAT infection in the human population after a given number
of years and no further human infection emerges in the following year from infected
tsetse, we say in this simulation there is local disease elimination with no immediate
threat of re-emergence (Figure 3.15A provides a justification for this criteria). This
procedure is repeated for multiple population sizes; the proportion of simulations that
retain infection after a given number of years determines the probability of persistence
(Figure 3.13).
We focus on settlements with fewer than 2,000 inhabitants, typical of Yasa-Bonga and
Mosango (Figure 3.2), and using our regionally specific parameters. In all scenarios
investigated, we find that persistence increases with increasing population size (Figure
3.13). This echoes results from other infections [255–258], where small populations with
low incidence experience a greater impact of stochasticity and chains of transmission
that are more likely to be broken.
The addition of active screening (leading to the treatment of detected cases) decreases
the probability of persistence across all population sizes, since removing infected in-
dividuals leads to a greater chance of breaking chains of transmission (Figure 3.13A).
Increasing levels of screening, beyond the observed 21% average, leads to further re-
ductions for persistence. We compare three assumptions for active screening (Figure
3.13B): that each population is screened annually at a fixed coverage equal to the
regional average (21%); that each population experiences screening coverages sampled
from the regional pattern including not screening in a given year; and simply replaying
the recorded pattern of active screening in each village. Despite the very different
distributions of screening effort, all three of these assumptions produce comparable
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levels of persistence. As a control strategy, we also find that randomly selecting the
screening coverage from all reported coverages slightly out-performs screening annually
at the mean coverage (21%), kept fixed across all years, but there is minimal difference
(Figure 3.14A). In addition, given that long-term persistence relies on persistence for
shorter time intervals, the probability of persistence decreases with time (Figure 3.14B–
C). The relatively long persistence times of gHAT, compared to the frequently studied
persistence of childhood diseases [255, 256], are attributable to the long time-scale of
gHAT infection in the absence of active interventions [245].
3.5 The probability of re-invasion
Following localised elimination of infection, populations remain vulnerable to re-
invasion; we investigate the potential for re-establishment of sustained transmission in a
settlement for different invasion scenarios. For a village of 1,000 individuals, following
the elimination of infection in humans, the level of infection in tsetse falls rapidly, even
when starting at the endemic level in these vectors (Figure 3.15A). In approximately
65% of simulations, the initially infected tsetse generate human cases, and the level of
infection in vectors rapidly plateaus; otherwise, infection is eliminated from the location
within six months due to short vector life expectancies in comparison to the human
hosts. This validates the previous simulation assumption (Figure 3.13) that local disease
elimination can be considered achieved after a period of one year in which there are no
infected humans, as the number of infected tsetse will also become negligible.
The probability that a population of tsetse, infected at the endemic equilibrium (0.02%
of tsetse exposed or infected), will lead to re-establishment of infection is predicted
to be a function of settlement size (Figure 3.13C). Small populations are unlikely to
see any new human infections, and those that are generated fail to persist. This is
because tsetse have short lifespans and so are only able to interact with a few humans
over their lifetime. However, even for large population sizes of 2,000 individuals, the
chance of continued transmission beyond one year is only 55% and is less than 10%
over 15 years. For lower levels of infection in the tsetse population, the risk of successful
re-establishment is proportionally reduced.
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A B
C
Fig 3.14: Factors affecting predicted probability of HAT persistence in isolated settlements.
(A) Impact of active screening on disease persistence: both random screening
(sampling from all screening coverages, including zeros) and annual screening at
a fixed coverage (the mean annual coverage of 21%) yield a drop in persistence.
Choosing the coverage randomly slightly out-performs screening annually at the
mean coverage. (B) Probability of HAT persistence 5, 10 and 15 years after
starting at the endemic equilibrium. (C) For villages with populations of sizes 500
and 2,000, the probability of HAT persistence in time for the uncontrolled setting
(U), random active screening coverage (R) and annual screening at the average
coverage of 21% (Y).
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In contrast, if re-invasion of an infection-free population is due to the movement of an
infected person into the settlement (in the absence of infected tsetse) the probability of
re-establishment over different time-frames is largely unaffected by the population size
(Figure 3.15B). This is because infection in a human will be present in the population for
much longer and so population size will have less impact on whether new transmission
events occur. We predict a high probability (> 70%) of short term re-invasion, but a
more limited chance (< 20%) that this will generate persistent infection for 15 years
or more. This is typical of stochastic dynamics of infection with low basic reproductive
ratio (R0), where, although short chains of transmission are likely, it is difficult for
the infection to fully establish. The probability of new transmission events is further
increased by the addition of an infected human to endemic levels of tsetse infection
(Figure 3.15D).
3.6 Detecting elimination
As discussed above, zero-detections may be an indication that there is no infection in a
settlement; however, it may simply be that infected individuals were not screened or
were false negatives. Despite this, there is a temptation to associate zero-detection with
zero infection; we therefore use our simulations to tease apart this complex relationship.
The model replays the observed pattern of screening in each settlement, but we perform
multiple simulations to ascertain the probability that infection has been locally eliminated
following one, two or three consecutive zero-detection screenings, in which at least 20%
of the population are screened (Figure 3.16). We also insist that no passive cases were
detected between the screening events. Our standard assumption, in agreement with
parameter inference for this region, is that 26% of Stage 2 infections, where people
either self-report or likely die of gHAT infection, are detected and reported [219], but
we also investigate 0% (no passive reporting) and 100% (all passive cases and deaths
are reported) for comparison.
For small settlements, given that long-term persistence is unlikely (Figure 3.13), even
a single zero-detection screen (Figure 3.16, blue) is frequently associated with local
elimination. For larger populations, a single zero-detection has limited predictive power
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Fig 3.15: Dynamics of extinction and reintroduction. (A) Starting with no infected humans
but the tsetse population at its endemic equilibrium and a settlement size of
1,000 individuals, the model predicts a dramatic decline in the infected tsetse
population, depending on whether subsequent human cases are generated by
the infected tsetse. (B–D) Extending this model further for a range of initial
conditions. We examine the probability that at least one human case is generated
and the infection persists for a given time, when starting with (B) one infected
human and no infected tsetse for both uncontrolled and random screening, (C)
with no human infection and endemic-equilibrium levels of infected tsetse, (D)
with one infected human and endemic-equilibrium levels of infected tsetse.
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Fig 3.16: Probability of elimination in a settlement, given consecutive zero-detections with
no detected passive cases. Consecutive zero-detections means consecutive in
the observed years of screenings, not necessarily in consecutive years, and with
no passive cases detected in between. Each point represents the average from
multiple simulations of individual settlements where the reported pattern of
screenings is replayed. The points and solid lines assume a reporting rate of 26%
[219], while the dashed and dotted lines show reporting rates of 0% and 100%,
respectively. Sufficient simulations are used such that the confidence intervals
are small (unobservable on the scale of this graph). Lines represent a weighted
local regression fit. Active screenings where fewer than 20% of the population are
assessed are excluded from our analysis due to the small sample sizes (alternative
cut-offs of less than 10% and less than 50% are presented in Figure 3.17).
and three consecutive zero-detections are needed to have any degree of confidence, in
which case the reporting of passive cases plays a noticeable role. There is, however,
significant variation between settlements, reflecting very different patterns of reported
screening. Moderate population sizes of between 200 and 1,000 individuals show
extreme variation in the ability to predict local elimination, while smaller villages have
less variation, in part due to rarely being screened before 2009 (Figure 3.7C).
In calculating the probability of infection on detecting no cases, a zero-detection event is
different for different screening percentages. We use 20% of the population screened to
define a ‘full screening’; however, similar results are achieved for the screening regime
of Yasa-Bonga and Mosango 2000–2012 when 10% is used. If 50% is used, and so all
screenings are of very reasonable quality, there is more confidence that the same number
of consecutive zero screenings are a proxy for no infection in the population (Fig 3.17).
When screening coverage is higher and no infection is detected, there is more certainty
that no infection is present.
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A
B
Fig 3.17: The probability of a settlement containing no infection given that a number of
consecutive active screenings detecting no cases have occurred. (A) Only active
screenings where at least 10% of the population are included are used to calculate
the probability. (B) At least 50% of the population must be screened for the
screening to be included.
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3.7 Estimating the rate of importation
For the majority of this thesis, we have modelled the dynamics as a closed population,
without emigration or immigration, so that once the disease has gone extinct in a
population it cannot be re-introduced. This removes a critical dependency in model
formulation, and greatly simplifies the presentation of results. In many cases, such as
community-level persistence, this approach is justified, as we wish to understand the
stochastic dynamics in the absence of confounding imports. In reality, no population
is ever completely isolated. Regional persistence relies on more than independent
persistence in individual settlements. It is likely that the occasional movements of
infected people lead to a stochastic meta-population paradigm [259], where rare local
extinctions of infection are balanced by external imports. However, the agreement
between model and data (Figure 3.11), together with the low prevalence of infection,
indicates that imports are likely to be rare.
We make this more quantitative by fitting an importation rate of infection, proportional
to the size of the population. Before interventions, the presence or absence of infection
in a population reflects the equilibrium balance between extinction and re-colonisation;
we can therefore use the presence of infection at the first recorded active screening
within a village as measure of the equilibrium state. Fitting the external importation rate
to the probability of detecting infection in a village at the first active screen gives the
best fit when the rate is small at just 3.4× 10−6 per person per day using least squares
regression (Figure 3.18A). This rate is small and so can be reasonably ignored on the
studied time scales, particularly as there is some probability that this importation will
not cause any subsequent transmission. Moreover, we can assume that the importation
rate declines over time since the overall prevalence in DRC is declining [20]. By fitting
the reduction in total cases in the DRC to an exponential decay function, we get a decay
rate of 0.1071, which we apply to the import rate (Figure 3.19). In addition, since we
are only using villages included in the WHO HAT Atlas [106, 107], we may overestimate
importation rate for the whole region as we do not consider the villages not presenting
cases.
















Fig 3.18: Simulating external importations of infection into village populations. (A) By
running simulations with different values for the external infection parameter, we
find the best fit — to data binned by population size from the WHO HAT Atlas
on whether there are any detected cases on the first active screening — is when
imports per susceptible individual are equal to 3.4× 10−6 days−1 (solid line). (B)
Curves of the expected time for an external importation into a village population
using the fitted importation parameter. The importation parameter is assumed to
decay at the same rate as the total number of cases in time in the DRC (see Figure
3.19).
For most population sizes in the region, the expected time to importation is therefore
relatively long (Figure 3.18B), and in many cases a single importation will not cause
further transmission events (Figure 3.15), leading us to conclude that in general the
level of importation will not qualitatively change our results. As a validation of our
assumption that importations can be safely ignored over the time-scales of this study,
we re-examine the match between active-screenings that fail to detect cases and model
results including imports (Fig 3.20). This is a counterpoint to Figure 3.11. We find that
the inclusion of imports has an extremely small difference on the model predictions:
slightly improving the fit between model and data (Fig 3.20A). However, under this new
model, there is now an additional village where the model significantly predicts fewer
zero-detections than observed, decreasing the percentage of villages within the model
prediction intervals to 91.4% (Fig 3.20B). We conclude that this justifies our modelling
assumptions that villages act as isolated populations and that importation of infection is
unlikely to perturb the dynamics; instead, we are able to separate the processes of local
elimination and re-invasion.
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Fig 3.19: Change in the importation of infection parameter in time. (A) New cases of gHAT
detected in the DRC with fitted exponential decay [20]. (B) The decay of the rate
of importation of infection parameter is matched to the decay rate of cases of HAT
in the DRC.
The model predicts:
More zero-detections than observed
Fewer zero-detections than observed
Zero-detections like observed
B



























Fig 3.20: Comparison of model predictions and data for active screenings with no detected
cases (zero-detections) for the model with importations of infection. (A) His-
togram by population size of the percentage of active screenings that find no new
HAT cases for both the model and the HAT Atlas data. The differences between
this histogram and without importations of infection are very small. (B) Map of
populations in Yasa-Bonga and Mosango showing the settlements with significant
differences (at the 95% level) in the expected proportion of active screenings with
no cases detected. The addition of importations of infection means this model
fits the data less well, with an additional village falling outside the prediction
intervals. The underlying Landsat-8 satellite map is shown courtesy of the U.S.
Geological Survey.
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3.8 Discussion
Despite global declines in reported cases over the last decades, gambiense gHAT remains
a problem in many focal areas [79]. These regions, concentrated primarily in the
DRC, represent a significant challenge to achieving the WHO 2020 and 2030 goals
of elimination as a public health problem and zero transmission, respectively. Robust
models, matched to the available data, are the only viable means of quantitatively
assessing future dynamics and the long-term impact of controls [219, 220, 223, 224].
Active screening followed by treatment is one of the main control measures, but this
action is deployed at the village level suggesting that village-scale models (which
recognise the effects of small population size) may be needed to optimise deployment;
these results can then be scaled to an infection focus or national level to measure
regional elimination, which is especially important as we approach zero transmission.
We have introduced a dynamic, mechanistic, stochastic gHAT model, which is applied
to 559 settlements in the Yasa-Bonga and Mosango health zones within the former
Bandundu province of the DRC (Figure 3.2). Using parameters inferred from a deter-
ministic model fitted to aggregated reported cases, our model reliably captures observed
detection patterns at the village-scale (Figure 3.11). This comparison highlighted some
spatial heterogeneity associated with the local environmental conditions (significantly
fewer zero-detections than predicted occurred in regions close to large rivers, where the
tsetse density is presumably high); however, 91.6% of settlements fell within the model
(95%) prediction intervals, giving us confidence in our predictive ability. The inclusion of
such local environmental factors, which modify the underlying parameters, is clearly an
area for further research into refining this small-scale model and may help to practically
focus localised control measures, in particular for planning tsetse control.
Throughout our simulation experiments, we consistently find that gHAT persists better
in larger populations. This is as expected and agrees with theoretical work and analysis
of other diseases [255–258, 260, 261]; in small populations, the behaviour of the
individual is more important, and hence stochastic effects are magnified. The degree of
persistence predicted is, however, surprising; settlements of around 2,000 inhabitants,
where yearly incidence is only 13 new infections, frequently persist for 15 years or more
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(Figure 3.13). This should be contrasted with frequently studied, highly transmissible
diseases, such as measles, where local extinctions are common in population sizes of less
than 300,000[255, 256]. We attribute this pronounced difference to the much longer
time scales associated with gHAT, meaning single individuals can maintain infection,
and the vector-borne nature of gHAT transmission, such that the tsetse act as a short-
lived reservoir. We consistently find that incorporating active screening reduces the
persistence of infection (Figure 3.13A), although the distribution of screening across
years has only a small effect (Figure 3.13B). Increasing the screening coverage beyond
the average reported levels (of 21% per year) is predicted to lead to further reductions
in persistence, but infection is still predicted to be maintained for over 15 years in many
larger populations.
Throughout, we have generally ignored the impact of new infectious individuals entering
the population, and indeed have shown that this rate of importation is very low. If
re-invasion following local elimination is due to the movement of a single infected indi-
vidual into the settlement (Figure 3.15B), we predict that the probability of subsequent
cases is high (70–80%) and largely independent of population size. However, only
a small proportion (10–20%) of such invasions lead to long-term persistence of over
15 years. Re-establishment of infection due to the movement of a limited number of
infected tsetse is even less likely. Current uncertainties about the impact of potential
reservoirs — either a human reservoir of asymptomatic infections or an animal reservoir
— mean there is insufficient knowledge for resurgence to be explicitly modelled by these
mechanisms [184], but an animal reservoir that can maintain infection in the absence of
humans is likely to represent a worst-case scenario.
A key question, as we approach the 2030 goal of zero transmission, is to ascertain when
local elimination has been achieved, allowing policy-makers to scale back control if the
infection is no longer present. Due to only a limited proportion of each settlement being
screened and the potential for false negatives, a screening can fail to detect any cases
even when there is infection in the population. We have shown that, while a single
zero-detection screening provides relatively little information of the probability of local
gHAT elimination, multiple consecutive zero-detection screenings are a strong indicator
of elimination (Figure 3.16). This can be further strengthened if only large screens
3.8 Discussion 71
(> 50%) are included in the analysis (Figure 3.17B), providing valuable public health
information. This concurs with WHO guidelines for active screenings, as villages are no
longer considered in planning by mobile screening teams after three consecutive years
of zero-detections, followed by a further zero-detection after three years [240]; our
model would predict local elimination with large probability for this level of surveillance.
Consistent with the observed patterns in high endemicity regions, we have assumed that
the screening coverage and frequency remains constant over these time scales but note
that in other regions it may be important to consider the reduction in active screening
as reported gHAT cases decline and elimination is approached.
The ability to capture the stochastic dynamics and persistence of gambiense gHAT
infection at the village-scale is a major advance in public health modelling, with far-
reaching consequences for informing policy decisions. This is particularly pertinent as our
models operate at the same spatial scale as controls and can capture the local elimination




Optimising active screening for
gambiense human African
trypanosomiasis
Traditionally, the most effective form of controlling gambiense human African trypanoso-
miasis (gHAT) infection has been active screening and treatment [12, 97, 246]. This is
the screening that is carried out by mobile teams that travel to villages in focal disease
regions and target the screening of the full village population for gHAT; those deter-
mined to have the infection can then be treated at the closest health facility offering
treatment.
While active screening has been very effective in reducing case numbers and still has
an important role to maintain surveillance and availability of treatments, particularly
where access is a problem, it is an expensive intervention in both time and money [123,
154]. As some local elimination of gHAT is seen in focal areas, active screening will be
scaled back and gHAT testing will become more integrated into fixed health facilities,
as resources can be reallocated and it becomes no longer necessary to screen entire
village populations for the infection [127]. Reactive screening can also be implemented,
whereby after active screening has stopped, it can return upon a new case being reported
due to a diagnosis at a fixed health centre in the area [156].
In this chapter, we weigh up the costs and benefits of different active screening strategies,
by considering them in a net monetary benefit (NMB) framework. We explore the
modelling results from invoking different active screening intervention strategies and, by
applying costs to the outcomes of simulations, consider which strategies prove optimal
in both maximising the NMB and having the highest probability of being cost-effective.
With a limited number of active screening teams and resources for them to carry out
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their duties, it is imperative to optimise their activities whilst sustaining the aim of
driving towards elimination.
4.1 Considering the factors in optimising active
screening
HAT, including both gHAT and rHAT, caused an estimated 1,364 deaths in 2017 with
the global burden approximately 78,990 disability-adjusted life years (DALYS) [262].
The health problems caused by HAT are not just a burden for the individual, but are an
obstacle to economic and human development [3]; investments in health are profitable
in macroeconomic analysis. Thus, we aim to consider monetary benefits associated with
implementing interventions to reduce the health burden, alongside the monetary costs
of performing these different interventions.
We have explored mathematical models of gHAT and how they have been used for the
prediction of future case numbers and effect of a range of plausible control strategies
[146, 179, 186, 219, 220, 223, 224]. However, these have typically considered the
infection dynamics and impact of interventions without accounting for the costs of
implementing such strategies. We explicitly use an adapted stochastic model of gHAT
infection in a village population developed in Chapter 3 of this thesis to simulate different
plausible active screening programmes (and passive surveillance) to quantify the relative
costs of implementation as well as the effect on averting DALYs compared to a baseline
of only considering passive surveillance (the comparator strategy).
The costs of interventions have been previously been evaluated [154, 263–266] and
the different strategies for intervention types considered for large populations [142,
182]. We consider the effect of active screening on individual villages in the drive for
elimination of transmission (EOT), by determining how active screening can be best
implemented to achieve this goal whilst providing value for money.
4.1 Considering the factors in optimising active screening 74
Tab 4.1: Descriptions of the variables used for defining an active screening strategy.
Variable Name Definition Value range
c Screening
coverage
Proportion of the village popu-




Time between active screening




Number of consecutive active
screenings where no cases are





Number of consecutive reactive
screenings where no cases are
detected for the cessation of re-
active screening.
1–3 screenings
4.1.1 Active screening strategies
In determining how active screening should be performed, we consider four factors
that we construct to formulate a screening strategy for a village: screening coverage
c, screening interval t, active zero-detections za, and reactive zero-detections zr (see
Table 4.1). Like in the model from Chapter 3, individuals in the human population are
classified as either high-risk or low-risk [219], whereby the high-risk population have a
higher exposure to tsetse and do not participate in active screening. This means that
the screening coverage is assumed to have a maximum of less than 100%, since only
the low-risk human population participate (randomly) in active screening. We have
estimated in model fitting that the maximum screening coverage is therefore 91.4%
(see Section 4.2.2, note that this is a different value from Chapter 3). The screening
interval t is the length of time between active screening visits to a village, which we
limit to being between four visits per year and one visit every five years. The active
zero-detections za represent the cessation criterion for the strategy, whereby if a village
is screened za times consecutively, with no cases detected on each screening, the active
screening should terminate. Reactive screening is the resumption of active screening
and occurs upon detection of a case in passive surveillance after active screening has
been stopped; reactive zero-detections zr are the number of these screenings that should
occur consecutively with no cases detected before this screening is stopped again.
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An active screening is generally assumed to aim for as high a screening coverage as
possible, depending on the availability and consent of the population to be tested.
However, there is limited evidence for how frequently these active screenings should
occur and when they should stop if no cases are found. Several active screening strategies
have been proposed including a recommendation of three repeated screening rounds
with one year intervals [118], or using six month intervals [119]. The cessation criteria
also has limited evidence to support its value, although, as we showed in Chapter 3,
multiple active zero-detections in a village are required to have confidence of local
gHAT elimination. The WHO guidelines currently recommend three years of zero case
reporting before stopping active screening in previously endemic villages [267].
To consider how to optimise over these four variables, we return to our stochastic
gHAT model to obtain output on the infection dynamics for different active screening
strategies.
4.2 Adapting the gHAT model
To capture how implementing different active screening strategies affects the underlying
infection dynamics on a village population, we use the stochastic compartmental model
from Chapter 3. The stochasticity incorporates the chance events involved in infection
transmission into the mechanistic model and is more suited than a deterministic model
for the case of optimising active screening for a village population. This is because
the population, and hence the number of people infected, is small and so, for the
pre-elimination setting, extinction of gHAT can be directly reflected with a stochastic
framework. A deterministic formulation, which captures average dynamics, would be
less suitable to capture the chance events associated with village level extinction of
infection.
The previous stochastic gHAT model from Chapter 3 is updated based on model re-
finements from Crump et al. [268] to both more accurately fit the data from the WHO
HAT Atlas [106, 107] (now using data from years 2000–2016) and to better reflect
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the underlying biology of the system. This is done by both re-structuring the exact
formulation of our model and by re-fitting to the data.
4.2.1 Modifying the model
The tsetse modelling compartments are updated from the model structure used in
[219] to include tsetse beginning life in the pupal stage, rather than simply being born
susceptible [223, 224]. This introduces four additional parameters, BV , a constant
deposit rate into the pupal stage (a birth rate), ξV , the pupal death rate, KV , pupal
density dependence, and P (survive), the probability of pupating. These parameters
are not fitted, but taken as fixed values from the literature (see Table 4.2). This new
model with an explicit pupal stage, density dependent mortality and target-dependent
deaths only occur with feeding, increases the biological relevance of the model by
incorporating further aspects of the life cycle explicit to tsetse, while not introducing too
many parameters and remaining tractable.
Additionally, we had previously assumed that passive infections were only detected,
and hence moved to the hospitialised class, RH , from Stage 2 infection. We therefore
introduce an exit rate from Stage 1 infection ηH . Both the exit rates from Stage
1 and Stage 2, ηH and γH , are found in model fitting, but we also assume these
values change in time. We assume a sigmoid function, to increase the rate in time,
as passive surveillance quality increases. This is parameterised using an additional
four parameters that are also found in model fitting. The parameters ηHamp and γHamp
specify the maximum increase in the value of their respective parameters, dsteep specifies
the steepness of the improvement rates, and dchange gives the switching year of the
improvement rate. We also distinguish between baseline exit rates for pre-1998 and
post-1998, whereby there is a step change at 1998 before the sigmoid function is
introduced. The pre-1998 rates are used for determining the initial conditions at






















These changes to the model structure are summarised in Figure 4.1.
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Fig 4.1: An updated model schematic for the gHAT infection dynamics used in this chapter.
4.2.2 Fitting to a new health zone
In this chapter, we choose to use model fitting for a different health zone in the DRC.
This health zone, Kwamouth, is located close to Yasa-Bonga and Mosango, but in the
Mai-Ndombe province (yet also still in the former Bandundu province) and is highly
endemic with gHAT. This health zone was chosen as an example with a high number of
gHAT cases and, at the time of choosing, had had no vector control activities that would
complicate the modelling dynamics. We will also briefly consider using our methods in
this Chapter on the same model, but parameterised for Mosango (rather than Mosango
and Yasa-Bonga in Chapter 3) for comparison.
The active screening coverages of these two health zones have similar median values
(when ignoring outliers of very high coverages or small coverages, that are likely to be
residents of villages that travel to a different active screening, yet are recorded as their
home village). We see the median coverage for Kwamouth is 55% and Mosango is 57%.
The full distribution is shown in Figure 4.2.
We will primarily focus on Kwamouth in this chapter. A full list of the fitted and fixed
parameter values for our model is shown in Table 4.2. These parameter values are
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Fig 4.2: Histograms of screening coverages for (A) Kwamouth and (B) Mosango. We show
the coverages below 20% in grey and above the full low risk group population
screened in red, with typical screening coverages shown in green.
taken from Crump et al. [268], which were either sourced from literature, where well-
defined, or otherwise (in the case of meff, R1, R2, r, u, others) taken as the median of
the distribution obtained by model fitting using a Metropolis–Hastings MCMC algorithm
that matched the deterministic version of the model to incidence data from the WHO
HAT Atlas [106, 107].
4.2.3 Simulating active screening
In villages targeted for active screening, we consider how the infection dynamics are
affected by: the screening coverage c; the screening interval t; active zero-detections za;
reactive zero-detections zr (see Table 4.1). This is modelled by taking all combinations of
c, t, za and zr for the values c = 0, 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70,
75, 80, 85, 90, 91.4%, t = 0.25, 0.33, 0.5, 0.67, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5,
4, 4.5, 5 years, za = 1, 2, 3, 4, 5 screenings, and zr = 1, 2, 3 screenings. The specified
screening procedure is then implemented in the model by using the screening coverage
to randomly select this proportion of the population from the low-risk sub-population,
which move into the hospitalised class if they are correctly identified as being exposed
to the infection after each screening interval. This process is stopped after the given
number of zero-detections. However, if the infection has not been eliminated after the
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Tab 4.2: Parameter notation and values for the gHAT infection model.
Parameter Description Value Source
µH Natural human mortality rate 5.4795 × 10−5
days−1
[269]
ωH Human recovery rate 0.006 days−1 [117]
σH Human incubation rate 0.0833 days−1 [214]
φH Stage 1 to 2 progression 0.0019 days−1 [77, 245]










ηHamp Maximum increase in the stage 1 exit
rate
0.922 [268]
γpreH Pre-1998 exit rate from Stage 2 by treat-
ment or death
0.006 days−1 [268]
γpostH Post-1998 exit rate from Stage 2 by
treatment or death
0.006 days−1 [268]
γHamp Maximum increase in the stage 2 exit
rate
0.922 [268]
dsteep Steepness of the improvement rates for
stage 1 and stage 2 passive detection
1.106 [268]
dchange Switching year of the improvement rate
for stage 1 and stage 2 passive detection
2008 [268]
NH Human population size Varies N/A
µV Tsetse mortality rate 0.03 days−1 [214]
σV Tsetse incubation rate 0.034 days−1 [242, 270]
ε Reduced non-teneral susceptibility fac-
tor
0.05 [268]
α Tsetse bite rate 0.333 days−1 [267]
m Relative tsetse density Varies N/A
pH Probability of human infection per sin-
gle infective bite
Varies N/A
meff Effective tsetse density 6.56 [268]
pV Probability of tsetse infection per single
infective bite
0.065 [214]
fH Proportion of blood-meals on humans 0.09 [243]
KV Pupal density dependence 111.09 [223]
P (survive) Probability of pupating 0.75 [223]
ξV Pupal death rate 0.037 [223]
BV Total deposit rate 0.0505 [223]
Se Sensitivity 0.91 [252]
Sp Specificity 0.99958 [268]
R1 Proportion of low-risk humans, ran-
domly participating in screening
0.924 [268]
R2 Proportion of high-risk humans, not par-
ticipating in screening
0.076 [268]
r Relative bites taken on high-risk hu-
mans compared to low-risk
6.6 [268]
u Reporting probability for Stage 2 cases 0.26 [268]
δ Importation of infection rate 3.4 × 10−6
days−1
Chapter 3
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active screening has been halted, there is a chance that a new case can be reported
by the individual attending a fixed facility to be tested for the infection. The model
explicitly incorporates under-reporting of passive case detections, such that only 29% of
cases not picked up through active screening will be reported in passive surveillance.
This parameter was estimated in model fitting, taken as the median of the distribution
inferred using MCMC methodology applied to the aggregate annual data from Kwamouth
from the WHO HAT Atlas [106, 107]. Thus, we re-start the screening procedure as
reactive screening upon identification of these passive cases, stopping again after the
given number of consecutive reactive zero-detections, zr.
The WHO propose to aim for high screening coverage in active screenings for villages in
gHAT-endemic foci, and guidelines suggest these screenings should continue annually
until there have been three consecutive years of no new cases, followed by a further
screening after three years if there are no detected cases [267]. Our modelling aims
to provide evidence to support this strategy or recommend how the strategy could be
adapted to make more efficient use of resources.
4.3 Using the net monetary benefit framework
We want to apply costs to our models, since while without costs, we can still provide
recommendations on strategies that will achieve elimination or a reduction in cases and
the timescales involved, we know there will be monetary constraints on which strategies
are feasible to fund. Thus, considering costs and also providing cost-effectiveness
analysis provides additional information, important to the potential funders of these
programmes.
The cost of an active screening strategy is a function of several component costs:
implementing the screening test, confirmation of the infection, carrying out treatments,
setting up and maintaining the mobile screening teams, and the change in number of
passive tests and treatments caused by the change in active screening activity. We do
not consider the additional costs of passive surveillance, such as capital costs, only the
costs directly affected by active screening. The active screening strategy costs will vary
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depending on the type of screening test and treatment used, and also the type of mobile
screening team, like a truck team that can carry more tests and equipment, such as a
generator, or a motorbike team, which can reach more remote villages [271].
As well as considering the changes in monetary costs, we want to consider the change in
the health benefit of implementing different active screening programmes. Therefore, we
consider the number of DALYs averted [272]. The number of DALYs are the discounted
sum of the number of years of life lost (YLL) and years lived with disability (YLD), where
YLL is the number of years of life lost due to premature death and YLD is the number
of years of healthy years lost with a weighting for the severity of the condition [273].
We calculate the number of DALYs averted by a particular screening programme by
comparing with a baseline of doing only passive surveillance and no active screening
(our comparator strategy).
We evaluate the net monetary benefit (NMB) to assess the cost-effectiveness. For each
active screening strategy, the NMB was calculated as:
NMB = WTP× DALYs averted
− Cost of active screening strategy compared to passive surveillance only.
(4.1)
The willingness to pay (WTP) is the maximum amount of money that the funder is
prepared to pay to gain the health benefit of averting one DALY. The number of DALYs
averted is the negative change in DALYs from the comparator strategy (specifically,
implementing the active screening programme from only passive surveillance and no
active screening). The change in costs is the cost of implementing the active screening
strategy, including the consequential change in cost of passive surveillance, minus the
cost of baseline passive surveillance. A particular strategy is more beneficial than the
comparator strategy if the NMB is positive. The NMB will be highly dependent on the
value of the WTP, hence, we consider a range of fixed WTP thresholds, such that an
optimal strategy can be determined for a given WTP. Typically, the WTP is taken as the
product of the gross domestic product (GDP) per capita of a country and a multiplying
factor. This factor is traditionally given as 3 [274], but this is often considered too high
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for low-income countries [275] and so 0.5 is also used [276, 277]. Additional to the
WTP, the NMB will be affected by the population size of a village, NH , the proportion of
infections, excluding those detected in active screening, that are detected and treated
passively pt, and the initial level of infection in the population.
To evaluate the NMB, we consider all component costs and the associated health benefits
of implementing an active screening strategy. However, we do not consider out-of-
pocket expenses, and so frame the model as from the perspective of the funder of the
programme. Since we are considering the NMB of an active screening strategy, we
only consider costs impacted by this and so do not consider costs such as maintaining
a fixed health centre, which would exist regardless, given our baseline strategy of
continued passive surveillance. We do note that passive treatment costs will depend
on the quantity of active screening carried out and additionally on the proportion of
infections that are detected passively. Since we assume 29% of infections that are not
found in active screening are reported, we can make the worst case assumption that
while all these reported infections are treated passively, none of the unreported infections
will be treated. Alternatively, we use the parameter pt for the proportion of infections,
excluding those detected in active screening, that are treated passively. This parameter
takes values in the interval 29–100%, such that the proportion of infections being treated
is between only those reported being treated and all infections being treated.
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Using the formulation of the NMB given by 4.1, we then define the constituent parts of
the equation as follows:





(Change exits from Stage 2 infection ) (t) ζ (t) (4.3)
+D2
∫
(Change in Stage 1 infections) (t) ζ (t) dt (4.4)
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(Treatment of Stage 2 cases) (t) ζ (t) . (4.13)
The willingness-to-pay, which is in units of 2018 US dollars per DALY, is split into the
GDP per capita of the DRC, G, and a multiplying factor, WTPc as is common in the
literature (Equation 4.2) [274]. For the health benefit of the intervention, the DALYs
averted is the discounted sum of the number of years of life lost (YLL) and years lived
with disability (YLD). The number of years of life lost is given by the sum of the change in
number of people that exit the Stage 2 infection class multiplied by both the proportion
of these infections not treated (1− pt) and the discounted average years of life lost per
death (Equation 4.3). The number of years lived with disability is given by the total time
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spent in each infection class multiplied by the associated disability weight (Equations
4.4 and 4.5).
The change in costs is simply the costs incurred by implementing the active screening
strategy and the effect on costs of operating passive surveillance. This is given as a capital
cost of active screening (Equation 4.6) and the recurrent cost of operating each visit
(Equation 4.7), the number of screening tests carried out (Equation 4.8), confirmation of
the infection and stage determination for the true positive (Equation 4.9) and negative
confirmation for the false positives (Equation 4.10), the change in testing, confirmation
and stage determination for passive infections (Equation 4.11), and the treatment of
detected cases (Equations 4.12 and 4.13).
For calculating both the health benefit costs and active screening implementation costs,
we use a discounting rate of 3% annually [278], denoted in the equations by ζ(t) =
exp (−δt). The time horizon used is 30 years, which is sufficient to capture almost all
the costs of the active screening programme (see Figure 4.12). The cost parameters are
taken as fixed values and are a function of the cost of the test or treatment, the cost of
implementation and the cost of hospitalisation [142]. These costs are also dependent on
the type of treatment; we primarily consider active screening to use the CATT algorithm,
while Stage 1 and Stage 2 treatments use pentamidine and NECT respectively, but later
consider the additional treatments of fexinidazole and acoziborale. The former we
expect to become the standard in 2020 for many gHAT patients [279], and the latter
could replace it as a single dose cure a few years later if it passes phase III clinical trials
and receives an appropriate recommendation [280] (see Figure 4.13).
4.4 Determining cost and health parameters
In developing a parameterised cost function for active screening strategies, we have
ensured transferability of costs across time by updating all values to 2018 US dollars
(USD). All costs are converted to local currency units in the year of the study, inflated
with the consumer price index (CPI) to find the 2018 values, and then converted to
2018 USD with the exchange rate. We also ensure transferability of costs across settings,
4.4 Determining cost and health parameters 85
by following the 2003 WHO Guide to Cost-effectiveness recommendations [278]. For
non-traded items (nurse and doctor time) we turn the USD or local currency unit (LCU)
prices into PPP (international dollars) in the year of the cost study and then turn the
value in international dollars to local currency (still in the year of the study) of the
country where a cost estimate is needed. Then, we use the CPI to inflate costs to 2018
levels and then use the exchange rate with USD to get 2018 USD values.
We provide a list of all the component parameters we used to determine our model cost
parameters (Table 4.3). We then convert these parameters into values that can be used
directly in our NMB function (Table 4.4). All NMB parameters are taken as fixed values
in this study.
All parameters were obtained by an extensive literature search, which were then
converted, as described above into 2018 USD. Alternative costings are available in
Table 4.3 and explored in Figure 4.13. We are aware that costs change over time
and people can have different opinions on the value they should take [7]. We there-
fore provide a full choice for the values of our cost parameters in generating our
results. These can be selected using the developed companion webapp at https:
//christopherdavis.shinyapps.io/optimising-ghat-active-screening/, where
a selection of results from this chapter can be viewed for any chosen parameter value.
4.5 A breakdown of the costs of active screening
We now use the stochastic compartmental model from Chapter 3 with updated model
structure and a new parameterisation for the Kwamouth health zone in the DRC to
simulate our different strategies for active screening. We simulate each strategy by
changing the value of our variables: screening coverage c, screening interval t, active
zero-detections za, and reactive zero-detections zr (see Table 4.1). In particular we note
that in the model, individuals in the human population are classified as either high-risk
or low-risk [219], whereby the high-risk population (a small minority, which has been
previously estimated to be 8.6% the study health zone of Kwamouth [268]) have a
higher exposure to tsetse and do not participate in active screening. This means that the
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Tab 4.3: Net monetary benefit component parameters that determine our full NMB param-
eters. All values are assumed fixed. All costs are in 2018 USD.
Parameter Description Value Source
Ddeath Age of death from infection 27 years [281]
Dlife Life expectancy 60.21 years [244]
Dstage1 Disability weight – Stage 1 0.133 [282]
Dstage2 Disability weight – Stage 2 0.5432 [282]
Ncap Active screening capacity per
year
60,000 [154]
Ccap Capital costs of a traditional
active control team
$11,406 [266]
Crec Recurrent costs of a traditional
active control team
$40,000 [266]
Ccatt CATT algorithm cost $0.57 [154, 263]
Mwasa CATT wastage in active screen-
ing mark up
1.08 [266]
Mwastep CATT wastage in passive
surveillance mark up
1.25 [265]
Crdt RDT algorithm cost $1.496 [154]
Cmic1 Microscopy (blood sample,
LNA, mAECT)cost
$9.53 [265]
Cmic2 Microscopy (blood sample,
LNA, CTC, mAECT) cost
$11.30 [265]
Clumb Lumbar puncture and labora-
tory exam cost
$23.02 [283]
Cout Outpatient consultation cost $0.43 [284, 285]
Cin Hospital day cost $1.40 [284, 285]
Cpent Course of pentamidine cost $54 [264]
Lpent Length of hospital stay for pen-
tamidine
7 days [286]
Cnect Course of NECT cost $460 [178]
Lnect Length of hospital stay for
NECT
10 days [178]
Cfex Course of fexinidazole cost $50 [142]
Lfex Length of hospital stay for fex-
inidazole
10 days [178]
Mdel Drug delivery mark up 1.45 [284, 285]
Mprog National programme mark up 1.15 [266]
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Tab 4.4: Parameters for calculating the NMB.




G GDP per capita for the
DRC1
$457.85 G
D1 Discounted average years
of life lost per death
21.03 years Dlife −Ddeath
D2 Stage 1 disability weight 0.1330 Dstage1
D3 Stage 2 disability weight 0.5432 Dstage2
C1 Active screening capital
cost per person
$0.22 CcapMprog/Ncap
C2 Active screening recurrent
cost per person
$0.77 CrecMprog/Ncap
C3 Active screening test per
person 2
$1.03 CcattMdelMwasteaMprog
C4 Confirmation per person 3 $10.96 (Cmic1 + Clumb)Mprog
C5 Stage determination per
person 3
$26.46 Cmic1Mprog
C6 Passive screening person 3,4 $39.12 (CcattMdelMwasp + Cout+
Cmic1 + Clumb)Mprog
C7 Stage treatment per person
5
$101.32 (CpentMdel + CinLpent)Mprog
C8 Stage 2 treatment per per-
son 6
$783.15 (CnectMdel + CinLnect)Mprog
NH Population size Varies NH
12018 value used. 2We assume the use of the card agglutination test for trypanoso-
miasis (CATT) test. 3We assume confirmation is by microscopy using a blood
sample, lymph node aspiration (LNA) and mini Anion Exchange Centrifugation
Technique (mAECT). 4Passive screening includes the screening test (CATT),
outpatient consultation, confirmation and stage determination. 5We assume the use
of pentamidine. 6We assume the use of nifurtimox-eflornithine combination therapy
(NECT).
screening coverage is assumed to have a maximum of 91.4%, since only the low-risk
human population participate (randomly) in active screening.
We first consider an active screening strategy with a typical screening coverage of
55% (median coverage for Kwamouth), carried out annually, and with three active
zero-detections and one reactive zero-detection required for the cessation of screening
(c = 55%, t = 1 year, za = 3, and zr = 1), for a village population starting from
endemic equilibrium of size NH = 1, 000, and with 29% of infections not detected in
active screening treated passively (pt = 29%). We simulate the model for one million
realisations and calculate mean values of the simulations. For the chosen strategy,
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the infection in both the human and tsetse populations rapidly decays towards zero
(Figure 4.3A). The annual cost of implementing this strategy also decreases with time
(Figure 4.3B); this is in part due to 3% discounting, the method of adjusting future
costs to present day value (which is applied to both costs and DALYs averted) [278], but
also because decreasing the infection in the population reduces the required number
of treatments. Since even with no active screening, the infection may die out in the
village due to stochastic fade out, there is a small annual increase in costs after ten
years since the difference in the number of infections treated in passive surveillance
is smaller in later years, however, this decays towards zero as the probability of gHAT
extinction increases with time. While some recurrent costs will remain, the number
of treatments will decrease in time with the corresponding reduction in infections. In
addition, the cost also decreases since if the consecutive zero detection threshold is
reached, the cost of the active screening is completely removed. With the assumption of
pt = 29%, the number of DALYs averted will initially increase each year, due to the effect
of fewer people becoming infected and more being treated, before decreasing with the
discounting (Figure 4.3B).
A breakdown of the components for the NMB of implementing this active screening
strategy shows that the biggest costs are the treatment of Stage 2 individuals, the
recurrent costs of the active screening and screening populations with the CATT test
(Figure 4.3C). However, assuming a WTP of 50% of the GDP per capita of the DRC
(WTPc = 0.5 giving a total WTP of $280.89 [287]) the monetary benefit in reducing the
years of life lost is dominant and the biggest factor in maximising the NMB. The total
NMB (black bars) shows the full benefit of this active screening strategy is always positive
and so, on average, this strategy is better than the comparator of no active screening.
Further into the future, the NMB moves closer to zero, both because of discounting and
since there is a higher probability the infection will be locally extinct, and so active
screening not required. The table in Figure 4.3C shows the NMB breakdown in full.
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Annual net monetary benefit in year n ($)
Colour Benefit/cost description n = 1 n = 5 n = 10 n = 20 n = 30
Active screening tests −559.45 −496.19 −426.52 −252.74 −28.74
Active Stage 1 treatment −642.69 −278.26 −143.37 −13.58 −1.36
Passive Stage 1 treatment +25.10 +38.16 +73.69 +17.21 +3.31
Active Stage 2 treatment −7, 259.56 −1, 304.34 −614.10 −54.08 −5.42
Passive Stage 2 treatment +1, 006.08 +1, 407.29 +1, 203.59 +199.86 +36.48
Active gHAT confirmation −579.10 −106.30 −78.14 −5.12 −0.76
Passive gHAT confirmation −308.39 −216.94 −193.73 −27.83 −4.26
Active capital costs −215.37 −191.01 −164.20 −97.30 −11.06
Active recurrent costs −766.67 −679.97 −583.27 −324.41 −34.81
Averted years of life lost +18, 448.30 +25, 805.15 +22, 069.92 +3, 664.74 +669.01
Averted years lost due to
Stage 1 disability
+174.77 +251.10 +187.28 +36.36 +6.98
Averted years lost due to
Stage 2 disability
+1, 286.63 +1, 770.72 +1, 077.10 +162.83 +29.76
Total +10, 967.30 +26, 237.66 +22, 682.17 +3, 345.44 +666.50
Fig 4.3: The cost of active screening for a coverage of 55%, a screening interval of 1
year, stopping active screening after 3 screenings when no cases are detected and
stopping reactive screening after 1 screening with no cases. (A) The number of
infected people dramatically decreases with time for this coverage (total shaded
blue area, with left axis) with the majority of these infections being in the high-risk
group (darker blue fraction). The proportion of tsetse that are also infective is
reduced with time (green line, with right axis). (B) The mean total change in costs
of implementing a particular screening strategy (left axis) and the mean number of
DALYs averted from the baseline of only passive surveillance (right axis). (C) The
contribution to the cost from each component of the cost function for years 1, 5,
10, 20 and 30 after starting an active screening program. Full costs are given in the
table below. A population size of NH = 1, 000 is used. All costs in 2018 US dollars.
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Fig 4.4: The NMB of different active screening strategies for given WTP per DALY averted
(given as multiplication factor WTPc of GDP per capita from the DRC) and the
proportion of passive infections that are treated, pt. We show the mean NMB value
over one million simulations. The red areas show a negative NMB, while blue areas
are positive NMB, with white at the boundary of no change. The maximum NMB
for each WTPc and pt combination is marked by a yellow circle on each heatmap,
with a cross if the maximum is for no active screening (only observed here for
WTPc = 0 and pt = 29%). A population size of NH = 1, 000 is used and we fix
za = 3.
4.6 Variations of costs between strategies
The NMB for some strategies is highly dependent on both the WTP and the proportion
of passive infections treated pt, with (1− pt) suffering disease-induced mortality. Thus,
for different values of WTP and pt, we directly consider the value of the NMB across
different screening strategies, by varying the screening coverage c and screening interval
t (Figure 4.4). Increasing the WTP is particularly effective in increasing the NMB for
active screening strategies where lots of people are screened who otherwise would not
have been; more infections are likely to be detected and so more DALYs will be averted,
which are increasingly high valued.
When pt = 100%, the assumption is that all infections are eventually treated; this means
that there is no loss of life, which would otherwise be a large component of the change
in NMB. Thus, for high pt, active screening strategies with low coverage will have a
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lower NMB than for when pt is smaller, since the implementation costs will be high,
but the effect will be minimal as baseline passive surveillance is already very effective.
Fewer strategies will achieve a positive NMB for higher pt, however, if the coverage is
high enough, these strategies can still have a positive NMB (Figure 4.4).
For WTPc = 0.5 and pt = 29% (our standard assumption), the maximum NMB is found
when the screening coverage is at the maximum of 91.4% and the screening interval is
at 0.75 years (Figure 4.4; yellow dot in top centre panel). This is true for all values of
the number of zero-detections, with the minimum found at za = 1 and zr = 1.
4.7 Maximising the net monetary benefit
We present the active screening strategy that gives the maximum increase in NMB over
our comparator strategy over a range of values of WTP, since the actual value of WTP is
entirely at the discretion of the funder. To do this, we apply costs (see Table 4.4) to the
mean simulation outputs to see which strategy, on average, provides the largest NMB.
Each line in Figure 4.5A–C shows the value of c, t and za that together give the optimum
strategy, for given pt values at each value of WTP. For WTPc = 0.5 and pt = 29%, we
maximum NMB is obtained for c = 91.4%, t = 0.75 years, and za = 1 (Figure 4.5A–C).
Figure 4.5D–F considers the same results for different fixed NH and initial conditions of
the simulation, all with pt = 29%. We fix zr = 1 for all simulations.
Screening coverage, c, is optimal when either 0% (not doing any screening) or at a
very high coverage (the maximum of 91.4%). For pt = 29%, active screening at the
maximum coverage becomes optimal for WTPc > 0.03 (Figure 4.5A). This means if
there is no WTP to avert DALYs, it is best not to incur any screening costs, since the
NMB will be negative, however, if the WTP is above this threshold it becomes worth
screening entire village populations to reduce the number of infected people and prevent
further transmission. The threshold WTP where maximal screening coverage becomes
optimal decreases for larger values of pt. This is because more infections are already
being treated and so the additional cost of active screening is smaller and it becomes
beneficial to treat all cases faster if they will eventually be treated regardless.
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Fig 4.5: Theoretical optimum strategy for mean simulation of infection dynamics given WTP.
(A-C) The screening coverage, screening interval and number of zero-detections
required to stop screening (respectively) that achieves the highest NMB for given
WTP assuming a village population of 1,000, where the disease is endemic. (D-F)
Optimum screening coverage, screening interval and number of zero-detections
required to stop screening additionally for a village population of 250, a population
of 1,000, where only one person is initially infected (S) as opposed to endemic
(E), and an endemic population of 1,000 with a small probability of infectious
importations being introduced (I).
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The screening interval, t, decreases with increasing WTP, since screening more fre-
quently will reduce transmission more quickly, which is more advantageous when DALYs
are valued more highly. We also show that in this scenario active screening can only
be optimal when it is implemented every two years or more frequently, typically ap-
proximately annually (Figure 4.5B). For most WTP values, a single zero-detection is
enough to justify cessation of active screening, however as the funder becomes willing
to pay larger amounts to avert DALYs caused by gHAT, there is benefit in waiting longer
before stopping active screening to ensure the infection is completely removed from the
population and to prevent any DALYs being incurred (Figure 4.5C).
Additionally, we have considered three other scenarios: a smaller village population
NH = 250; the population starting with a single infection as opposed to the disease being
endemic, mimicking a local post-elimination reintroduction of the infection; and when
a small chance an imported infection is present (Figure 4.5D–F). For scenarios where
the population size NH = 1, 000, the results are qualitatively similar, with less active
screening optimal for when there are fewer infections (due to the single reintroduction),
and more active screening optimal when there are more infections (due to a low level of
imported infections). For a smaller population NH = 250, it is more effective to have
a shorter screening interval and more zero-detections to be sure of local elimination,
since the cost of active screening is smaller when there are fewer people needing to be
screened.
The results in Figure 4.5 calculate the optimal strategy for the mean infection dynamics
for specific pt values. However, since pt is a continuous variable that can take any
value in the interval between the values presented in Figure 4.4, we additionally show
heatmaps for the optimal strategy across all pt values (Figure 4.6A–C). The associated
NMB of the optimal strategy and broken down into the cost of the strategy and the
number of DALYs averted is also displayed in Figure 4.6D–F).
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Fig 4.6: Theoretical optimum strategy for mean simulation of infection dynamics given
WTP and pt. (A-C) The screening coverage, screening interval and number of
zero-detections required to stop screening (respectively) that achieves the highest
NMB. (D) The NMB of that strategy. (E) The change in cost. (F) The number of
DALYs averted. We use a village population of 1,000, where the disease is endemic.
The plots are grey where no active screening is the optimal strategy.
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4.8 Limiting analysis to practical strategies
A high screening coverage on an active screening is desirable for strategy planners in
order that the maximum number of people are screened for a minimum number of visits
[115]. We have also shown that this is the most beneficial way of implementing active
screening (Figure 4.5). However, unlike the screening interval and active zero-detections,
which are determined by when active screening teams choose to visit, it is not realistic to
choose a level of screening coverage. The screening coverage will depend on availability
and consent of the population to be tested. The village population may be reluctant to
submit to screening or simply not be present in the village when the screening teams
arrive [117]; attendance at active screening is often low [288]. In Kwamouth, for
2000–2016, a median screening coverage of 55% was achieved for all village-level active
screenings taken from the WHO HAT Atlas [106, 107].
Therefore, since a high screening coverage cannot be guaranteed, we consider the
optimum active screening strategy over mean infection dynamics when we have imposed
a maximum on the screening coverage. This achieves an understanding of what the best
strategy could be for a given level of obtainable screening coverage. A higher maximum
level of screening coverage means the optimum active screening strategy will have a
large screening interval and a small number of zero-detections required to justify the
cessation of active screening. For the very low maximum screening coverage of 5%, the
optimum is a screening four times a year t = 0.25 and five zero-detections to stop za = 5,
while for high coverages, we see the expected result of t ≈ 1 and za = 1 (Figure 4.7). For
the median screening coverage in Kwamouth of 55%, the optimal strategy is an active
screening every six months, with two active zero-detection required for cessation.
4.9 Considering cost-effectiveness
While we have determined which strategy, on average, maximises the NMB and so can be
considered optimal (and for achievable levels of screening coverage), we now consider
cost-effectiveness. Therefore, we now restrict the number of strategies we consider to a
smaller number of options. For this process, we have selected seven options: doing no
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Fig 4.7: Optimal strategy given a maximum screening coverage. Results are shown for a
WTPc = 0.2, 0.5, 3. zr = 1, pt = 29%, NH = 1, 000 are fixed and the optimum
t and za is found simultaneously. (A) Optimal screening interval t. (B) Optimal
number of zero-detections to stop screening za.
active screening and six realistic proposal schemes for active screening including biennial
and annual screening with different cessation criteria. These active screening strategies
are shown in Table 4.5 and we keep zr = 1, pt = 29% and NH = 1, 000 constant, with
simulations started from the endemic equilibrium initial conditions.
For our comparator strategy, passive surveillance only, the total cost of implementing
this as a strategy for active screening, is the cost of testing and treating self-presenting
individuals infected with gHAT. We still do not include the fixed costs of continually
operating passive surveillance, as we assume that implementing a strategy does not
change this cost. Thus, Table 4.5 shows the average cost of only treating self-presenting
patients is $36,255.05 and since we are considering this our baseline strategy, zero
DALYs are averted from this process.
By implementing some active screening, the total costs increase, and the strategies are
able to avert DALYs. Annual screening costs more than biennial screening, since the
screening is occurring more regularly, but a correspondingly larger number of DALYs
are averted. Increasing the number of active zero-detections, increases costs, but on
average, only a very small number of additional DALYs are averted for annual screening
(and indeed the 95% confidence intervals for total DALYs averted slightly overlap).
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Tab 4.5: Active screening strategies considered in the probability of cost-effectiveness
























2 Biennial screening with
one zero for cessation





3 Biennial screening with
two zeros for cessation





4 Biennial screening with
three zeros for cessation





5 Annual screening with
one zero for cessation





6 Annual screening with
two zeros for cessation





7 Annual screening with
three zeros for cessation





1The comparator strategy. 2Relative to Strategy 1. 3Relative to Strategy 2. 4Relative
to Strategy 3. 5Relative to Strategy 5. 6Relative to Strategy 6.
The ICER is the ratio of the change in cost to change in DALYs averted relative to the
next best option. These values are shown in Table 4.5. The values determine the WTP
thresholds for a screening strategy to be chosen over the next best option in terms of
DALYs averted. For biennial active screening to occur the funder needs to be willing to
pay $17.91 per DALY, and for annual screening to occur over biennial active screening,
$24.60 per DALY is required. Significantly larger WTP values are needed for multiple
active zero-detections, but if the WTP was large enough these could be implemented,
although not instead of a shorter time interval. However, in considering the high WTP
needed for multiple active zero-detections, we have not included any additional benefits
for achieving local gHAT elimination that may be highly valued enough to include more
active zero-detections in the screening strategy at the additional cost.
Not every village will experience gHAT infection the same as the mean infection profile.
Hence, we aim to account for uncertainty and consider each individual realisation of the
stochastic epidemic process to measure the probability a strategy is cost-effective. Using
the full range of possibilities for the infection dynamics is particularly important for
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gHAT infection in a village as we know there is potential for large differences between
seemingly identical villages, due to the focal nature of the infection. Therefore, we have
simulated the infection dynamics of each strategy one million times to compare how the
costs and number of DALYs averted vary.
Evidently, even when there is no active screening, there will be variations in the cost
and the number of DALYs incurred. Here, this is particularly well correlated as the cost
is due solely to passive detection and treatment. The more infections there are in the
village, the more treatments that will be performed at increased cost and the more DALYs
that will be incurred, decreasing the total number of DALYs averted from the expected
value. When there are few infections, the total number of DALYs for the village will be
lower (and so more DALYs averted) and the cost of detection and treatment will also be
lower. There is a large variation in the possible outcome in terms of both cost and DALYs
averted when there is no active screening, which is entirely dependent on the number of
cases of infection that occur (Figure 4.8A).
There is a similar pattern for when active screening exists at some coverage, but the
range of introduced costs and the number of occurring treatments increases, expanding
the number of possibilities for the overall infection dynamics, and so the correlation is
smaller. However, reducing the screening interval, both increases the costs and reduces
the number of DALYs incurred. Results for varying the number of zero-detections are
still marginal when considering all realisations of the process, as compared with the
mean values (Figure 4.8A).
We have calculated the probability a strategy is cost-effective for a given WTP value by
taking the proportion of our one million simulations that each strategy has the largest
NMB (Figure 4.8B). These are the cost-effectiveness acceptability curves (CEACs). The
strategy with no active screening has the highest probability of being cost-effective for
low WTP, however, the probability is approximately 50% for the lowest WTP, meaning
that the probability of doing some active screening being cost effective, is still relatively
high. No active screening has negligible probability of being the most cost-effective for
approximately WTPc > 0.3. For the largest WTP values, Strategy 7 (annual screen-
4.9 Considering cost-effectiveness 99
Fig 4.8: The cost-effectiveness of active screening strategies. See Table 4.5 for full descrip-
tion of strategies. (A) Cost-effectiveness plane showing the total cost of a strategy
and the associated total number of DALYs averted from the mean value of the
comparator strategy. Mean values for each strategy are shown by the coloured
crosses. (B) Cost-effectiveness acceptability curves (CEACs) for each strategy are
shown by lines, with the cost-effectiveness acceptability frontier (CEAF) shown by
the numbered background colour, which demonstrated the values for the ICER.
WTP is shown in 2018 USD on the top and as the WTPc coefficient on the bottom,
where the coefficient is the multiplier of the GDP per capita of the DRC.
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ing with three zero-detections), marginally has the largest probability, with similar
probabilities for the other strategies with annual screening.
It is notable that for values of WTP, the one with the highest probability of being cost
effective does not directly correspond with the outcome from the ICER calculations.
These calculations are demonstrated by the cost-effectiveness acceptability frontier
(CEAF), the optimal strategy in maximising the expected NMB, which is shown as the
shaded and numbered background (Figure 4.8B). It is the CEAF which is used to provide
the recommended strategy for a given WTP threshold.
4.10 The effects of reactive screening
So far we have only considered when only one reactive screening with no cases detected
is required to stop screening again zr = 1. However, to be more certain that there is no
infection, more may be required. By considering when c = 91.4%, t = 1, and za = 3,
we calculate the probability of being most cost-effective for the four strategies of no
active screening and zr = 1, 2, 3 (Figure 4.9). Similarly to Figure 4.8B, a low WTP of less
than 3.5% of the GDP per capita of the DRC means no active screening has the highest
probability of being cost-effective, and for higher WTP, active screening is beneficial.
The effect of zr is, however, very minimal, with the chosen three values of zr giving
almost equal probability, although zr = 1 has the highest probability and zr = 3 the
lowest.
This is explained by there only being a small probability that a reactive screening
occurs at all (Figure 4.10A). When za = 3 and three consecutive zero-detections have
already occurred, the probability of continuing to find cases to restart screening is small,
roughly 5%. Secondly, if reactive screening does occur, it will occur a long time in the
future, where discounting has more of an effect and hence the differences in zr will be
negligible.
We observe when za = 1 the expected number of screenings will vary a little depending
on zr, but much less for larger values (Figure 4.10B). Indeed, when looking at the
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Fig 4.9: The effect of the number of zero-detections in reactive screening. Probabilities
that a reactive screening strategy is the most cost effective (CEACs) and the cost-
effectiveness acceptability frontier shown in the coloured background. The CEACs
for different zr values show very similar results and cannot be distinguished in the
figure. We assume c = 91.4%, t = 1, and za = 3 and the population is of size 1,000
starting from endemic equilibrium with pt = 29%.
Fig 4.10: Active and reactive screenings. (A) The probability that reactive screening starts
for different za values. (B) The expected number of screenings. Active screening
are solid bars, while striped bars are reactive screenings. The colour of the bar
indicates the value of the reactive zero-detections. 95% prediction intervals are
shown. (C) The expected proportion of screenings where there is no infection.
Sufficient simulations have been run such that confidence intervals are too small
to plot.
4.10 The effects of reactive screening 102
number of screenings that were unnecessary, with full information of the infection (since
there was actually no infection), there are more unnecessary screenings when there
are more active zero-detections, but more reactive zero-detections only has significant
impact when za =1 and 2 (Figure 4.10C).
Hence, we cannot say much about the optimum number of reactive screenings when
considering the NMB. The model does not directly consider the benefit of extensively
screening a village to achieve local elimination in a village and there is little differentia-
tion in the values for zr.
Also important to determine reactive screening strategy, is the time between the detection
of a passive case when there is no active screening in the village and the starting of
reactive screening to that detection. We have primarily assumed that reactive screening
restarts immediately, although we recognise there would be some delay. However, we
show that there is limited effect of this time interval, except for when the number of
active zero-detections is small (Figure 4.11). When za = 1, there is only one active zero-
detection required to stop active screening, and so very possible there is still infection
despite when no cases are observed on a particular screening. This means that when the
time interval for reactive screening is small, reactive screening can resume very quickly
upon a false zero detection. We see the effect of a delay in reactive screening reduces the
total NMB slightly for za = 1 and very negligibly for za = 2, with any effect of higher za
values completely outweighed by the stochasticity of the epidemic process. We note in
practice, there would be some delay before reactive screening began, but this difference
is small, less than $1,000 difference for a delay between 0 and 1 years for the za = 1
value with the largest effect.
4.11 Time horizons
In all simulations in this chapter, we have used a time horizon for 30 years, since this
is sufficient to capture the majority of the costs of an active screening strategy on a
village until cessation and similarly the number of DALYs averted. Figure 4.12 shows
the distribution of the change in costs and the number of DALYs averted when the
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Fig 4.11: The time interval between observing a passive detection and resuming reactive
screening for different values of active zero-detections za.
simulation is run for both 30 and 100 years using a 55% screening coverage annually
with 3 zero-detections in a population of 1,000 starting from endemic equilibrium with
29% of passive infections treated (c = 55%, t = 1 year, za = 3, NH = 1, 000, pt = 29%).
The distribution is broadly identical since only a minimal amount of cost is included
additionally after the 30 years. Indeed, we see that in 94.6% of the simulations no
additional cost is included or DALYs incurred by expanding the time horizon to 100
years. The mean cost for 30 years is 99.2% of the mean cost for 100 years, with the
mean DALYs incurred in 30 years being 99.8% of those incurred over 100 years. Hence,
we are satisfied using a time horizon of 30 years.
4.12 Alternative diagnostics, treatments are active
screening methods
We have used fixed cost and benefit parameters for all simulations. These costs are
liable to change over time and have the potential to change dramatically if new
practices are implemented, such as a change in treatment. Thus, we have a sup-
plementary R Shiny [289] web app at https://christopherdavis.shinyapps.io/
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Fig 4.12: Distributions of (A) the change in cost of an active screening strategy and (B)
number of DALYs averted for 30 and 100 year time horizons. The simulation is for
55% screening coverage annually with 3 zero-detections in a population of 1,000
starting from endemic equilibrium with 29% of passive infections treated.
optimising-ghat-active-screening/. A selection of figures can then be generated
for any updated costings for the active screening strategies.
In particular, we focus here on how the change in costs would change in four different
scenarios: CATT screening tests were replaced by RDT; capillary tube centrifugation
(CTC) was additionally used in the microscopy procedure; NECT for Stage 2 treatment
was replaced by fexinidazole; all treatments replaced by fexinidazole (Figure 4.13). The
assumed increased cost of RDT compared to CATT increases the total change in cost
most significantly as it would be applied to all those undergoing active screening, while
the reduced cost of fexinidazole treatment, reduces costs slightly. The effect of CTC in
microscopy is negligible when considering a whole village for 30 years.
4.13 Differences between health zones
We have only considered the health zone Kwamouth in the analyses in this chapter.
To consider different health zone parameterisations show vastly different results, we
use our gHAT model parameterised to incidence data from the Mosango health zone
and compare the probability of a strategy being cost-effective the same strategies as
Kwamouth, but using the median screening coverage of the typical screenings from
Mosango (57%), along with the model parameters for this health zone.
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Fig 4.13: Mean change in costs relative to the assumed interventions for a village with 55%
screening coverage annually with 3 zero-detections. We consider the replacement
of CATT with RDT, the addition of CTC in microscopy and the use of fexinidazole
in Stage 2 patients and all patients. We use a population of 1,000 starting from
endemic equilibrium with 29% of passive infections treated.
Qualitatively, we see that the cost-effectiveness plane for Mosango looks similar to
Kwamouth, however, since there are fewer reported cases in Mosango, it is not possible
for so many DALYs to be averted. Hence the cost of implementing the active screening
strategies is less, as they are terminated earlier than Kwamouth (Figure 4.8; Figure
4.14). The WTP required to carry out active screening is also less for Mosango, shown
by the cost-effective acceptability frontier (Figure 4.14), but for WTPC > 0.03, annual
active screening is the most cost-effective strategy in terms of both the cost-effective
acceptability frontier and cost-effective acceptability curves.
4.14 Discussion
To achieve the goal of eliminating gHAT it is essential to have robust models that can
inform policy makers about the potential of different intervention strategies [201].
Furthermore, the addition of economic analysis will further develop the use of this work,
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Fig 4.14: The cost-effectiveness of active screening strategies for the health zone Mosango.
(A) Cost-effectiveness plane showing the total cost of a strategy and the associated
total number of DALYs averted from the mean value of the comparator strategy.
Mean values for each strategy are shown by the coloured crosses and ellipses
are fitted, which contain 95% of all data points from the one million simulated
realisations of the infection process for each strategy. (B) Cost-effectiveness
acceptability curves (CEACs) for each strategy are shown by lines, with the cost-
effectiveness acceptability frontier (CEAF) shown by the numbered background
colour, which demonstrated the values for the ICER. WTP is shown in 2018 USD
on the top and as the WTPc coefficient on the bottom, where the coefficient is
the multiplier of the GDP per capita of the DRC.
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as to not only evaluate which strategies are able to decrease infection in the population,
but which are additionally cost-effective.
We have presented a stochastic model for individual villages that demonstrates how ac-
tive screening should be considered, by determining costs of implementing the screening
for different screening coverages c, screening intervals t, and the number of zero-
detections observed to stop screening za and zr. Unsurprisingly, we find that a big factor
in choosing a strategy to implement is how much the programme funder, ministry of
health or external donor is willing to pay to avert a DALY. Thus, we present our results
across a range of WTP values. We have typically used a WTP value of 0.5 of the GDP
per capita of the DRC (WTPc = 0.5), which is commonly used in the literature [276,
277]; and we find on average that ideally screening would be done approximately yearly
with maximal screening coverage and ceased when no infection is found in a single
screening (c = 91.4%, t = 0.75 years, za = 1) (Figure 4.5). While the optimum for
the screening interval is found to be 0.75 years, practically this might be difficult to
implement when it is close to yearly. It is noted that screening coverages will rarely be
able to be achieved this high and so multiple visits where no infection is observed may
be necessary to optimise control. This is in line with WHO guidelines of annual active
screenings until there have been three consecutive years of no new cases, followed by a
further screening with no cases after three years [267].
In particular, we note that the modelling assumption that after stopping screening, the
reactive screening should be immediately resumed on identification of a passive infection
will not actually occur, but has little effect on the results (see Figure 4.10). In fact, this
can lead to an optimal solution with a low za, such that it is possible to restart screening
many times after quickly reaching the cessation criteria and so induce a higher frequency
of screening. However, the time horizon of 30 years is sufficient in the village context to
capture the dynamics with roughly 99.2% of costs and 99.8% of DALYs attributable to
the first 30 years (Figure 4.12).
As new treatments and active screening modes are introduced, the costs of the model
will change, however, the biggest effect is that of the number of DALYs averted, assuming
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the WTP threshold is set to a reasonable level. Details of the variation in NMB for
different screening diagnostics and medical treatments can be found in Figure 4.13.
We also note that from the perspective of cost-effectiveness of a single village, we do not
put any weighting on the benefit of extensive active screening in a village to achieve
local elimination, so that this village does not have to be re-visited in the future. This
means we often observe the result that the optimum screening strategy should be to
terminate the programme after a single zero-detection (za = 1), rather than continuing
to screen to aim for local elimination. However, there will only be high confidence that
local gHAT elimination has been achieved with at least three zero-detections for villages
of this size (NH = 1, 000) (see Chapter 3), but it is unclear how much monetary value
we should attribute to meeting EOT targets.
The result of a single zero-detection being optimal is particularly notable in conjunction
with when the screening coverage c is at the maximum. In this case, there is higher
confidence that local gHAT elimination is achieved, as almost all the population is
screened, above what is typically seen, and there are no cases detected. Even if infection
temporarily persists after this, there is a large probability it will soon die out due to
stochastic fade out (see Chapter 3). More realistic screening coverages will require more
zero-detections are required to terminate active screening (Figure 4.7).
Additionally, we note that there will also be additional costs in restarting active screen-
ing as reactive screening, if regional cessation has led to trained mobile teams being
disbanded. We have not accounted for this in our model and it may increase the optimal
number of active zero-detections. In particular we note there is a high probability of
reactive screening being required in a village where the number of active zero-detection
required to stop screening is only one (Figure 4.10A).
When considering different gHAT interventions, active screening is known to be effective
in reducing case numbers and hence the infection in the population [12, 97, 290]. Thus,
with a limited number of active screening teams and resources for them to carry out




Exploring simplified dynamics of
gambiense human African
trypanosomiasis
We have so far used simulation-based methods to consider the dynamics of gHAT
infection, primarily using the tau-leaping algorithm. However, through the use of
master equations (forward Kolmogorov equations), we can consider the full probability
distribution of being in all possible infection states. This method enables us to explore
the dynamics further, including giving exact methods to calculate expected disease
extinction times.
In this chapter, we develop a simplified model of gHAT infection that reduces the possible
state space, to analytically investigate our model for probabilities of gHAT persistence
and expected times until elimination of transmission (EOT). Furthermore, we explore the
interaction between villages using this method, by considering importations of infection
into each individual village population as proportional to the global level of infection
across all villages. This provides a link between all villages in a region, whereby we can
scale up the village-level model to consider elimination on a larger scale. This method
retains both the stochastic properties of the model and allows us to continue to consider
interventions at the level at which they occur, the village-level. We use an adapted model
structure and parameterisation from Chapter 3.
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5.1 Considering the master equations
The purpose of considering the master equations of our system in this chapter is due
to the disadvantages of using the event-driven simulation approaches in analysing our
models.
Both the tau-leaping algorithm and the Gillespie direct algorithm are integer-based
event-driven simulations, which capture the dynamics of random events, allowing for
deviations from the deterministic equilibrium solution to be observed. However, each
realisation of the process is just one simulation and so rather than capturing something
fundamental of the model, they can be considered as the result of an in silico experiment,
and thus should be treated in the same way as any other statistical observation [291].
This means a large number of replicates are required to have confidence in the results
and this is still only an approximation of the true probability distribution of the potential
trajectories for the infection dynamics in time. Furthermore, if we are particularly
interested in an incredibly rare event, to ensure we capture the frequency at which this
event occurs, or even to observe it at all, a vast number of simulations may be required,
and these will take time to compute.
An alternative is to consider the full probability distribution of all combinations of
individuals being in each infection state. This complete ensemble, known as the master
equations (forward Kolmogorov equations) [292], will comprise of a very large number
of ordinary differential equations (ODEs). The system can be written in a matrix
formulation, since it is linear in terms of the probability of being in each state [291, 293].
The system is thus easy to solve and provides a complete description of the dynamics.
Furthermore, using this approach we are able to directly calculate quantities of interest,
such as probabilities of persistence or expected extinction times using exact methods.
The drawback of such methods, and the reason for using the tau-leaping algorithm
to approximate the dynamics in previous work (Chapter 3 and Chapter 4), is that the
method becomes infeasible for very large population sizes and more biologically realistic
models [291]. In the case of our gHAT model, we have two populations of humans in
five infection states and a population of tsetse in six infection states. Since the master
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equation approach requires the full state space of all possible combinations of this would
be a practically impossible number of equations, particularly considering we do not
know the total number of tsetse in our populations (and are already taking the infinite
limit and approximating their dynamics as ordinary differential equations in previous
chapters). Simulation methods take a lot of computation time, master equation methods
take a lot of memory storage capacity [294].
To calculate the number of equations required for the full system, we note that there
are (




ways of putting n indistinguishable objects in k distinguishable classes [295]. Thus if







, as there are five classes for each risk group. If we
only considered the humans in a typical village population of 1,000 people, using the
parameterisation from Chapter 3, with 924 low-risk people and 76 high-risk, this is a




= 30, 702, 178, 200




= 1, 581, 580 for the high-risk
group, leading to 48,557,950,997,556,000 (∼ 4.8×1016) ODEs for the master equations,
even before vectors are considered. For a population of 10,000, this number grows to
∼ 1.7 × 1022. Therefore, we need to simplify our model if we are going to take this
approach.
5.2 Simplifying the gHAT model
To simplify our model, we need to reduce the potential state space, so that the model can
be studied at larger population sizes. As such, one immediate simplification of the model
is to observe that the vector dynamics occur at a faster rate than the human dynamics,
due to the short life span of the tsetse (approximately one month [230]), compared to
the long infections times of humans (typically three years if untreated [77]). Thus, we
can assume that the vector dynamics are at quasi-equilibrium and solve the model ODE
equations for the vectors (i.e. dIVdt = 0) to find I
Q
V , which we can then substitute into
our expressions in the human dynamics. This is common method in the literature for
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removing vector dynamics [6, 210, 211, 296, 297], alternative to simply modelling with
a force of infection term [298].
Our full vector equations at steady state (for full mode equations and parameters
descriptions see Table 3.1 and Table 3.2 respectively):
dSV









(SV + εGV )
− (3σV + µV )E1V = 0, (5.3)
dE2V
dt = 3σV E1V − (3σV + µV )E2V = 0, (5.4)
dE3V
dt = 3σV E2V − (3σV + µV )E3V = 0, (5.5)
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εGV − µV GV = 0. (5.7)
Solving these equations gives:


















(3σ + µV )3
. (5.8)
This expression is a function of just IH1 and IH2, since the vectors becomes infected
upon taking a blood-meal on an infected human, and so we can replace the occurrence
of IV terms in our description of the human dynamics with this term I
Q
V .
If we were considering the model in the deterministic ODE framework, this simplification
reduces the number of ordinary differential equations (ODEs) from sixteen to ten. We
further note that as we are using a constant population size for each risk class, we don’t
need to consider one class explicitly, since, for example, RH1 = NH1 − (SH1 + EH1 +
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I1H1 + I2H1). However, this is still an eight dimensional system for the state space of the
master equations, and, as calculated above, already requires a huge number of ODEs to
present the master equations for the system. We need to simplify the system further.
In all our model simplifications, we want to retain the risk structure in the human
population as different behaviour is observed from the risk groups, with individuals
in the high-risk group having a higher risk of exposure to tsetse and not participating
in active screening [117, 219]. Therefore, we simplify the infection profile of humans
from passing through exposed, Stage 1 infection and Stage 2 infection, to just a single
infected state that includes all these stages. We are reducing the model from a two
population SEIIR model to a two population SIR model. Directly adapting the existing
model this would now be described in the ODE framework as:
dSHi
dt = µHNHi + ωHRHi − αmeff
fiSHi
NHi





IQV − (µH + ψH)IHi, (5.10)
dRHi
dt = ψHIHi − (ωH + µH)RHi, (5.11)
for i = 1, 2 for both low- and high-risk humans. We also introduce new parameter
ψH = 1/(1/σH + 1/φH + 1/γH), as the mean expected time to hospitalisation from
exposure. We also scale IHi terms in I
Q
V by (1/φH + 1/γH)/(1/σH + 1/φH + 1/γH) to
account for the lack of infectiousness when only recently exposed.
To achieve minimal dimensionality for our model, while keeping the risk structure, we
could further reduce the number of ODEs from six to four, by removing the recovered
(hospitalised) class. Since the total number of people in the recovered RH class is
small (typically less than 0.4% of the population, unless a large active screening occurs,
when using the ODE framework; Figure 5.1), we choose to simply omit this class in
our simplified model approximation and move individuals straight from infected (I) to
susceptible (S) following treatment.
5.2 Simplifying the gHAT model 114
Fig 5.1: Dynamics of gHAT infection in the recovered class using the full deterministic
model for 15 years with active screening.
This means the model structure is given by the following four ODES, two for each risk
class:
dSHi








IQV − (µH + ψH) IHi, (5.13)
for i = 1, 2.
We note that µHIHi = µHNHi − µHSHi, since NHi = SHi + IHi. These terms ensure
the population size remains constant in time. The constant population size also means
that the system is now two dimensional, and we only need to consider the number of
infected individuals in each risk class.
To understand the effects of changing the model structure, while retaining the same
parameterisation of Chapter 3, we plot the infection dynamics of the simple ODE model
with different levels of active screening (Figure 5.2).
All of the infection dynamics are qualitatively the same, with minor differences in the
exact proportions for the different models (Figure 5.2). Removal of the explicit vector
dynamics means that the vector dynamics happens instantaneously, dependent on the
human population, rather than with the delay of infection decline due to a reduced pool
of human infection due to active screening. Hence, with active screening, the infection
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Fig 5.2: Number of infected individuals for 15 years with active screening using different
model structures. We consider 10% (low), 50% (medium) and 92.4% (maximum,
full low-risk population).
decays faster than it otherwise would. However, because of the short lifespan of the
tsetse, meaning that the vector dynamics are much faster than the human infection
dynamics, the change is very minimal (<0.05%). This means removing the vector
dynamics is still a very good approximation.
The amalgamation of the exposed class and the two infected classes reduces the number
of compartments in our model to a simple SIRS model. This means that instead of
assuming separate exponentially distributed time periods in each class, we assume one
exponentially distributed infected period with a mean time in the class equal to the
sum of the mean times in the original classes. This is achieved by the definition of
our parameter ψH = 1/(1/σH + 1/φH + 1/γH). We expect that by removing the latent
period, the infections will increase slightly [250], however this effect is counteracted by
scaling the infected compartment by the expected proportion of those that are infectious
(not exposed), (1/φH + 1/γH)/(1/σH + 1/φH + 1/γH). Indeed, there are fewer infected
humans in time with this model, particularly when the active screening coverage is
small and so these effects are at a maximum. When the screening coverage is high, this
greatly disrupts the dynamics and so relatively dampens the effect of the model structure
(Figure 5.2).
Our final reduction of our model to the simplest form removes the recovered (or
hospitalised) class and so reduces the time for potential reinfection in the model. This
will have the effect of increasing the number of infected humans, as more will be
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susceptible to be infected (as opposed to hospitalised and hence immune). Since the
number of recovered humans is small compared to the susceptible individuals (Figure
5.1), the effect is however minimal and furthermore counteracts the other effects of
other model reductions. This means that we observe the SIS dynamics to be very similar
to the dynamics of the full model (Figure 5.2).
This evidence means that the SIS model is a good approximation to the full dynamics
and greatly decreases the complexity of the model to allow for a master equation
approach to the analysis, without an infeasible number of equations. However, while
this parameterisation gives a very good approximation to our full model, we note
that future work would be to actually obtain a new parameterisation for this reduced
model by fitting it to the underlying case data used to fit the full model. For the
rest of this chapter, we will however only consider this SIS model with the current
parameterisation.
5.2.1 The master equation
From the ODE equations for the SIS model (Equations 5.12 and 5.13), we can construct
the master equation by considering the possible events that occur. There are four possible
events that can change the probability of the low-risk population being in that state with
SH1 susceptible people and IH1 infected people:
• an infected human can recover or die at rate (µH + ψH)IH1 to decrease the
infected population from IH1 to IH1 − 1,
• an infected human can recover or die at rate (µH + ψH)(IH1 + 1) to decrease
the infected population from IH1 + 1 to IH1,
• a susceptible human can get infected at rate αmefffH1 SH1NH I
Q
V to increase the
infected population from IH1 to IH1 + 1,




the infected population from IH1 − 1 to IH1.
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The same four events can also occur in the high-risk population, meaning a total of eight
possible events exist.
Since SHi + IHi = NHi, for i = 1, 2, with NHi fixed, we can also write SHi = NHi − IHi
and only consider the equations in terms of IHi henceforth. Thus, we introduce the
notation PIH1,IH2 for the probability of being in the state with IH1 low-risk infected
people and IH2 high-risk infected people, which totally describes the state of the system.
We also write IQV (IH1, IH2) as a function of the number of infected people in each risk
class. By using this notation in conjunction with the eight possible events, we derive the
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fH2 (NH2 − IH2 + 1)
NH2
)
+ PIH1+1,IH2 (µH + ψH) (IH1 + 1)
+ PIH1,IH2+1 (µH + ψH) (IH2 + 1) , (5.14)
where IH1 = 0, ..., NH1 and IH2 = 0, ..., NH2.
5.2.2 Calculating the rate matrix
The master equations (Equation 5.14) comprise of (NH1 + 1)(NH2 + 1) equations (since
the low-risk infected population can take any value between 0 and NH1 and similarly for
the high-risk, or alternatively using Equation 5.1). We simplify the notation by writing
the equations in matrix form. This is possible since all the equations are linear in terms
of the probabilities. Thus, by defining the probability vector:
p = (P0,0, P1,0, ..., PNH1,0, P0,1, ..., PNH1,NH2), (5.15)
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we obtain the master equations in matrix form as:
dp
dt = pQ, (5.16)
where Q is the rate matrix of all transition rates. Q will be a sparse matrix, with elements
only on the tridiagonal (for exiting the current state and transitioning in the low-risk
population) and two further diagonals (for transitioning in the high-risk population).
Since Q, is still a very large matrix for large populations and using this matrix may
be infeasible when computation time and memory is considered, we further simplify
Equation 5.16. Since the prevalence of gHAT is typically very low, even in the most
highly endemic areas [102], and we know that at steady state in our model the infected
population is only ∼ 1.25%, the probability of being in highly infected states such as
PNH1,NH2 will be very small. Therefore, we can impose maxima MH1 and MH2 on the
values that IH1 and IH2 can take. If we choose the maxima large enough, there will be a
negligible impact on the dynamics. When considering the dynamics with a high number
of cases, we typically take the approach that if IHi = MHi, the probability of further
infection is zero. However, if we are interested in how often our approximation fails, we
can additionally add a fail class, PF , whereby if IHi = MHi and an infection occurs, the
state moves to PF and does not return. This means there are now (MH1 + 1)(MH2 + 1)
equations, or (MH1 + 1)(MH2 + 1) + 1 if the fails are explicitly tracked.
5.2.3 Solving the master equations
Once we have formulated the master equations in the form of Equation 5.16, this
differential equation is easy to solve, as
p(t) = p(0) exp (Qt). (5.17)
This provides a full analytic form for the solution of the master equations, which is easy
to compute, by just taking a matrix exponential [299]. Alternatively, we can also solve
the system by taking an eigenvalue approach [291]. If we define the eigenvalues of Q
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as (λ1, ..., λ(MH1+1)(MH2+1)) and the left eigenvectors as (l1, ..., l(MH1+1)(MH2+1)), we can




qn exp (λnt)ln, (5.18)
where qn = rn · p(0), with rn the normalised right eigenvectors. This formulation
of the solution does not rely on computing exponential of large matrices, which can
take a long time and we can also exploit some useful properties due to the system
we are studying. We will order the eigenvalues such that 0 = λ1 > Re(λ2) > ... >
Re(λ(MH1+1)(MH2+1)).
5.2.4 Finding the endemic equilibrium
Without the inclusion of infectious imports in the model, there are two long term steady-
state solutions of our equations. There is probability 1 of being in the state with no
infected individuals or of failing, since these states are absorbing. This can be seen by
considering the eigenvectors, or taking the matrix exponential at large times. However,
by considering the steady-state of the deterministic model, we can construct a state
vector using the product of two binomial distributions, B(MHi, IHi0) for i = 1, 2, where
IHi0 is the expected proportion of infected in risk class i. Considering a population of
size 1,000, this distribution is centered around approximately eight low-risk infected
people and four high-risk infected people (Figure 5.3). By using the rate matrix Q, we
can also show how the dynamics are likely to change from a particular initial condition.
The probability distribution is very tight with less than 0.001 probability of IH1 > 20 or
IH2 > 13. Alternatively, and more accurately, we could calculate the limiting conditional
distribution of the model to obtain the endemic quasi-equilibrium.
5.2.5 Adding active screening
With the infection dynamics described and passive detection assumed to be included in
the rate of returning from the infected class to the susceptible class, we model active
screening by the removal of a subset to individuals in the low-risk infected class into the
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Fig 5.3: Distribution of initial conditions starting from endemic equilibrium with a pop-
ulation NH = 1, 000 and no infectious imports. We show percentiles of highest
cumulative probabilities with a quiver plot overlaid to show the dynamics.
corresponding susceptible class. In our master equation framework, we do not consider
this action as part of the rate matrix Q, but as a separate action we can simulate when
considering the time evolution of our master equations. However, this is not as simple
as the ODE or tau-leaping framework, as we still need to consider the action of active
screening in the probabilistic sense. (Alternatively, we could represent active screening
by a lower-triangular transition matrix A and embed this as a discrete time Markov
chain.)
We do this by considering the hypergeometric distribution HG(NH1, c, k) to get the
number of real infected individuals chosen for screening. We consider the number of
infected people detected c from the population NH1 of low-risk people available to be
screened, when a total of k people are screened. Subsequently, if c infected people are
screened, we use a binomial distribution B(c,Se), where the test sensitivity is Se = 91%
[252] to get the number of infected people screened that are identified. We assume
specificity is 100%. Taking the product of these probabilities and applying them to every
possible state in terms of number of infected people in the low-risk class, we formulate
a probability vector for the probability of detecting each different number of people,
given the number screened and the number infected. Hence, given the probability of
being in each state at time t, we can apply these probability vectors to determine a new
probability of being in each state after an active screening of given coverage.
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Using this method and calculating the expected number of infected people with time,
we see that active screening is working correctly in our simulations (Figure 5.4). Larger
population sizes have more infected people and a lower probability of extinction of
infection, as expected, with active screening reducing the number of infected with
time.
5.2.6 Choosing the maximum number of infected individuals
Since the number of ODEs in the master equations can be very large for villages with
large population sizes and so induce memory problems, as mentioned in Section 5.2.2,
we can limit the state space to only realistic numbers of infected people. However, this
needs to be done such that the probability of being in the state space excluded by this
artificial cut off is negligible.
We first consider the probability of failure (the probability of being in the excluded
state space) after 15 years for different population sizes given fixed thresholds for the
maximum number infected, where ML is the maximum number of low-risk and MH
is the maximum number of high-risk. We exclude active screening here, since this will
reduce the infection level and we want to consider the worst case scenario.
Using fixed thresholds, it is immediate that increasing the maximum threshold for the
number of infected people, decreases the probability of the state space being too small
(Figure 5.5). Using typical village population sizes of less than 2,000 people, using a
maximum size of 200 in each risk group achieves effectively no error, with a maximum
of 150 achieving less than 10−10 probability of failure. For larger population sizes, such
as NH = 100, 000, these approximations are certain to fail however, as the expected
number of infected people is larger than the imposed maxima. For a maximum of 300,
reasonable results are obtained up to approximately NH = 10, 000, however, we may
want to consider larger populations.
It is evident that the maximum should be chosen as a function of population size. Thus,
we start using ML = MH = 50, and increase either maxima in increments of 50 if
either the expected number of infected individuals is larger than the maximum, or if
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Fig 5.4: Probability of being in any given infection state in time for 15 years with an active
screening coverage of 50%. Marked in red is the expected number of infected
people. Populations size of NH = 100, 1, 000 and 10, 000 are used. For larger
populations, there are a greater number of possible states and so the scale on the
colour bar is adjusted for the smaller probabilities of being in individual states. We
assume no imports of infection into these villages.
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Fig 5.5: The probability that the state space for the number of infected individuals is not
sufficiently large for a given imposed maximum. Probabilities of approximately
10−16 are due to using floating point numbers, which are only accurate to 2−52
(∼ 2.22× 10−16), and so these values can be assumed approximately zero.
the probability of failure is determined to be greater than 10−8 when considering the
dynamics after 15 years with no active screening (Figure 5.6).
By increasing the maximum threshold number of infected people if the population size
means the error is too large, it is possible to model larger populations with a reasonable
state space size and negligible probability that the state space is too small. This ensures
the full probability distribution is captured (Figure 5.6). Even for very large villages of
size NH ∼ 20, 000, using ML = 550 and MH = 300 captures all the dynamics (with a
probability less than 10−8 of the maximum infected exceeding either limit). The values
of maxima shown in Figure 5.6 do not always fall on 50 unit increments, since, for the
high-risk individuals, this can exceed the number in the population, which is a small
minority of the total population.
Using this knowledge, for the rest of this thesis, we can use the correct limits to ensure
this condition and exclude the probability of failure from calculations as it will always
be small. We however will always keep ML > 150 and MH > 150, since there is little
issue with memory or computation speed for matrices of this size.
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Fig 5.6: The probability that the state space is too small when increasing the maximum
number low- and high-risk infected people in intervals of 50, to ensure there
is negligible probability that the state space is too small (less than 10−8). The
probability and resulting maxima in state space are shown in the two panels.
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Fig 5.7: Time evolution of the infection distribution in the absence of imports from the
deterministic endemic equilibrium both with and without active screening.
5.3 Considering a single village
Similarly to Chapter 3, we can consider the dynamics of gHAT using our master equation
approach on a single village, isolated from other populations. Without importations
of infection, the first row of the rate matrix will consist entirely of zeros, meaning the
largest eigenvalue will be zero, with the corresponding eigenvector being a one in the
first entry, indicating a steady state of disease extinction.
5.3.1 The distribution of infection
The dynamics of the infection with time will always move towards a disease-free popula-
tion, since this state is absorbing. Beginning at the endemic equilibrium found in Section
5.2.4, and considering the time evolution of the system for an example population
of size 1,000, we see that infection levels fall, particularly in the low-risk population,
although there is some probability that the number of infections would increase in
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individual simulations (Figure 5.7). The addition of active screening accelerates the
process of disease extinction within the population, such that at large times, almost all
the probability is given by no infection, whereas without the screening, there is some
probability the disease will persist.
5.3.2 Elimination of gHAT in the absence of importations
Probability of persistence
In Chapter 3, we considered the probability of local gHAT persistence and how this was
linked to the population size of the village. We found that persistence increases with
increasing population size, since transmission chains are more likely to be broken when
there are fewer people to infect and there is greater impact of the stochasticity (Figure
3.13). While we are using a different model structure here and the method of simulation
is also different, we confirm that we observe very similar results to this original model
when using the master equation approach (Figure 5.8). In this figure, the dashed lines
correspond to the results found in Figure 3.13, with the new results plotted as solid lines.
Hence, we are confident of achieving qualitatively meaningful results in this chapter,
even if the model needs to be fully parameterised.
We also note that in this model, when comparing the results for different population
sizes, the effect of rounding on the fixed number of people in each risk class is large, due
to the small population size of villages. For example, increasing the population size from
19 people to 20 people will mean the rounded number of high risk people increases from
1 to 2, greatly changing the dynamics. Hence, in Figure 5.8, we consider the number of
high-risk people to be both integer values either side of the proportion R2 ×NH and
take a weighted average of the resulting two values for the probability of persistence to
achieve a smooth curve for this probability plotted against population size. We do not
need to take account of this effect when considering single large populations.
Similarly, considering the dynamics in time and comparing to Figure 3.14, the thinner
darker lines in Figure 5.9 show the local gHAT persistence for the master equation model.
5.3 Considering a single village 127
Fig 5.8: Probability of gHAT persistence in isolated settlements for the two different models.
As in Figure 3.13, the tau-leaping algorithm was used with 100,000 realisation,
such that the confidence interval for the mean persistence was too small to be
plotted in this figure. In both models annual screening at a fixed coverage per year
yields a drop in persistence with increased coverage. Uncontrolled means passive
surveillance only.
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Fig 5.9: The probability of gHAT persistence in time for the uncontrolled setting (U), and
annual screening at the average coverage of 21% (Y) for villages with populations
of sizes 500 and 2,000. The thick lighter colours show the tau-leap results, and the
thin dark colours show the master equation results.
For large times, the results are very similar; there is some discrepancy for smaller times,
likely due to the potential for a faster recovery, compared to the full model with multiple
infection classes [250]. However, qualitatively the same dynamics are observed, in both
different population sizes and active screening statuses (Figure 5.9). Note that as in
Figure 3.14 we plotted the time series from one data point per year, the active screening
is not visible, which is retained in Figure 5.9. Whereas for the master equation approach
we plot additional time points, such that the active screening events are visible.
Expected number of infecteds
In addition to the probability of local gHAT persistence, the expected number of infected
people is another quantity easy to calculate from this model. It is simply obtained by
taking the dot product of the probability vector and the number of infected people in
each state.
The expected number of infections increases linearly for large population sizes, with
smaller populations having fewer expected infections due to the effects of an increased
number of disease extinction events (Figure 5.10A). Larger active screening coverage, as
expected, also reduces the expected number of infections. Without infectious imports to
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Fig 5.10: The expected number of gHAT infections for different annual screening coverages
for (A) population sizes, and (B) time points, using the master equations.
balance the population of infected individuals, the expected number will also decrease
in time, even without active screening, due to local gHAT elimination, with further
reductions, when active screening is also added (Figure 5.10B).
Since the increase in the expected number of infections is almost linear in population
size (Figure 5.10A), there is a similar relationship between the expected number of
infections and the probability of gHAT persistence, as there is between the population
size and the probability of gHAT persistence. Larger populations, with lower active
screening coverage and small times have the highest persistence, as is intuitive. However,
if the expected number of infections is known the biggest factor in determining the
probability of gHAT persistence is the time since the simulations began, irrespective of
the active screening coverage or population size (Figure 5.11).
Time to extinction
Since the disease-free state is absorbing, an additional quantity of interest is the expected
time to reach this state. This time to extinction can be calculated very simply using the
master equation approach. By taking the rate matrix Q and removing the rows and
columns corresponding to the absorbing state, we obtain the matrix Q0. The expected
time to extinction from each state T is now given by the solution to the equation
Q0T = −1 [300].
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Fig 5.11: Scatter plot of the probability of gHAT persistence and the expected number of
gHAT infections for different population sizes, annual screening coverages, and
time points.
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Fig 5.12: The expected time to extinction for different population sizes, given the initial
number of high- and low-risk infected people and no active screening. The
red cross marks the expected number of high- and low-risk individuals for the
population size, given the endemic equilibrium.
The expected time to extinction is small if initial states are close to the absorbing state,
however, the time is very long for large populations with a large number of infections
in the absence of interventions (Figure 5.12). Corresponding with the previous results
on persistence, large populations have longer expected times to extinction. When a
population size of NH = 10, 000 is considered, and is started from endemic equilibrium,
the expected time to extinction is 400 years.
When considering active screening, the same method cannot be used with this formu-
lation to calculate the time to extinction since active screening is not part of the rate
matrix formulation. We would need to implement an additional discrete time Markov
chain. However, the result can be obtained by calculating the state space up to large
time intervals. By considering 100 years, we can obtain the probability that the infection
went extinct within each of these years, and the probability the infection remains, to
get the full probability distribution of the time to extinction for different annual active
screening coverages, starting from endemic equilibrium. Considering NH = 1, 000, there
is a small probability of not achieving local gHAT elimination within 100 years without
active screening, but with increased active screening coverages, this becomes negligible,
with a high probability of local elimination, even within ten years (Figure 5.13).
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Fig 5.13: Distribution of the expected time to extinction for a population of NH =1,000,
for different levels of annual active screening coverage.
The extinction rate
The rate of extinction is the rate that the population moves from one high-risk infected
and no low-risk infected to none infected at all, or one low-risk infected and no high-risk
infected to none infected at all. In our model, this will occur at rate (µH +ψH)(P0,1+P1,0).
The extinction rate increases as the expected infection decreases and so there is a higher
probability the populations are approaching extinction. This rate will then plateau
and decay as more populations actually go extinct (Figure 5.14A). Similar behaviour is
observed for the probability that an active screening causes an extinction event. However,
for very high coverages, all the infected low-risk population will be detected and treated
(except false negative test results), and so future active screening will have a lower
probability of causing gHAT extinction, since all infection is in the high-risk population
that are not screened (Figure 5.14B).
5.3.3 The effects of active screening
So far we have always assumed that all active screening occurs at the very start of
each year, however, this will not actually be the case and active screening will occur
throughout [115]. For a single village, however, it is only likely to occur once, rather
than multiple times in a year. We show that there is minimal effect on whether the
active screening occurs at the start or end of the year, other than a year delay in starting
the screening (Figure 5.15). However, if the same amount of active screening is done
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Fig 5.14: (A) Extinction rate of gHAT in time for a population of NH =1,000. (B) The
probability that an active screening in each year causes a gHAT extinction event.
Fig 5.15: Timing of active screening. Active screening at the start of each year, throughout
or at the end of the year affects (A) the probability of gHAT persistence, and (B)
the expected number of infections.
in the village, but throughout the year, there will be more infection in the populations
with more frequent screening with a higher probability of persistence. This is dual-fold;
the largest factor being that since we consider a single annual screening and screening
throughout the year to have the same number of people screened, but at different time
points, there is the opportunity for individuals to be screened multiple times, effectively
reducing the screening coverage. In addition, there is a smaller effect of the village
missing out on the benefit of mass screening all at once, and so removing infected people
from transmitting the infection throughout the year. A similar effect to this was seen
in Figure 3.13B, where a random screening coverage level, which could be large, was
more effective in reducing the infection level than regular screening at a lower coverage.
We consider these effects in more detail in Section 5.5.3.
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5.4 Importation of infection into a village
While considering villages as separate populations provides information on the duration
of persistence (or time to extinction) of the infection, we know that the populations
are not actually isolated and the movement of people can both sustain the infection in
villages and re-introduce the disease where it is previously been locally eliminated (see
Section 3.5). We have previously estimated a value for the rate of importation into a
village population of 3.4× 10−6 days−1 due some background level of infection (Figure
3.18), and so can introduce this into our SIS model using the master equations.
5.4.1 Considering invasion
The introduction of a single infected person into a village with no infection may have no
effect on the population if this person is treated (or dies) before infecting other people.
However, as shown in Figure 3.15, there is a very significant probability that further
transmission will occur after an infectious import.
Using our master equation approach, with the initial condition of full probability of
starting with one infected individual (in the high-risk class), the probability of the village
returning to elimination grows quickly with time, although there is a significant probabil-
ity of further transmission causing more infections (Figure 5.16). The expected number
of infections increases above one in the first ten years, since there is a small probability
that a single infectious import can cause a very large number of new infections, despite
the overwhelming probability that there is a return to local elimination.
With only one initial infection and no subsequent invasion, the time to extinction is
not greatly impacted by the population size of the village, with very similar results for
populations varying between NH = 100 and 10, 000 (Figure 5.17). The probability of
extinction within one year is just less than 0.3, with the infection otherwise persisting.
This probability of persistence on this reintroduction means we now consider the effect
of regular imports into a population.
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Fig 5.16: The distribution of states of a village upon the reintroduction of a single infected
high-risk individual and no subsequent invasion. The red line in the top panel
shows the expected number of infected people. The distribution between the risk
classes is shown in panels below at times t = 0, 1, 5, and 10 years. A population
size of NH = 1, 000 is used.
Fig 5.17: The distribution of time to extinction of gHAT infection without any active screen-
ing for populations of different sizes from the initial conditions of a single infected
person from the high-risk class.
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5.4.2 Explicit inclusion of infectious imports
For the explicit and continuous inclusion of imports, we can expand our rate matrix
by the addition of a new component that describes the infectious importation events
into the village E. As such, our full rate matrix will now be Q+E, where Q describes
the disease events of infection and recovery and E describes the movement events of
importation of infection. We assume the import can occur by a susceptible person
travelling to another village, being infected there, and returning to their home village.
To calculate the matrix E, we consider the two possible changes of state for each risk
class:
• a susceptible human can become infected by movement and introduce the
infection into the village at rate δSH1 to increase the infected population from
IH1 to IH1 + 1,
• a susceptible human can become infected by movement and introduce the
infection into the village at rate δ(SH1 + 1) to increase the infected population
from IH1 − 1 to IH1.
By introducing importations of infection into the equations, while still considering just a
single village, long term local elimination is no longer possible, since there is now always
a chance of recrudescence due to a person visiting another village with the infection
and bringing it back to their home village. Thus, starting with the endemic equilibrium
distribution, including the imports, and simulating forwards in time with annual active
screening with 50% coverage, the level of infection decays, however it will reach an
equilibrium due to the number of imports entering the village (Figure 5.18).
We can also measure the extinction rate as in Figure 5.14 for a village with imports (Fig-
ure 5.19). When there is no active screening from endemic equilibrium, the extinction
rate remains constant, but it will increase in time if active screening is causing additional
removals of infected people due to hospitalisation and treatment.
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Fig 5.18: The probability of infection in a village of size NH = 1, 000 with infectious imports
given the rate 3.4×10−6 per day); the red line in the top panel shows the expected
number of infected people. The distribution between the risk classes is shown in
panels below at times t = 0, 5, 15, and 50 years.
Fig 5.19: The extinction rate for a single village with a population size of NH = 1, 000 with
infectious imports for different levels of active screening.
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While the addition of infectious imports adds to the realism of the model, the assumption
of a constant rate of importation depends on other villages not undergoing changes
in their infection dynamics due to active screening and it is assumed they remain at
endemic equilibrium. For a better understanding of the infection dynamics of gHAT
around local elimination, we need to consider the interactions between villages, such
that the importation rate into a village decays as the global infection rate falls.
5.5 Considering multiple villages
When considering elimination of gHAT, elimination in a whole region will depend
on both the persistence in individual settlements and the interaction between these
settlements. Local extinctions of infection will be balanced by external imports until
global elimination is achieved.
5.5.1 The model with multiple villages
To construct a model where multiple villages can interact, we consider the villages for
the most part as independent, as we have done throughout. We construct rate matrices
Q for each population size and solve the equations, as before, where each rate matrix
represents an infinite number of realisations of a single village of a given population
size. For a group of villages, we can calculate the total expected number of infected
people by summing the expected number from each population size, counting some
population sizes multiple times, if there are multiple villages of the same size within the
group. Similarly, the probability of local gHAT extinction for the group is calculated by
the product of extinction probabilities of the single populations, noting again that the
rate matrix will not need to be calculated multiple times for the same population size,
but will be repeated in this calculation.
However, when importations of infection are considered in each village of a given
population size, rather than giving the rate of importation by δ(NHi − IHi), where δ is
the rate of importations, we multiply this whole term by ITotal(t)/ITotal(0), where ITotal
is the sum of all expected infections across all the villages we are considering. This
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gives the term δ(ITotal(t)/ITotal(0))(NHi− IHi). This means that our fitted importation of
infection rate in any given village will decay with time as the total number of infections
in all villages falls. We are making the simplification that ITotal(t), the total expected
number of infections across all the villages, is not dependent on the current state of a
particular village, but formed simply from the total expected number across all villages.
We do not want to compute the probabilities of all possible combinations of village
states, as this would greatly increase the size of our system. This is assumption will be a
good approximation for a large number of villages, although we note in making it we
are neglecting second order effects. However, with this method, we have now linked
the villages so that when there is no infection ITotal will be zero and so there will be
no importations of infection and elimination of transmission will have occurred in the
region.
Since our model is fitted to data from the WHO HAT Atlas [106, 107], we explore this
data to get reasonable village parameters for our model. As in Figure 3.3A, we have
census estimates of the villages sizes (Figure 5.20A). We can also obtain reasonable
parameters for the expected screening behaviours by considering the mean active
screening coverage across all villages than have been screened and the probability that
any particular village listed in the WHO HAT Atlas is screened in a given year (Figure
5.20B–C). The mean of these values from 2000–2012 are given by 62.5% and 36.8%
respectively (dashed red lines). We can then incorporate this into the model by a new
parameter for the probability of a screen. Thus, when a screening can occur we take
the full probability distribution and take the linear combination of the probability of
no screening multiplied by the current distribution plus, the probability of a screening
multiplied by the distribution after an active screening of given coverage.
5.5.2 An example of villages interacting
To show how the dynamics are affected by the interactions of villages, we take two
hypothetical areas with 10 villages. In the first each village has a population size of
NH = 1, 000; in the second, each has NH = 10, 000.
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Fig 5.20: The villages of Yasa-Bonga and Mosango health zones, DRC. (A) Histogram of
the estimated population sizes of the villages from 2012, based on census data
from the WHO HAT Atlas [106, 107]. (B) The annual mean screening coverage
for a village when it is screened in Yasa-Bonga and Mosagno (2000–2012). (C)
The proportion of the villages of Yasa-Bonga and Mosagno listed in the WHO HAT
Atlas that are screened each year (2000–2012).
For NH = 1, 000, there is a strong increase in the probability of gHAT becoming extinct
within the first three years, although there infection also has the potential to grow,
shown by the expected number of infections decaying much slower (Figure 5.21). For
NH = 10, 000, because the populations are so much larger, the probability of extinction
is very low (Figure 5.22). The effect of some villages being screened and others not, is
very clear in the risk distribution plots, that is not apparent for the smaller population
sizes due to the low numbers of infected individuals. After one active screening, the
number of low-risk can decrease or remain constant, to give a bimodal distribution
across the villages. This slowly merges at later time points.
In considering gHAT persistence in time, we know that larger populations will have a
higher probability of persistence (see Chapter 3). It is also intuitive that a collection
of populations of the same size together will have a higher level of persistence, since
there are more people total. We additionally show that one population will have a
higher probability of persistence than ten populations, each a tenth of the size (Figure
5.23). For example, after 50 years, the probability of persistence of one population of
size NH = 1, 000 is approximately 0.35, while the total probability of persistence of ten
populations of size NH = 100 is less than 0.05. This is because each village is more likely
to observe a local extinction with fewer susceptible people to infect and less mixing of
the whole population than in a single village.
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Fig 5.21: Example early infection dynamics for ten village populations of size NH =1,000.
Risk distributions are shown in the panels below for one of these villages.
Fig 5.22: Example early infection dynamics for ten village populations of size NH =10,000.
Risk distributions are shown in the panels below for one of these villages.
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Fig 5.23: Probability of gHAT persistence in time for different populations. The paler dotted
lines show the persistence for a single village within the larger cluster of ten, and
the darker solid lines show the persistence across all ten villages.
This effect is pronounced when comparing back to Section 5.4, with a single population
with imports. Single village populations with imports have much higher probabilities
of gHAT persistence, than when multiple villages with a connecting importation rate
(Figure 5.24).
5.5.3 Varying active screening procedures
As previously mentioned, in most model simulations in this thesis, we have considered
that active screening occurs on the first day of the year. However, this is not truly
representative of the real system, since screening occurs throughout the year. With a
model with multiple villages we can test the effect of this simplification by considering
a hypothetical region of 12 villages, each with a population of 100 people. If all 12
villages are screened on the first day of the year we observe an immediate large drop in
the expected number of infected individuals, however slow resurgence in infections will
occur throughout the year.
Alternatively, if one village was screened on each first day of the month across all years,
the decrease in the expected number of infections will be more staggered. However,
we show that at the end of each year, when the same total amount of active screening
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Fig 5.24: Probability of gHAT persistence in time for different model structures. Either a
single village with importations of infection, or ten villages where imports are
proportional to the total infection.
will have been done, there is very little difference in the expected number of infections
(Figure 5.25). There are very marginally more infections when the screening is spread
across the year, as there is benefit in reducing the infection numbers as much as possible
at a given time to reduce transmission within the year, but the difference is so negligible,
it is a reasonable approximation to assume all screening occurs on the first day of the
year (or indeed any other day of the year). Therefore, in the modelling, assuming that
all screening is done on the first day of the year is a useful simplification, since the
available data will often not indicate exactly when active screenings occurred, simply
providing a year; this lack of information will have minimal impact on predictions.
Furthermore, we can also explore other active screening strategy factors, such as the
coverage, frequency and probability of villages being screened (Figure 5.26). If the
probability of a village being screened is reduced, while the coverage of the proposed
active screening increased, such that the expected number of people screened remains
constant, there is almost no difference in the expected number of infections over time.
Higher coverage reduces the infection marginally (as shown in the inset panel of Figure
5.26A). Similarly, this provides evidence of the validity of using higher-aggregation
models when only the total number of people screened is known.
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Fig 5.25: The effect of the timing of active screening interventions on the expected number
of infections. Dynamics are shown for all villages screened annually at the same
time and for different villages screened each month.
The same message is however not true of trading screening coverage for increased
frequency of active screenings. Higher coverages are better than frequent screenings, as
demonstrated in Chapter 4. In this case, more frequent screenings at lower coverages
may involve screening the same people multiple times and so the effective coverage will
be larger for a single large screen that ensures a larger proportion of the population
have been screened (Figure 5.26B).
5.5.4 The interactions of villages in Yasa-Bonga and
Mosango health zones, DRC
Finally, using all this information, we can carry out a full simulation of the infection
dynamics for all the villages of the two health zones of Yasa-Bonga and Mosango in the
DRC. We consider all villages using the estimated population sizes given in Figure 5.20A
and also use the mean screening coverage and village active screening probability, also
from this figure.
5.5 Considering multiple villages 145
Fig 5.26: Active screening probability, coverage and frequency. (A) The effect of changing
the screening coverage and the probability a village is screened. The inset panel
shows a close up for the last year plotted. (B) The effect of changing the screening
coverage and screening frequency.
In simulating this system, we obtain a full probability distribution in time for each
village, of which we present the probability distribution of a selection for certain time
points (Figure 5.27). For the smallest villages, there is a large probability of local gHAT
elimination, as given the probability distribution of the endemic equilibrium, there is
likely to be no infection in a given village.
However, for the largest villages, such as the one with a population of NH = 12, 645
(displayed in the rightmost column of Figure 5.27), there is a high probability of a large
number of cases. This reduces in time, particularly as active screening begins to remove
some of the low-risk infections; the panel after a year (t = 1), clearly shows the effect
active screening can have in reducing infection, with the distribution reflecting peaks of
a village, where screening has and has not occurred. While after 50 years (t = 50), the
number of infected humans has decreased greatly, there is still a very high probability of
a small number of cases persisting. This is shown more clearly in Figure 5.28.
Each village will have a probability of persistence that depends on the population
size, with many small villages being very likely to achieve gHAT elimination, and
largest villages being unlikely to obtain elimination, particularly with the high levels
of imports, unless active screening is further intensified (Figure 5.28). The largest
villages correspond to the greener lines than are plotted at the top of the left hand
panel, showing the probability of persistence as close to one across the fifty years. The
mean probability of gHAT persistence (the probability of persistence in a randomly
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Fig 5.27: The risk distribution of infection in a subset of the villages of Yasa-Bonga and
Mosango and selected time points. There are 559 villages with populations
ranging between 3 and 12,645.
5.5 Considering multiple villages 147
Fig 5.28: The probability of gHAT persistence in the villages of Yasa-Bonga and Mosango in
time with mean active screening. Each blue/green line shows a single village, with
the red line giving the average over all villages. The probability of simultaneous
extinction across all villages is shown in the right panel.
selected village), decreases from approximately 0.8 to 0.2 in the simulated 50 years,
reflecting the effects of active screening and stochastic extinction when the imports
start to decrease. However, the continued persistence of infection in the largest villages
means that the total probability of disease extinction across the whole health zones is
exceedingly unlikely, even in the long time frames simulated here.
5.6 Discussion
By simplifying the gHAT model from a Ross–MacDonald–type model that includes vector
dynamics (humans SEIIR, vectors SEEEI) to a simple Susceptible–Infected—Susceptible
(SIS) model of infection, has allowed us to utilise a powerful master equation approach
to our modelling, while maintaining a good correspondence to the original model.
The SIS master equation model is now very fast to evaluate, and the nature of the
implementation means that various interesting properties can easily be explored, with
exact methods for calculating extinction times and expected dynamics [291]. This
approach has also allowed the model to be easily extended to consider the interaction of
multiple villages and even to consider the dynamics of persistence at the health zone
level by linking the total number of infected individuals to the rate of infectious imports
into the villages.
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Using this model, we conclude that based upon the strategy of active screening at the
mean level, gHAT will continue to persist in Yasa-Bonga and Mosango for more than 50
years. This is in line with deterministic predictions using this parameterisation; Rock
et al. [219] predicted that the year of elimination as a public health problem would be
2140 (95% confidence interval (2103, 2199)) using the most similar model (Model 4 in
that study) and the mean coverage of active screening.
This simplified model would benefit from many of the recent improvements in the model
structure and model fitting of a more recent version of the full deterministic model [268],
many of which are detailed in Section 4.2.2. This updated model makes use of more
recent data from the WHO HAT Atlas [99, 106, 107] and considers improvements in the
interventions for gHAT. For example, in the model of this chapter, we do not account for
any improvement in the passive surveillance, which is known to have occurred [156],
and would contribute to a decline in infection.
We are also aware that we have only used village populations that are listed in the
WHO HAT Atlas for these predictions and there are known to be villages within these
health zones that are not listed as they have never been screened. As shown in Figure
3.7, we also know that screening coverage and frequency is correlated with population
size of a settlement, and so adapting our model to account for this would also likely
result in more accurate predictions. The proportion of people in each risk class is also
constant for all population sizes in the model, whereas we could speculate that the
larger populations are more town-like and perhaps have fewer high-risk members. This
potential over-estimation of high-risk people in the large populations could explain some
of the very high gHAT persistence probabilities seen in results for these populations
(Figure 5.28).
In addition, we consider a probability of active screening every year, despite the fact that
this is unlikely to be necessary for small villages, where the disease is almost certain to
be locally eliminated. To improve the plausibility of the model, we would like to add
a cessation criterion, similar to the work in Chapter 4. This is less straightforward to
implement in this probabilistic framework than in the tau-leaping scheme, as we do
not consider specific realisations of the model where the infection is either detected or
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not, but have a full probability distribution of all possible infection states. One potential
solution could be to link the probability of being screened to the probability of observing
a case in active screening.
As considered in Chapter 3, there is also no data on the movement of people between
villages, and so the rate of importation was estimated by matching to the probability
of detecting infection on the first active screening in a village. However, since in this
model, we initially simulate forward in time with a given level of importations until the
balance between extinction events and importations means we have found the endemic
equilibrium, we could estimate this parameter more accurately for a given health zone,
by matching the rate of importation to achieve the expected number of infected people
at the endemic equilibrium; the import parameter currently gives an over-estimate of
the endemic equilibrium found in the ODE framework.
Overall in this chapter, we have shown that a simplified model can achieve very similar
results to a more biologically realistic version, while introducing a method of obtaining
analytic results for extinction times and expected number of infected individuals. The
results would benefit from updating the model parameterisation to fit to more recent
data, however the predictions provided are inline with previous deterministic and
stochastic results. The model implementation provides a framework to scale between
modelling at a health zone or national level and at the village level. This is an important
development, since the data obtained and the actual interventions (active screening)
are provided at village level.
The current model from this chapter suggests that with mean active screening and
limited passive surveillance, and with no additional interventions, such as vector control,
the infection is almost certain to persist for long periods. This indicates that additional
controls are required to achieve elimination of transmission, such as tsetse control or
improved passive surveillance. Recent known improvements in the detection rates in
passive surveillance could be added to this model however, and would decrease the
probability of gHAT persistence. Indeed, this model structure with further refinements





6.1 Aims and previous work
The aim of this thesis was to take the existing modelling literature on gambiense human
African trypanosomiasis (gHAT) and extend the work in terms of modelling at different
spatial scales and incorporating stochasticity into the models. There was already a
substantial amount of literature regarding the modelling of gHAT, considering its status
as a neglected tropical disease, of which research started appearing from the 1980s
[214, 215]. Many of the underlying epidemiological features of the disease were well-
understood; some literature also gave insights into the effectiveness of control strategies
and their potential to achieve elimination [14, 186, 218, 220]. However, since the
beginning of this PhD thesis in 2016, there has been a large increase in the number of
mathematical modelling publications for gHAT (for example the following studies [146,
179, 190, 221, 223–226]).
The work within this thesis has contributed significantly to this literature in many ways,
having successfully formulated a stochastic infection model for gHAT that has been
applied to village-level analyses, and with the ability to scale this model to a health zone,
while maintaining village interactions. I detail the developments made in the work in
the discussion below.
6.2 Discussion of the thesis and future work
In Chapter 2, I have described HAT with an introduction to its biology, transmission
and disease symptoms. The history is then examined to put the current status of the
disease into context. Subsequently, I aimed to build an understanding of the previous
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Fig 6.1: The expected number of infected individuals in time using deterministic ODEs
and the stochastic tau-leaping algorithm for the same model structure of the full
vector-host model for villages of different population sizes, NH .
modelling literature for HAT, by reviewing the types of models and methods used for
HAT and some other vector-borne diseases, before the implications of these models were
considered.
In Chapter 3, I introduced a stochastic model for gHAT infection dynamics. At the time,
this was one of the first models to use this methodology, although others have introduced
stochastic gHAT models to the literature subsequently [225]. In particular, the use of
the stochastic model was most appropriate in this thesis, since the focus is on small
scale dynamics, modelling village populations with population sizes of typically less than
2,000 people (Figure 3.3).
These small population sizes mean that extinction events are more common, since the
chain of transmission can be broken more readily with fewer susceptible people available
to be infected. These extinction events are particularly common for a disease such as
gHAT, where the incidence is so low. This means that the expected number of infected
people will be less in stochastic models than deterministic models using the same model
structure. It is evident that this effect is negligible for large populations, for example
at the health zone scale with approximately 100,000 people, however, there is a large
effect for smaller populations of size 100 or 1,000 people (Figure 6.1).
Throughout this chapter, I demonstrated that by using parameters fitted to the deter-
ministic version of the model at the health zone level, and applied to an event-driven
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stochastic simulation at the village level, provided a good correspondence with expected
trends, seen from data (Figure 6.1). I also show that gHAT infection is able to persist
for surprisingly long times when compared to other infectious diseases, even in these
small populations and without the influence of infectious imports (Figure 3.13). An
important result for policy is considering the distinction between the observation of
detecting no cases of gHAT by an active screening and the actuality of that village having
achieved elimination of transmission (EOT). I show that we would typically need at least
three observations of no cases detected on active screenings and no passive detection
in between them to have high confidence that local elimination has been met (Figure
3.16).
This work was completed with parameters inferred for a region combined of the two
health zones, Yasa-Bonga and Mosango, and in particular I noted that there was some
spatial variation in the applicability of the model to different villages, seemingly de-
pendent on the proximity to a large river, where we know that the areas surrounding
rivers typically have the highest tsetse density [81]. I would therefore like to extend
this work, such that an updated model is parameterised based on the data from a
single health zone, and so consider the probability of persistence of gHAT in multiple
different health zones; by doing this we may better understand where the disease is
more likely to persist and the learn more about the impact of the underlying parameters
on gHAT persistence. In addition, this work assumed that all villages started with the
infection levels associated with the calculated endemic equilibrium for the year 2000.
It would be beneficial to consider the probability of persistence starting from different
initial conditions, given a variety of interventions, such as tsetse control, improved
passive surveillance and different coverages of active surveillance, have now been used
in different health zones. Furthermore, when considering the probability of elimination
of transmission in a village, we would like to relate the effects of the time of active
screenings in the history of the village to the probability of local elimination.
In Chapter 4, I used an updated stochastic model from Chapter 3, to consider the
potential efficiency of a range of plausible active screening strategies, which were defined
in terms of the screening coverage, screening frequency and cessation of screening
criteria. While, higher screening coverages, with increased frequency and no cessation
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would be the best strategy in terms of achieving and maintaining local gHAT elimination,
this is exceedingly unlikely to be an efficient use of resources, and completely infeasible
when scaled up a national level, or across every village located in the gHAT-endemic
regions.
Thus, I explore the potential of using the net monetary benefit (NMB) framework
for determining prospective optimal strategies. This involved running the stochastic
model simulations for a large range of strategies and applying an array of relevant
costs to the resulting output. The NMB of each strategy is considered to see where the
maximum was achieved for a given willingness to pay (WTP) of the funder (Figure 4.4).
A high screening coverage is particularly important when considering cost-effectiveness
of a strategy, however, this may be difficult to achieve practically, due to individuals
being not present or unwilling to be screened for gHAT. Therefore, I also limited the
strategies under consideration to a range of more practical strategies, to determine the
probability each was cost-effective (Figure 4.8). The results show that active screening
is typically cost-effective for low to moderate WTP thresholds, when screening is carried
out (approximately) annually with a high coverage.
The results from this chapter provide a quantitative backing to the current WHO guide-
lines for active screening [267] and indicates that annual screening should continue
to be a priority in the absence of additional interventions, such as tsetse control. The
work provides an important confirmation of the benefit of active screening programmes
within a cost-effectiveness framework.
This work used a model that was matched to the health zone Kwamouth, while a
comparison was also made for the health zone of Mosango. Future analyses could
therefore focus on extending the work to additional health zones to observe any local
variation in the results. Additionally, each village was considered independent of all
other villages in this modelling work, while in practice, the costs of maintaining active
surveillance teams in a region will depend on the interaction with all villages in that
region. For example, it may not be cost-effective to have a fully-staffed mobile team
conducting active screenings, if this was only required for a single village in the health
zone.
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Therefore, this model could be extended to consider a model based upon all the villages
visited by a single mobile screening team, rather than a single village. The availability of
active screening is dependent on the number and location of the mobile active screening
teams [97]. The whole system would therefore be captured and modelled, since the
basis of this chapter is optimising the use of a mobile team. This would also allow for a
better understanding of the costs involved and clarify the use of reactive screening in a
village, whereby if cases are presented in a village previously thought to have locally
eliminated gHAT, reactive screening could quickly occur in a region where there already
exists a mobile screening team, however, there may be greater costs involved if such
a team has already been disbanded from the whole region. In addition, additional
strategies could be modelled such as the reactive use of the oral acoziborale drug in
mass administration for single villages.
In Chapter 5, I considered a different methodology for exploring gHAT dynamics — the
use of the master equations. Through the use of a master equation model I obtained
numerically exact results, rather than relying on a large number of realisations from
an event-driven simulation model. Furthermore, rather than examining the summary
statistics of these many replications, the full probability distribution for the state space of
possible infection states in time could be analysed. Exact methods to calculate expected
disease extinction times were also used.
To use the master equation approach, I simplified the model dynamics, using the quasi-
equilibrium assumption for the tsetse infection dynamics and reducing the number of
human infection classes to simply susceptible infected, although maintaining the risk
class structure. This reduction in state space allowed for the rate matrix of the system to
be formulated within the boundary of reasonable memory allowance.
The examination of the reduced model using the three different methodologies discussed
in this thesis — deterministic ordinary differential equations, the stochastic tau-leaping
approximation and the use of the master equations — shows that we observe expected
results. Using sufficient tau-leaping realisations will provide identical expected infec-
tion dynamics to the master equations, however due to extinction events in the two
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Fig 6.2: The expected number of infected individuals in time using deterministic ODEs,
the stochastic tau-leaping algorithm and the master equations for the same model
structure of the simplified SIS model.
stochastic methods, the expected number of infected individuals will be lower than the
deterministic model for small populations (Figure 6.2).
The use of the master equations provided the necessary computational efficiency to
evaluate the effect of the infection dynamics in a group of villages, where movement
between them can introduce importations of infection. This link between all villages in
a region, means that results at the village-level can be scaled up to consider regional
infection dynamics, probabilities of persistence, and the effects of different intervention
strategies.
In particular, by using the model parameterisation and calculated rate of importations
of infection (3.4 × 10−6 per day, proportional to the number of susceptible people
in the village), we can simulate the gHAT dynamics for a full region comprised on
individual villages, using village and screening parameters directly from the WHO HAT
Atlas [106, 107] (Figure 5.20). Furthermore, we can also compare these results to a
deterministic model of a single population the size of the entire health zones (Yasa-Bonga
and Mosango), using the same total annual active screening coverage for the region
(Figure 5.27).
We see that for the same total population size that with the level of infectious imports
calculated in Section 3.7 gives a higher number of initial infected than the deterministic
equivalent with one population for the whole region. This overestimation of the impor-
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Fig 6.3: The expected number of infected individuals in time using deterministic ODEs
for the whole region of Yasa-Bonga and Mosango, and the master equations for
connected villages, using the SIS model structure. The rate of importations is given
by 3.4× 10−6 per day (blue) and 1.7× 10−6 per day (yellow), both proportional to
the number of susceptible people in the village.
tation rate may be that the rate was obtained using only data from villages included in
the WHO HAT Atlas [106, 107], and thus we have not accounted for the villages not
thought to be presenting cases, which would reduce this rate for the whole region. By
matching the rate of importation to the initial conditions from the deterministic model,
we can achieve a better fit (Figure 6.3). As we expect, the expected number of infected
people will reduce faster in the master equation method than the deterministic model in
time because of the local extinction events and because the population is subdivided
into villages, in which people will primarily only mix with other people within their own
village, limiting the potential infection spread.
Future work for this model would be to update the model structure and model pa-
rameters to more recent model fits and to focus more upon the calculation of the rate
of infectious imports between the villages. We could also simulate a large number of
villages with spatial interaction if there were sufficient data to support this. However,
this methodology is an important step in the scaling between models at the village level
and more broadly considering gHAT across larger regions.
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6.3 Conclusions
Overall, this thesis has thoroughly investigated the dynamic, system behaviour of gHAT
infection in individual village populations with some implications for modelling gHAT at
different spatial scales. The development of stochastic infection models for gHAT and
the ability to capture processes such as village persistence and to be able to make recom-
mendations using these models in cost-effectiveness frameworks is a major advance in
gHAT modelling for public health.
To achieve the elimination target set by WHO for 2030 [11], the infection needs to be
understood at the scale of the village, since it is at this level the controls are implemented.
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